|
Symbol |
Object Name |
Qualifiers
|
Evidence |
Notes |
Source |
PubMed Reference(s) |
RGD Reference(s) |
Position |
|
G
|
Aarsd1
|
alanyl-tRNA synthetase domain containing 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of AARSD1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:86,340,625...86,353,732
Ensembl chr10:86,340,626...86,353,729
|
|
G
|
Abat
|
4-aminobutyrate aminotransferase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G
|
Abca1
|
ATP binding cassette subfamily A member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein
|
CTD |
PMID:27580383 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions increases response to substance decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate Dextran Sulfate results in decreased expression of ABCB1A mRNA
|
CTD |
PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G
|
Abcb1b
|
ATP-binding cassette, sub-family B member 1B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
|
CTD |
PMID:29950665 PMID:30701287 |
|
NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:25,242,798...25,325,199
|
|
G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:26,106,895...26,164,440
Ensembl chr 4:25,151,953...25,209,202
|
|
G
|
Abcb6
|
ATP binding cassette subfamily B member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:76,668,554...76,676,924
|
|
G
|
Abcc10
|
ATP binding cassette subfamily C member 10
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:22,154,811...22,174,743
Ensembl chr 9:14,657,264...14,677,178
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
decreases expression affects response to substance multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein ABCC2 protein affects the susceptibility to Dextran Sulfate ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
|
CTD |
PMID:27580383 PMID:30701287 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
decreases expression multiple interactions affects response to substance
|
ISO
|
Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCC3 protein affects the susceptibility to Dextran Sulfate
|
CTD |
PMID:27580383 PMID:29950665 PMID:30701287 PMID:38844255 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G
|
Abcc4
|
ATP binding cassette subfamily C member 4
|
multiple interactions decreases expression
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein
|
CTD |
PMID:26271895 PMID:27580383 PMID:29950665 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G
|
Abcc5
|
ATP binding cassette subfamily C member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:93,975,579...94,071,659
Ensembl chr11:80,473,872...80,567,253
|
|
G
|
Abcc6
|
ATP binding cassette subfamily C member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:96,447,251...96,501,464
|
|
G
|
Abcc9
|
ATP binding cassette subfamily C member 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:175,532,547...175,655,356
|
|
G
|
Abcf2
|
ATP binding cassette subfamily F member 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ABCF2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606
|
|
G
|
Abcg1
|
ATP binding cassette subfamily G member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,126,687...9,182,948
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions affects response to substance decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCG2 protein affects the susceptibility to Dextran Sulfate Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]
|
CTD |
PMID:29950665 PMID:30701287 PMID:38423481 PMID:38844255 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G
|
Abi1
|
abl-interactor 1
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
|
|
G
|
Abraxas2
|
abraxas 2, BRISC complex subunit
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ABRAXAS2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ABRAXAS2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:197,077,177...197,102,753
Ensembl chr 1:187,647,067...187,672,655
|
|
G
|
Abtb1
|
ankyrin repeat and BTB domain containing 1
|
multiple interactions affects response to substance
|
ISO
|
[ABTB1 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein
|
CTD |
PMID:38866194 |
|
NCBI chr 4:121,299,302...121,305,667
Ensembl chr 4:121,299,304...121,305,620
|
|
G
|
Acaa1a
|
acetyl-CoA acyltransferase 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:119,079,775...119,088,624
|
|
G
|
Acaa1b
|
acetyl-Coenzyme A acyltransferase 1B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:127,750,771...127,759,589
Ensembl chr 8:118,872,997...118,881,825
|
|
G
|
Acaa2
|
acetyl-CoA acyltransferase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:70,620,310...70,648,417
Ensembl chr18:68,345,012...68,373,249
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]
|
CTD |
PMID:32272095 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457
|
|
G
|
Acads
|
acyl-CoA dehydrogenase short chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:47,154,259...47,163,580
Ensembl chr12:41,493,626...41,502,898
|
|
G
|
Acadsb
|
acyl-CoA dehydrogenase, short/branched chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:195,619,088...195,660,564
Ensembl chr 1:186,188,987...186,230,379
|
|
G
|
Acap2
|
ArfGAP with coiled-coil, ankyrin repeat and PH domains 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ACAP2 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACAP2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr11:69,538,487...69,654,156
Ensembl chr11:69,538,546...69,654,151
|
|
G
|
Ace
|
angiotensin I converting enzyme
|
multiple interactions increases abundance
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space
|
CTD RGD |
PMID:29950665 PMID:26401072 |
RGD:11555935 |
NCBI chr10:91,410,129...91,430,246
Ensembl chr10:90,910,316...90,931,131
|
|
G
|
Ache
|
acetylcholinesterase
|
multiple interactions decreases activity
|
ISO
|
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA Dextran Sulfate results in decreased activity of ACHE protein
|
CTD |
PMID:29950665 PMID:31226429 PMID:31807802 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G
|
Ackr1
|
atypical chemokine receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:85,782,396...85,784,015
Ensembl chr13:85,782,398...85,783,983
|
|
G
|
Ackr2
|
atypical chemokine receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:130,438,703...130,451,106
Ensembl chr 8:121,561,211...121,573,582
|
|
G
|
Ackr3
|
atypical chemokine receptor 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G
|
Ackr4
|
atypical chemokine receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:104,716,537...104,720,972
Ensembl chr 8:104,716,067...104,723,617
|
|
G
|
Acp6
|
acid phosphatase 6, lysophosphatidic
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACP6 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:184,711,975...184,733,067
Ensembl chr 2:184,711,619...184,733,017
|
|
G
|
Acsbg2
|
acyl-CoA synthetase bubblegum family member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:1,770,971...1,802,635
Ensembl chr 9:1,683,847...1,714,518
|
|
G
|
Acsm1
|
acyl-CoA synthetase medium-chain family member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:183,417,052...183,451,897
Ensembl chr 1:173,984,672...174,025,495
|
|
G
|
Acsm3
|
acyl-CoA synthetase medium-chain family member 3
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ACSM3 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACSM3 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 1:183,564,652...183,591,328
Ensembl chr 1:174,133,288...174,160,184
|
|
G
|
Acss1
|
acyl-CoA synthetase short-chain family member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:159,910,809...159,960,748
Ensembl chr 3:139,450,383...139,500,325
|
|
G
|
Acss2
|
acyl-CoA synthetase short-chain family member 2
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACSS2 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:144,004,336...144,059,675
|
|
G
|
Actl6a
|
actin-like 6A
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:115,492,374...115,508,401
Ensembl chr 2:115,492,285...115,508,401
|
|
G
|
Actn1
|
actinin, alpha 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G
|
Actn2
|
actinin alpha 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:62,835,055...62,902,331
Ensembl chr17:58,142,625...58,210,622
|
|
G
|
Actr2
|
actin related protein 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ACTR2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524
|
|
G
|
Actr3
|
actin related protein 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ACTR3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr13:39,353,413...39,396,509
Ensembl chr13:36,800,093...36,844,124
|
|
G
|
Acvr1
|
activin A receptor type 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:63,387,378...63,506,980
Ensembl chr 3:42,978,561...43,098,241
|
|
G
|
Acy1
|
aminoacylase 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:107,072,354...107,077,756
Ensembl chr 8:107,072,358...107,077,682
|
|
G
|
Ada
|
adenosine deaminase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ADA protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:152,398,747...152,447,088
|
|
G
|
Adam10
|
ADAM metallopeptidase domain 10
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ADAM10 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ADAM10 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 8:80,226,862...80,358,728
Ensembl chr 8:71,345,837...71,477,889
|
|
G
|
Adam17
|
ADAM metallopeptidase domain 17
|
multiple interactions affects response to substance increases expression
|
ISO
|
ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA] ADAM17 protein affects the susceptibility to Dextran Sulfate
|
CTD |
PMID:24548422 |
|
NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:40,872,856...40,920,639
|
|
G
|
Adamts1
|
ADAM metallopeptidase with thrombospondin type 1 motif, 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:38,418,565...38,427,384
Ensembl chr11:24,931,761...24,941,103
|
|
G
|
Adamts14
|
ADAM metallopeptidase with thrombospondin type 1 motif, 14
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866
|
|
G
|
Adamts2
|
ADAM metallopeptidase with thrombospondin type 1 motif, 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821
|
|
G
|
Adamts4
|
ADAM metallopeptidase with thrombospondin type 1 motif, 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G
|
Adamts5
|
ADAM metallopeptidase with thrombospondin type 1 motif, 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G
|
Adcy2
|
adenylate cyclase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236
|
|
G
|
Adcy4
|
adenylate cyclase 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:29,266,280...29,282,153
Ensembl chr15:29,266,287...29,282,108
|
|
G
|
Adcy6
|
adenylate cyclase 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:131,621,860...131,642,923
Ensembl chr 7:129,742,838...129,763,754
|
|
G
|
Adcy7
|
adenylate cyclase 7
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA Dextran Sulfate results in decreased expression of ADCY7 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
|
|
G
|
Adcyap1
|
adenylate cyclase activating polypeptide 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:113,103,718...113,109,773
|
|
G
|
Adcyap1r1
|
ADCYAP receptor type I
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G
|
Adgra2
|
adhesion G protein-coupled receptor A2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:64,932,964...64,971,433
Ensembl chr16:64,933,315...64,971,483
|
|
G
|
Adgrb1
|
adhesion G protein-coupled receptor B1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902
|
|
G
|
Adgre1
|
adhesion G protein-coupled receptor E1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ADGRE1 protein flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein]
|
CTD |
PMID:38583725 |
|
NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,242,474...2,398,000
|
|
G
|
Adgre5
|
adhesion G protein-coupled receptor E5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638
|
|
G
|
Adgrf1
|
adhesion G protein-coupled receptor F1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:17,661,258...17,696,359
Ensembl chr 9:17,660,930...17,711,704
|
|
G
|
Adgrf5
|
adhesion G protein-coupled receptor F5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968
|
|
G
|
Adh1c
|
alcohol dehydrogenase 1C (class I), gamma polypeptide
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G
|
Adh5
|
alcohol dehydrogenase 5 (class III), chi polypeptide
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:229,648,557...229,660,964
Ensembl chr 2:226,947,466...226,987,591
|
|
G
|
Adm
|
adrenomedullin
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA Dextran Sulfate results in increased expression of ADM mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:164,745,466...164,747,654
|
|
G
|
Adora2a
|
adenosine A2a receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,853...13,333,386
|
|
G
|
Adora2b
|
adenosine A2B receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G
|
Adora3
|
adenosine A3 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G
|
Adra2a
|
adrenoceptor alpha 2A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:253,060,218...253,064,365
|
|
G
|
Adrb2
|
adrenoceptor beta 2
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA
|
CTD |
PMID:26271895 PMID:29950665 |
|
NCBI chr18:57,912,760...57,914,802
Ensembl chr18:55,502,903...55,644,512
|
|
G
|
Agt
|
angiotensinogen
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA Dextran Sulfate results in decreased expression of AGT mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G
|
Ahnak
|
AHNAK nucleoprotein
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of AHNAK mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions increases response to substance
|
ISO
|
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA] AHR gene mutant form results in increased susceptibility to Dextran Sulfate
|
CTD |
PMID:36519841 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G
|
Ahsp
|
alpha hemoglobin stabilizing protein
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of AHSP protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:182,879,901...182,885,508
Ensembl chr 1:182,880,076...182,885,506
|
|
G
|
Aip
|
aryl-hydrocarbon receptor-interacting protein
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of AIP protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:201,408,002...201,419,220
Ensembl chr 1:201,407,288...201,419,122
|
|
G
|
Ak1
|
adenylate kinase 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of AK1 protein [Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G
|
Akap12
|
A-kinase anchoring protein 12
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of AKAP12 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G
|
Akap5
|
A-kinase anchoring protein 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
|
|
G
|
Akap8
|
A-kinase anchoring protein 8
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of AKAP8 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:11,316,224...11,332,523
Ensembl chr 7:11,316,228...11,332,399
|
|
G
|
Akr1b1
|
aldo-keto reductase family 1 member B1
|
decreases expression increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of AKR1B1 protein Dextran Sulfate results in increased expression of AKR1B1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA
|
CTD |
PMID:29950665 PMID:35093514 PMID:35999755 |
|
NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:62,932,031...62,946,157
|
|
G
|
Akr1c3
|
aldo-keto reductase family 1, member C3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:71,020,884...71,037,779
Ensembl chr17:66,110,963...66,127,873
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO EXP
|
[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein] banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:26262998 PMID:36806191 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G
|
Alb
|
albumin
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA
|
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G
|
Aldh1b1
|
aldehyde dehydrogenase 1 family, member B1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:60,063,225...60,068,378
|
|
G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:34,901,219...34,982,521
|
|
G
|
Aldh3a2
|
aldehyde dehydrogenase 3 family, member A2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:46,427,789...46,448,449
Ensembl chr10:45,908,524...45,949,281
|
|
G
|
Aldh7a1
|
aldehyde dehydrogenase 7 family, member A1
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr18:52,208,035...52,240,293
Ensembl chr18:50,009,934...50,042,193
|
|
G
|
Aldoc
|
aldolase, fructose-bisphosphate C
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ALDOC protein]
|
CTD |
PMID:35093514 PMID:35362542 PMID:35999755 |
|
NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,217,451...63,221,066
|
|
G
|
Alox12
|
arachidonate 12-lipoxygenase, 12S type
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ALOX12 protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:55,456,923...55,469,239
Ensembl chr10:54,958,271...54,970,542
|
|
G
|
Alox12b
|
arachidonate 12-lipoxygenase, 12R type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:54,361,898...54,373,776
Ensembl chr10:53,863,060...53,874,938
|
|
G
|
Alox5
|
arachidonate 5-lipoxygenase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:149,531,515...149,578,743
|
|
G
|
Alox5ap
|
arachidonate 5-lipoxygenase activating protein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:10,785,254...10,809,295
Ensembl chr12:5,748,944...5,772,986
|
|
G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
multiple interactions increases activity
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA Dextran Sulfate results in increased activity of ALPL protein
|
CTD |
PMID:29950665 PMID:30489199 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:149,951,409...150,006,446
|
|
G
|
Ampd3
|
adenosine monophosphate deaminase 3
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of AMPD3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G
|
Angpt4
|
angiopoietin 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:140,420,389...140,454,213
Ensembl chr 3:140,420,389...140,453,583
|
|
G
|
Angptl4
|
angiopoietin-like 4
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of ANGPTL4 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G
|
Ano1
|
anoctamin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G
|
Ano10
|
anoctamin 10
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ANO10 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr 8:130,719,177...130,838,243
Ensembl chr 8:121,841,665...121,962,670
|
|
G
|
Ano6
|
anoctamin 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589
|
|
G
|
Ano7
|
anoctamin 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:93,917,524...93,945,323
Ensembl chr 9:93,917,524...93,945,323
|
|
G
|
Ano9
|
anoctamin 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:196,208,863...196,230,381
Ensembl chr 1:196,197,341...196,229,900
|
|
G
|
Anxa1
|
annexin A1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:217,861,175...217,877,343
|
|
G
|
Anxa4
|
annexin A4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:120,741,750...120,798,534
Ensembl chr 4:119,184,374...119,241,161
|
|
G
|
Ap1m1
|
adaptor related protein complex 1 subunit mu 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403
|
|
G
|
Ap1s1
|
adaptor related protein complex 1 subunit sigma 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of AP1S1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G
|
Ap3m1
|
adaptor related protein complex 3 subunit mu 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of AP3M1 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of AP3M1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr15:3,246,616...3,264,846
Ensembl chr15:3,246,926...3,264,844
|
|
G
|
Apc
|
APC regulator of WNT signaling pathway
|
affects response to substance multiple interactions
|
ISO
|
APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate [APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:16049979 PMID:26262998 PMID:30188895 |
|
NCBI chr18:26,138,382...26,196,021
Ensembl chr18:25,864,222...25,922,696
|
|
G
|
Apcs
|
amyloid P component, serum
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of APCS protein
|
CTD |
PMID:35999755 |
|
NCBI chr13:87,905,532...87,906,508
Ensembl chr13:85,373,220...85,374,298
|
|
G
|
Apln
|
apelin
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA Dextran Sulfate results in decreased expression of APLN mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G
|
Apoa2
|
apolipoprotein A2
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr13:86,176,767...86,178,819
Ensembl chr13:83,644,470...83,646,355
|
|
G
|
Apoa4
|
apolipoprotein A4
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of APOA4 protein [Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]
|
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G
|
Apob
|
apolipoprotein B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G
|
Apoc2
|
apolipoprotein C2
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G
|
Apoe
|
apolipoprotein E
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of APOE protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of APOE protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:79,353,916...79,357,932
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G
|
Appl2
|
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of APPL2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:22,019,480...22,072,386
Ensembl chr 7:20,135,375...20,184,754
|
|
G
|
Aqp1
|
aquaporin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:84,482,512...84,494,690
|
|
G
|
Aqp11
|
aquaporin 11
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:152,046,515...152,056,675
Ensembl chr 1:152,046,517...152,056,725
|
|
G
|
Aqp2
|
aquaporin 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:132,590,286...132,595,321
Ensembl chr 7:130,711,413...130,716,468
|
|
G
|
Aqp3
|
aquaporin 3 (Gill blood group)
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:56,239,201...56,244,720
|
|
G
|
Aqp8
|
aquaporin 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:187,424,314...187,430,243
Ensembl chr 1:177,993,305...177,999,158
|
|
G
|
Aqp9
|
aquaporin 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA Dextran Sulfate results in increased expression of AR mRNA
|
CTD |
PMID:27920257 PMID:29950665 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G
|
Arf3
|
ARF GTPase 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ARF3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
|
|
G
|
Arfgap2
|
ARF GTPase activating protein 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ARFGAP2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ARFGAP2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:77,236,305...77,248,445
Ensembl chr 3:77,236,322...77,248,455
|
|
G
|
Arg1
|
arginase 1
|
multiple interactions decreases expression
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein] Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein
|
CTD |
PMID:25026504 PMID:38164749 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G
|
Arhgap1
|
Rho GTPase activating protein 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ARHGAP1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G
|
Arhgap15
|
Rho GTPase activating protein 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265
|
|
G
|
Arhgap20
|
Rho GTPase activating protein 20
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739
|
|
G
|
Arhgap25
|
Rho GTPase activating protein 25
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:119,896,844...119,974,982
|
|
G
|
Arhgap40
|
Rho GTPase activating protein 40
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203
|
|
G
|
Arhgdia
|
Rho GDP dissociation inhibitor alpha
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ARHGDIA protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G
|
Arhgdib
|
Rho GDP dissociation inhibitor beta
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of ARHGDIB mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA Dextran Sulfate results in decreased expression of ARHGDIB protein
|
CTD |
PMID:23894361 PMID:29950665 PMID:35999755 |
|
NCBI chr 4:171,554,139...171,573,057
Ensembl chr 4:169,822,952...169,841,658
|
|
G
|
Arhgef1
|
Rho guanine nucleotide exchange factor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953
|
|
G
|
Arhgef12
|
Rho guanine nucleotide exchange factor 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
|
|
G
|
Arhgef6
|
Rac/Cdc42 guanine nucleotide exchange factor 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:135,145,447...135,264,636
Ensembl chr X:135,146,786...135,275,304
|
|
G
|
Arl3
|
ARF like GTPase 3
|
increases expression decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ARL3 mRNA Dextran Sulfate results in decreased expression of ARL3 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ARL3 protein]
|
CTD |
PMID:35093514 PMID:35362542 |
|
NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820
|
|
G
|
Arl9
|
ARF like GTPase 9
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of ARL9 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699
|
|
G
|
Arpc2
|
actin related protein 2/3 complex, subunit 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ARPC2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 9:83,269,884...83,300,610
Ensembl chr 9:75,820,770...75,851,471
|
|
G
|
Arpc3
|
actin related protein 2/3 complex, subunit 3
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein Dextran Sulfate results in decreased expression of ARPC3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr12:39,833,569...39,847,436
Ensembl chr12:34,172,780...34,186,651
|
|
G
|
Arpc4
|
actin related protein 2/3 complex, subunit 4
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ARPC4 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 4:148,077,799...148,088,427
Ensembl chr 4:146,522,176...146,532,785
|
|
G
|
Arpc5
|
actin related protein 2/3 complex, subunit 5
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ARPC5 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ARPC5 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr13:67,454,379...67,463,288
Ensembl chr13:64,887,136...64,913,410
|
|
G
|
Arrb2
|
arrestin, beta 2
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,146,818...55,154,850
|
|
G
|
Arsb
|
arylsulfatase B
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ARSB mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 2:26,736,395...26,895,682
Ensembl chr 2:25,002,346...25,162,671
|
|
G
|
Asb2
|
ankyrin repeat and SOCS box-containing 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
|
|
G
|
Asic4
|
acid sensing ion channel subunit family member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900
|
|
G
|
Ass1
|
argininosuccinate synthase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ASS1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G
|
Atg5
|
autophagy related 5
|
multiple interactions increases expression
|
ISO
|
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]
|
CTD |
PMID:27611972 PMID:31676321 PMID:35439472 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209
|
|
G
|
Atg7
|
autophagy related 7
|
multiple interactions increases expression
|
ISO
|
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]
|
CTD |
PMID:31676321 |
|
NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:147,718,752...147,925,593
|
|
G
|
Atic
|
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ATIC protein
|
CTD |
PMID:35999755 |
|
NCBI chr 9:73,164,846...73,184,897
Ensembl chr 9:73,164,846...73,184,889
|
|
G
|
Atp10a
|
ATPase phospholipid transporting 10A (putative)
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:109,556,760...109,730,440
Ensembl chr 1:109,556,782...109,730,437
|
|
G
|
Atp11b
|
ATPase phospholipid transporting 11B (putative)
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:118,585,342...118,690,232
|
|
G
|
Atp12a
|
ATPase H+/K+ transporting non-gastric alpha2 subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:34,559,209...34,583,866
Ensembl chr15:30,443,571...30,468,229
|
|
G
|
Atp1a1
|
ATPase Na+/K+ transporting subunit alpha 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:189,020,722...189,048,837
|
|
G
|
Atp1a3
|
ATPase Na+/K+ transporting subunit alpha 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:89,700,645...89,729,782
Ensembl chr 1:80,572,796...80,601,918
|
|
G
|
Atp1a4
|
ATPase Na+/K+ transporting subunit alpha 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:87,216,139...87,252,155
Ensembl chr13:84,683,768...84,719,687
|
|
G
|
Atp1b1
|
ATPase Na+/K+ transporting subunit beta 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:79,319,708...79,340,226
Ensembl chr13:76,786,578...76,807,459
|
|
G
|
Atp1b3
|
ATPase Na+/K+ transporting subunit beta 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:105,789,824...105,821,151
Ensembl chr 8:96,910,309...96,941,598 Ensembl chr 8:96,910,309...96,941,598
|
|
G
|
Atp2a1
|
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:190,457,198...190,475,410
Ensembl chr 1:181,026,608...181,044,838
|
|
G
|
Atp2a3
|
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:58,079,710...58,111,279
Ensembl chr10:57,582,128...57,612,748
|
|
G
|
Atp2b1
|
ATPase plasma membrane Ca2+ transporting 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:33,735,871...33,843,295
|
|
G
|
Atp2c2
|
ATPase secretory pathway Ca2+ transporting 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:64,662,729...64,719,998
Ensembl chr19:47,754,120...47,811,368
|
|
G
|
Atp4b
|
ATPase H+/K+ transporting subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:76,144,150...76,153,063
Ensembl chr16:76,144,150...76,153,063
|
|
G
|
Atp5mf
|
ATP synthase membrane subunit f
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ATP5MF protein]
|
CTD |
PMID:35362542 |
|
NCBI chr12:14,535,435...14,542,007
Ensembl chr12:9,421,579...9,428,236
|
|
G
|
Atp6v0a2
|
ATPase H+ transporting V0 subunit a2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:37,608,211...37,640,860
Ensembl chr12:31,822,733...32,007,069
|
|
G
|
Atp6v0a4
|
ATPase H+ transporting V0 subunit a4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:67,727,145...67,809,092
Ensembl chr 4:66,760,159...66,842,110
|
|
G
|
Atp6v0c
|
ATPase H+ transporting V0 subunit C
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ATP6V0C protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ATP6V0C protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,196,204...13,201,500
|
|
G
|
Atp6v0d1
|
ATPase H+ transporting V0 subunit D1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ATP6V0D1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ATP6V0D1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:50,313,268...50,357,248
Ensembl chr19:33,403,355...33,447,450
|
|
G
|
Atp6v0d2
|
ATPase H+ transporting V0 subunit D2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:33,336,264...33,385,354
|
|
G
|
Atp6v1e2
|
ATPase H+ transporting V1 subunit E2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:13,417,046...13,425,628
Ensembl chr 6:7,667,564...7,672,626
|
|
G
|
Atp6v1f
|
ATPase H+ transporting V1 subunit F
|
increases expression decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ATP6V1F mRNA Dextran Sulfate results in decreased expression of ATP6V1F protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ATP6V1F protein]
|
CTD |
PMID:35093514 PMID:35362542 |
|
NCBI chr 4:59,033,020...59,035,980
|
|
G
|
Atp6v1g3
|
ATPase H+ transporting V1 subunit G3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:52,351,787...52,376,784
Ensembl chr13:49,794,222...49,825,247
|
|
G
|
Atp7a
|
ATPase copper transporting alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:71,094,202...71,198,354
|
|
G
|
Atp8b1
|
ATPase phospholipid transporting 8B1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G
|
Atp8b2
|
ATPase phospholipid transporting 8B2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883
|
|
G
|
Avpr1a
|
arginine vasopressin receptor 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G
|
Avpr1b
|
arginine vasopressin receptor 1B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:43,046,531...43,059,046
Ensembl chr13:43,046,267...43,057,792
|
|
G
|
Avpr2
|
arginine vasopressin receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989
|
|
G
|
Axin2
|
axin 2
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]
|
CTD |
PMID:31715269 |
|
NCBI chr10:94,393,379...94,426,579
Ensembl chr10:93,899,245...93,926,231
|
|
G
|
B3gnt3
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:18,434,114...18,444,851
Ensembl chr16:18,401,405...18,410,766
|
|
G
|
B3gnt7
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of B3GNT7 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of B3GNT7 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 9:94,404,197...94,408,148
Ensembl chr 9:86,956,220...86,960,170
|
|
G
|
B3gnt8
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:81,135,602...81,138,501
Ensembl chr 1:81,135,499...81,142,263
|
|
G
|
Baat
|
bile acid CoA:amino acid N-acyltransferase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:68,647,166...68,656,137
Ensembl chr 5:63,850,705...63,860,685
|
|
G
|
Banf1
|
barrier to autointegration nuclear assembly factor 1
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of BANF1 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188
|
|
G
|
Bank1
|
B-cell scaffold protein with ankyrin repeats 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of BANK1 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions increases expression
|
ISO
|
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]
|
CTD |
PMID:24146755 PMID:37209277 PMID:38583725 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G
|
Bche
|
butyrylcholinesterase
|
multiple interactions decreases activity
|
ISO
|
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein Dextran Sulfate results in decreased activity of BCHE protein
|
CTD |
PMID:31226429 PMID:31807802 |
|
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:158,307,584...158,401,148
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]
|
CTD |
PMID:25449198 PMID:37209277 PMID:38583725 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G
|
Bcl6
|
BCL6, transcription repressor
|
multiple interactions
|
ISO
|
BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]
|
CTD |
PMID:38164749 |
|
NCBI chr11:90,358,753...90,382,049
Ensembl chr11:76,854,090...76,877,389
|
|
G
|
Bcl7c
|
BAF chromatin remodeling complex subunit BCL7C
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of BCL7C mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:182,277,163...182,324,274
Ensembl chr 1:182,260,164...182,324,163
|
|
G
|
Bdkrb1
|
bradykinin receptor B1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:124,510,870...124,513,747
|
|
G
|
Bdkrb2
|
bradykinin receptor B2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:124,472,566...124,502,497
|
|
G
|
Becn1
|
beclin 1
|
multiple interactions increases expression
|
ISO
|
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
|
CTD |
PMID:27611972 PMID:31676321 PMID:31926917 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,231,388...86,246,742
|
|
G
|
Best1
|
bestrophin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:216,054,395...216,071,012
Ensembl chr 1:206,629,500...206,646,063
|
|
G
|
Bgn
|
biglycan
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:156,348,633...156,360,797
Ensembl chr X:151,197,273...151,209,461
|
|
G
|
Bin2
|
bridging integrator 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of BIN2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]
|
CTD |
PMID:25449198 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G
|
Birc6
|
baculoviral IAP repeat-containing 6
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of BIRC6 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 6:20,722,922...20,916,396
Ensembl chr 6:20,722,922...20,916,434
|
|
G
|
Bmp1
|
bone morphogenetic protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G
|
Bmp10
|
bone morphogenetic protein 10
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:119,872,066...119,877,694
Ensembl chr 4:119,872,045...119,878,627
|
|
G
|
Bmp7
|
bone morphogenetic protein 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:161,516,462...161,716,788
|
|
G
|
Bmpr1b
|
bone morphogenetic protein receptor type 1B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G
|
Bmpr2
|
bone morphogenetic protein receptor type 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G
|
Bpifa1
|
BPI fold containing family A, member 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:142,627,810...142,633,553
Ensembl chr 3:142,627,810...142,633,552
|
|
G
|
Bpnt2
|
3'(2'), 5'-bisphosphate nucleotidase 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of BPNT2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of BPNT2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:17,775,684...17,802,570
Ensembl chr 5:17,772,608...17,802,570
|
|
G
|
Brk1
|
BRICK1 subunit of SCAR/WAVE actin nucleating complex
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of BRK1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of BRK1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:146,750,821...146,766,050
Ensembl chr 4:146,750,821...146,768,856
|
|
G
|
Bspry
|
B-box and SPRY domain containing
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of BSPRY mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583
|
|
G
|
Bst1
|
bone marrow stromal cell antigen 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180
|
|
G
|
Btf3l4
|
basic transcription factor 3-like 4
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of BTF3L4 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 5:123,567,902...123,587,527
Ensembl chr 5:123,567,907...123,586,866
|
|
G
|
C1galt1
|
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:36,894,440...36,932,434
Ensembl chr 4:35,928,104...35,961,831
|
|
G
|
C1galt1c1
|
C1GALT1-specific chaperone 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:122,243,736...122,248,217
Ensembl chr X:117,375,525...117,382,787
|
|
G
|
C1qa
|
complement C1q A chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:149,133,636...149,136,534
|
|
G
|
C1qb
|
complement C1q B chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:154,402,276...154,407,827
Ensembl chr 5:149,118,846...149,124,407
|
|
G
|
C1qtnf6
|
C1q and TNF related 6
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of C1QTNF6 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:111,958,348...111,964,948
Ensembl chr 7:110,077,878...110,084,412
|
|
G
|
C1s
|
complement C1s
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:157,430,117...157,442,303
|
|
G
|
C3
|
complement C3
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of C3 protein]
|
CTD |
PMID:29950665 PMID:35362542 PMID:35999755 |
|
NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,087,437...2,114,429
|
|
G
|
C3ar1
|
complement C3a receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:157,747,419...157,756,609
Ensembl chr 4:156,075,389...156,084,701
|
|
G
|
C4b
|
complement C4B
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,197,366...4,211,681
|
|
G
|
C4bpa
|
complement component 4 binding protein, alpha
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein
|
CTD |
PMID:35999755 |
|
NCBI chr13:44,627,959...44,663,552
Ensembl chr13:42,075,717...42,111,205
|
|
G
|
C5ar1
|
complement C5a receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:86,077,309...86,088,001
|
|
G
|
Cab39
|
calcium binding protein 39
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G
|
Cacna1f
|
calcium voltage-gated channel subunit alpha1 F
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:17,539,992...17,568,308
Ensembl chr X:14,868,024...14,896,413
|
|
G
|
Cacna1s
|
calcium voltage-gated channel subunit alpha1 S
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:50,045,668...50,115,903
Ensembl chr13:47,493,949...47,564,318
|
|
G
|
Calca
|
calcitonin-related polypeptide alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:168,878,214...168,883,105
|
|
G
|
Calcb
|
calcitonin-related polypeptide, beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125
|
|
G
|
Calm1
|
calmodulin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:125,217,191...125,227,855
Ensembl chr 6:119,487,621...119,498,227
|
|
G
|
Calm2
|
calmodulin 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CALM2 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 6:12,845,170...12,857,830
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G
|
Calr
|
calreticulin
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CALR protein
|
CTD |
PMID:35999755 |
|
NCBI chr19:40,213,367...40,218,262
Ensembl chr19:23,308,351...23,313,414
|
|
G
|
Camk2g
|
calcium/calmodulin-dependent protein kinase II gamma
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G
|
Camk4
|
calcium/calmodulin-dependent protein kinase IV
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:24,857,152...25,076,054
Ensembl chr18:24,585,269...24,802,487
|
|
G
|
Camkk1
|
calcium/calmodulin-dependent protein kinase kinase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G
|
Cap1
|
cyclase associated actin cytoskeleton regulatory protein 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CAP1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G
|
Capn13
|
calpain 13
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 6:22,071,845...22,166,864
Ensembl chr 6:22,071,845...22,166,850
|
|
G
|
Capzb
|
capping actin protein of muscle Z-line subunit beta
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CAPZB protein
|
CTD |
PMID:35999755 |
|
NCBI chr 5:151,435,600...151,535,409
Ensembl chr 5:151,434,871...151,535,409
|
|
G
|
Car1
|
carbonic anhydrase 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CAR1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:88,550,681...88,593,454
Ensembl chr 2:86,861,897...86,872,208
|
|
G
|
Car2
|
carbonic anhydrase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:86,741,626...86,756,818
|
|
G
|
Car3
|
carbonic anhydrase 3
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:86,770,420...86,784,280
|
|
G
|
Car4
|
carbonic anhydrase 4
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr10:70,325,102...70,333,916
Ensembl chr10:69,827,945...69,836,501
|
|
G
|
Cask
|
calcium/calmodulin dependent serine protein kinase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CASK protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CASK protein]
|
CTD |
PMID:35362542 |
|
NCBI chr X:11,572,328...11,915,831
Ensembl chr X:8,899,833...9,238,694
|
|
G
|
Casp1
|
caspase 1
|
multiple interactions increases expression
|
ISO EXP
|
3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; nuciferine inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein] Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]
|
CTD |
PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:36577154 PMID:37001609 More...
|
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage multiple interactions increases activity
|
ISO
|
Dextran Sulfate results in increased cleavage of CASP3 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]
|
CTD |
PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 PMID:37209277 PMID:38583725 PMID:38648921 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions decreases expression
|
ISO
|
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]
|
CTD |
PMID:29496522 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G
|
Cat
|
catalase
|
decreases activity multiple interactions increases activity
|
ISO
|
Dextran Sulfate results in decreased activity of CAT protein [Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]
|
CTD |
PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G
|
Cavin2
|
caveolae associated protein 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CAVIN2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147
|
|
G
|
Cbr1
|
carbonyl reductase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CBR1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr11:46,346,405...46,348,815
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G
|
Cbr3
|
carbonyl reductase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:46,478,295...46,486,555
Ensembl chr11:33,008,615...33,016,875
|
|
G
|
Ccdc12
|
coiled-coil domain containing 12
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCDC12 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:110,635,276...110,686,417
Ensembl chr 8:110,635,710...110,686,417
|
|
G
|
Ccdc124
|
coiled-coil domain containing 124
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCDC124 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr16:18,566,745...18,572,564
Ensembl chr16:18,566,745...18,572,564
|
|
G
|
Ccdc13
|
coiled-coil domain containing 13
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCDC13 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:130,335,797...130,391,658
Ensembl chr 8:121,457,697...121,502,337
|
|
G
|
Ccdc158
|
coiled-coil domain containing 158
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CCDC158 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr14:15,411,178...15,468,579
Ensembl chr14:15,411,163...15,468,581
|
|
G
|
Ccdc88b
|
coiled-coil domain containing 88B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCDC88B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:213,466,139...213,482,099
Ensembl chr 1:204,036,918...204,052,970
|
|
G
|
Ccdc9
|
coiled-coil domain containing 9
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCDC9 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:76,978,312...76,991,673
Ensembl chr 1:76,974,091...76,991,607
|
|
G
|
Cchcr1
|
coiled-coil alpha-helical rod protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCHCR1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308
|
|
G
|
Cckbr
|
cholecystokinin B receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:159,771,733...159,814,881
|
|
G
|
Ccl11
|
C-C motif chemokine ligand 11
|
increases secretion multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in increased secretion of CCL11 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]
|
CTD |
PMID:21858153 PMID:29950665 PMID:32033881 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions increases secretion increases expression
|
ISO
|
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]
|
CTD |
PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 PMID:31807802 PMID:38583725 More...
|
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G
|
Ccl21
|
C-C motif chemokine ligand 21
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:61,776,411...61,777,515
Ensembl chr 5:56,980,558...56,981,686
|
|
G
|
Ccl24
|
C-C motif chemokine ligand 24
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G
|
Ccl25
|
C-C motif chemokine ligand 25
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554
|
|
G
|
Ccl27
|
C-C motif chemokine ligand 27
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCL27A mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:61,737,261...61,744,375
Ensembl chr 5:56,941,402...56,948,506
|
|
G
|
Ccl28
|
C-C motif chemokine ligand 28
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G
|
Ccl3
|
C-C motif chemokine ligand 3
|
increases expression multiple interactions
|
ISO EXP
|
Dextran Sulfate results in increased expression of CCL3 mRNA Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein] ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]
|
CTD |
PMID:19645018 PMID:30811821 PMID:33130971 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G
|
Ccl4
|
C-C motif chemokine ligand 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G
|
Ccl7
|
C-C motif chemokine ligand 7
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CCL7 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]
|
CTD |
PMID:19645018 PMID:29950665 PMID:32033881 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G
|
Ccl9
|
C-C motif chemokine ligand 9
|
increases expression decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCL6 mRNA Dextran Sulfate results in decreased expression of CCL6 mRNA
|
CTD |
PMID:19645018 PMID:35093514 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]
|
CTD |
PMID:31715269 PMID:35439472 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G
|
Ccr2
|
C-C motif chemokine receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:123,734,430...123,742,100
|
|
G
|
Ccr4
|
C-C motif chemokine receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G
|
Ccr5
|
C-C motif chemokine receptor 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G
|
Ccr7
|
C-C motif chemokine receptor 7
|
multiple interactions
|
ISO
|
Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]
|
CTD |
PMID:36265525 |
|
NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,097,381...84,108,309
|
|
G
|
Ccr8
|
C-C motif chemokine receptor 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629
|
|
G
|
Ccrl2
|
C-C motif chemokine receptor like 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664
|
|
G
|
Ccsap
|
centriole, cilia and spindle-associated protein
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCSAP mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753
|
|
G
|
Cd14
|
CD14 molecule
|
affects response to substance multiple interactions
|
ISO
|
Dextran Sulfate affects the susceptibility to CD14 protein [Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]
|
CTD |
PMID:28411859 |
|
NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,335,340...28,337,261
|
|
G
|
Cd163
|
CD163 molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD163 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G
|
Cd177
|
CD177 molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD177 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 1:89,467,926...89,488,490
Ensembl chr 1:80,340,034...80,360,621
|
|
G
|
Cd180
|
CD180 molecule
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CD180 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA
|
CTD |
PMID:23894361 PMID:29950665 |
|
NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936
|
|
G
|
Cd19
|
CD19 molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD19 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 1:190,417,853...190,424,494
Ensembl chr 1:180,987,286...180,993,975
|
|
G
|
Cd200
|
Cd200 molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G
|
Cd247
|
Cd247 molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:80,576,264...80,651,422
Ensembl chr13:78,043,307...78,122,263
|
|
G
|
Cd274
|
CD274 molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:227,116,649...227,134,450
|
|
G
|
Cd28
|
Cd28 molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:69,660,316...69,689,192
Ensembl chr 9:62,166,192...62,194,685
|
|
G
|
Cd34
|
CD34 molecule
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CD34 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G
|
Cd4
|
Cd4 molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:159,355,147...159,381,636
Ensembl chr 4:157,668,878...157,695,191
|
|
G
|
Cd44
|
CD44 molecule
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620
|
|
G
|
Cd52
|
CD52 molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD52 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G
|
Cd53
|
Cd53 molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD53 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657
|
|
G
|
Cd55
|
CD55 molecule (Cromer blood group)
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:44,409,574...44,438,913
Ensembl chr13:41,857,395...41,885,831
|
|
G
|
Cd68
|
Cd68 molecule
|
increases expression decreases expression multiple interactions
|
ISO
|
dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice Dextran Sulfate results in decreased expression of CD68 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CD68 protein]
|
CTD RGD |
PMID:35362542 PMID:25004394 |
RGD:40925931 |
NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,381,815...54,383,697
|
|
G
|
Cd72
|
Cd72 molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD72 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 5:62,493,155...62,500,779
Ensembl chr 5:57,697,367...57,704,725
|
|
G
|
Cd74
|
CD74 molecule
|
increases expression decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CD74 mRNA Dextran Sulfate results in decreased expression of CD74 mRNA; Dextran Sulfate results in decreased expression of CD74 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CD74 protein]
|
CTD |
PMID:23894361 PMID:35093514 PMID:35362542 |
|
NCBI chr18:56,527,071...56,536,406
Ensembl chr18:54,256,778...54,266,003
|
|
G
|
Cd79a
|
CD79a molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD79A mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 1:89,621,460...89,625,813
Ensembl chr 1:80,493,581...80,497,935
|
|
G
|
Cd79b
|
CD79b molecule
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CD79B mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr10:91,739,134...91,742,312
Ensembl chr10:91,239,356...91,242,625
|
|
G
|
Cd81
|
Cd81 molecule
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CD81 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:207,665,274...207,681,094
Ensembl chr 1:198,241,484...198,251,660
|
|
G
|
Cd86
|
CD86 molecule
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein] Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein
|
CTD |
PMID:29950665 PMID:38164749 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:64,163,828...64,200,818
|
|
G
|
Cda
|
cytidine deaminase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions decreases expression
|
ISO
|
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein
|
CTD |
PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G
|
Cdh2
|
cadherin 2
|
multiple interactions increases expression
|
ISO
|
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein
|
CTD |
PMID:34273909 PMID:36543318 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:7,776,704...7,990,167
|
|
G
|
Cdh5
|
cadherin 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:821,875...860,931
Ensembl chr19:815,411...854,368
|
|
G
|
Cdhr2
|
cadherin-related family member 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CDHR2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr17:9,881,979...9,917,698
Ensembl chr17:9,876,860...9,912,575
|
|
G
|
Cdk11b
|
cyclin-dependent kinase 11B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CDK11B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:166,212,761...166,238,883
Ensembl chr 5:166,212,829...166,238,876
|
|
G
|
Cdkn1c
|
cyclin-dependent kinase inhibitor 1C
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G
|
Cds2
|
CDP-diacylglycerol synthase 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CDS2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CDS2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:139,967,870...140,006,459
Ensembl chr 3:119,515,000...119,553,541
|
|
G
|
Cdx2
|
caudal type homeo box 2
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of CDX2 protein 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein]
|
CTD |
PMID:29680209 PMID:38663798 |
|
NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
|
|
G
|
Cebpd
|
CCAAT/enhancer binding protein delta
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CEBPD mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G
|
Cel
|
carboxyl ester lipase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G
|
Cep131
|
centrosomal protein 131
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CEP131 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:105,844,433...105,868,811
Ensembl chr10:105,346,015...105,370,380
|
|
G
|
Ces1d
|
carboxylesterase 1D
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA Dextran Sulfate results in decreased expression of CES1D mRNA
|
CTD |
PMID:29950665 PMID:35093514 PMID:35999755 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035
|
|
G
|
Ces2c
|
carboxylesterase 2C
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G
|
Ces2e
|
carboxylesterase 2E
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856
|
|
G
|
Cfap184
|
cilia and flagella associated protein 184
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CCDC96 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888
|
|
G
|
Cfap45
|
cilia and flagella associated protein 45
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CFAP45 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878
|
|
G
|
Cfb
|
complement factor B
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein
|
CTD |
PMID:35999755 |
|
NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,951,474...3,976,505
|
|
G
|
Cfd
|
complement factor D
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CFD protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:10,463,773...10,465,496
Ensembl chr 7:9,813,150...9,815,053
|
|
G
|
Cfh
|
complement factor H
|
multiple interactions increases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein] Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein
|
CTD |
PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755 |
|
NCBI chr13:54,063,079...54,164,523
Ensembl chr13:51,511,828...51,613,838
|
|
G
|
Cfl1
|
cofilin 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CFL1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:202,786,627...202,817,587
|
|
G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]
|
CTD |
PMID:25449198 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:60,185,452...60,237,034
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G
|
Cgref1
|
cell growth regulator with EF hand domain 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G
|
Chaf1a
|
chromatin assembly factor 1 subunit A
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CHAF1A mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:961,225...987,825
Ensembl chr 9:874,051...900,654
|
|
G
|
Cherp
|
calcium homeostasis endoplasmic reticulum protein
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]
|
CTD |
PMID:32272095 |
|
NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507
|
|
G
|
Chga
|
chromogranin A
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CHGA protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G
|
Chmp2a
|
charged multivesicular body protein 2A
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CHMP2A protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:82,731,212...82,735,088
Ensembl chr 1:73,660,046...73,662,452
|
|
G
|
Chmp4b
|
charged multivesicular body protein 4B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CHMP4B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:163,631,054...163,671,569
Ensembl chr 3:143,170,902...143,210,844
|
|
G
|
Chn2
|
chimerin 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709
|
|
G
|
Chordc1
|
cysteine and histidine rich domain containing 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CHORDC1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CHORDC1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:15,374,471...15,399,162
|
|
G
|
Chp1
|
calcineurin-like EF-hand protein 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CHP1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:106,536,004...106,571,251
|
|
G
|
Chrdl2
|
chordin-like 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CHRDL2 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
|
|
G
|
Chrm4
|
cholinergic receptor, muscarinic 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G
|
Chrna2
|
cholinergic receptor nicotinic alpha 2 subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G
|
Chrna7
|
cholinergic receptor nicotinic alpha 7 subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:116,714,711...116,837,240
|
|
G
|
Chrnb3
|
cholinergic receptor nicotinic beta 3 subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360
|
|
G
|
Chrne
|
cholinergic receptor nicotinic epsilon subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530
|
|
G
|
Chst11
|
carbohydrate sulfotransferase 11
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:22,412,121...22,630,577
Ensembl chr 7:20,528,100...20,743,111
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CHUK protein modified form notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]
|
CTD |
PMID:25472953 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:242,959,760...242,995,065
|
|
G
|
Cisd1
|
CDGSH iron sulfur domain 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CISD1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr20:17,255,302...17,268,688
Ensembl chr20:17,255,151...17,284,924
|
|
G
|
Ckb
|
creatine kinase B
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CKB protein
|
CTD |
PMID:35999755 |
|
NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:130,729,423...130,732,315
|
|
G
|
Ckm
|
creatine kinase, M-type
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CKM protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:88,189,382...88,199,717
Ensembl chr 1:79,061,456...79,071,720
|
|
G
|
Clca1
|
chloride channel accessory 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G
|
Clca4
|
chloride channel accessory 4
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CLCA4 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089
|
|
G
|
Clcn2
|
chloride voltage-gated channel 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:93,702,382...93,716,059
Ensembl chr11:80,198,153...80,211,657
|
|
G
|
Clcn3
|
chloride voltage-gated channel 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G
|
Cldn1
|
claudin 1
|
multiple interactions decreases expression increases expression
|
ISO
|
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; isomaltulose inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 mRNA]; nuciferine inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein] Dextran Sulfate results in decreased expression of CLDN1 mRNA; Dextran Sulfate results in decreased expression of CLDN1 protein
|
CTD |
PMID:27920472 PMID:35894244 PMID:36543318 PMID:36577154 PMID:37001609 PMID:38648921 More...
|
|
NCBI chr11:87,926,376...87,941,533
Ensembl chr11:74,421,569...74,436,724
|
|
G
|
Cldn11
|
claudin 11
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:112,207,745...112,221,050
|
|
G
|
Cldn2
|
claudin 2
|
multiple interactions increases expression
|
ISO
|
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein
|
CTD |
PMID:26271895 PMID:29680209 PMID:36543318 |
|
NCBI chr X:108,248,383...108,258,847
Ensembl chr X:103,459,780...103,474,838
|
|
G
|
Clec10a
|
C-type lectin domain containing 10A
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CLEC10A mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435
|
|
G
|
Clic1
|
chloride intracellular channel 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CLIC1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G
|
Clpp
|
caseinolytic mitochondrial matrix peptidase proteolytic subunit
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CLPP protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CLPP protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 9:1,831,680...1,837,700
Ensembl chr 9:1,830,311...1,837,693
|
|
G
|
Cma1
|
chymase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:33,387,351...33,390,133
Ensembl chr15:29,417,451...29,420,233
|
|
G
|
Cmas
|
cytidine monophosphate N-acetylneuraminic acid synthetase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125
|
|
G
|
Cmpk1
|
cytidine/uridine monophosphate kinase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CMPK1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 5:128,480,301...128,507,830
Ensembl chr 5:128,480,301...128,507,830
|
|
G
|
Cnga4
|
cyclic nucleotide gated channel subunit alpha 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:159,752,357...159,756,369
Ensembl chr 1:159,752,357...159,756,375
|
|
G
|
Cnn2
|
calponin 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CNN2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:10,363,141...10,370,312
Ensembl chr 7:9,712,516...9,719,656
|
|
G
|
Cnr1
|
cannabinoid receptor 1
|
decreases response to substance multiple interactions increases expression
|
ISO
|
CNR1 results in decreased susceptibility to Dextran Sulfate SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]
|
CTD |
PMID:15085199 PMID:27920472 PMID:30611738 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G
|
Cnr2
|
cannabinoid receptor 2
|
multiple interactions increases expression affects response to substance increases response to substance
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein] CNR2 protein affects the susceptibility to Dextran Sulfate CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate
|
CTD |
PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:148,125,604...148,151,548
|
|
G
|
Cntfr
|
ciliary neurotrophic factor receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:61,619,326...61,657,359
Ensembl chr 5:56,823,965...56,841,392
|
|
G
|
Cntn1
|
contactin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G
|
Cog1
|
component of oligomeric golgi complex 1
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr10:98,695,481...98,708,495
Ensembl chr10:98,695,423...98,709,292
|
|
G
|
Col11a1
|
collagen type XI alpha 1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G
|
Col14a1
|
collagen type XIV alpha 1 chain
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G
|
Col16a1
|
collagen type XVI alpha 1 chain
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of COL16A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825
|
|
G
|
Col18a1
|
collagen type XVIII alpha 1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA Dextran Sulfate results in decreased expression of COL1A1 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G
|
Col1a2
|
collagen type I alpha 2 chain
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of COL1A2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:32,563,381...32,598,867
|
|
G
|
Col22a1
|
collagen type XXII alpha 1 chain
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of COL22A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462
|
|
G
|
Col23a1
|
collagen type XXIII alpha 1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314
|
|
G
|
Col28a1
|
collagen type XXVIII alpha 1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:36,069,980...36,223,128
Ensembl chr 4:36,069,970...36,223,220
|
|
G
|
Col3a1
|
collagen type III alpha 1 chain
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of COL3A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547
|
|
G
|
Col4a1
|
collagen type IV alpha 1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:84,885,597...84,996,482
Ensembl chr16:78,183,533...78,294,412
|
|
G
|
Col4a2
|
collagen type IV alpha 2 chain
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr16:84,749,672...84,885,520
Ensembl chr16:78,047,602...78,183,839
|
|
G
|
Col5a1
|
collagen type V alpha 1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G
|
Col5a2
|
collagen type V alpha 2 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G
|
Col6a1
|
collagen type VI alpha 1 chain
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COL6A1 protein] Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein
|
CTD |
PMID:32272095 PMID:35093514 PMID:35362542 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G
|
Col6a2
|
collagen type VI alpha 2 chain
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COL6A2 protein]
|
CTD |
PMID:32272095 PMID:35093514 PMID:35362542 |
|
NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,767...12,057,564
|
|
G
|
Col6a3
|
collagen type VI alpha 3 chain
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COL6A3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:91,361,583...91,439,471
|
|
G
|
Col8a1
|
collagen type VIII alpha 1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G
|
Colgalt1
|
collagen beta(1-O)galactosyltransferase 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COLGALT1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr16:18,319,796...18,332,106
Ensembl chr16:18,319,795...18,332,106
|
|
G
|
Copz1
|
COPI coat complex subunit zeta 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COPZ1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:134,409,523...134,435,661
Ensembl chr 7:134,409,799...134,435,662
|
|
G
|
Coq6
|
coenzyme Q6 monooxygenase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of COQ6 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COQ6 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:104,007,814...104,019,888
Ensembl chr 6:104,007,872...104,024,657
|
|
G
|
Coro1a
|
coronin 1A
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CORO1A protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:190,726,129...190,731,133
Ensembl chr 1:181,295,562...181,300,534
|
|
G
|
Coro1c
|
coronin 1C
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CORO1C protein
|
CTD |
PMID:35999755 |
|
NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179
|
|
G
|
Cotl1
|
coactosin-like F-actin binding protein 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of COTL1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G
|
Cox17
|
cytochrome c oxidase copper chaperone COX17
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of COX17 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COX17 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr11:62,400,733...62,406,507
|
|
G
|
Cox5b
|
cytochrome c oxidase subunit 5B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of COX5B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:46,417,735...46,419,664
Ensembl chr 9:38,921,967...38,925,052
|
|
G
|
Cox7a2
|
cytochrome c oxidase subunit 7A2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of COX7A2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COX7A2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 8:89,597,051...89,611,032
Ensembl chr14:51,301,168...51,301,633 Ensembl chr 8:51,301,168...51,301,633
|
|
G
|
Cp
|
ceruloplasmin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:102,439,624...102,498,075
|
|
G
|
Cpa1
|
carboxypeptidase A1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544
|
|
G
|
Cpb2
|
carboxypeptidase B2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:56,967,128...57,015,964
Ensembl chr15:50,557,717...50,606,556
|
|
G
|
Cpne1
|
copine 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CPNE1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:144,587,531...144,629,911
Ensembl chr 3:144,588,995...144,598,636
|
|
G
|
Cr2
|
complement C3d receptor 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CR2 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr13:109,207,034...109,244,980
Ensembl chr13:106,685,413...106,716,235
|
|
G
|
Cracd
|
capping protein inhibiting regulator of actin dynamics
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CRACD mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431
|
|
G
|
Crhr1
|
corticotropin releasing hormone receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G
|
Crhr2
|
corticotropin releasing hormone receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G
|
Crisp1
|
cysteine-rich secretory protein 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CRISP1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 9:20,741,775...20,768,796
Ensembl chr 9:20,741,777...20,768,796
|
|
G
|
Crtap
|
cartilage associated protein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G
|
Csf1
|
colony stimulating factor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:195,377,215...195,411,704
|
|
G
|
Csf2
|
colony stimulating factor 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]
|
CTD |
PMID:15652231 PMID:29950665 PMID:31442584 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G
|
Csf2rb
|
colony stimulating factor 2 receptor subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:111,756,950...111,782,089
Ensembl chr 7:109,886,425...109,904,157
|
|
G
|
Csf3
|
colony stimulating factor 3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CSF3 mRNA Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]
|
CTD |
PMID:32033881 |
|
NCBI chr10:84,157,485...84,159,860
Ensembl chr10:83,661,207...83,663,603
|
|
G
|
Csf3r
|
colony stimulating factor 3 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:143,583,126...143,604,382
Ensembl chr 5:138,301,506...138,317,881
|
|
G
|
Csnk1a1
|
casein kinase 1, alpha 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CSNK1A1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CSNK1A1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:57,285,156...57,320,540
Ensembl chr18:55,017,055...55,049,271
|
|
G
|
Cth
|
cystathionine gamma-lyase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CTH protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CTH protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G
|
Ctnnb1
|
catenin beta 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of CTNNB1 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]
|
CTD |
PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G
|
Ctps1
|
CTP synthase 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CTPS1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G
|
Ctsc
|
cathepsin C
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CTSC mRNA; Dextran Sulfate results in decreased expression of CTSC protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CTSC protein]
|
CTD |
PMID:35093514 PMID:35362542 |
|
NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:142,028,392...142,060,387
|
|
G
|
Ctsd
|
cathepsin D
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:197,527,467...197,539,488
|
|
G
|
Ctsk
|
cathepsin K
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:183,058,569...183,069,550
|
|
G
|
Ctsl
|
cathepsin L
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA
|
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr17:770,104...776,266
Ensembl chr17:764,309...770,548
|
|
G
|
Ctss
|
cathepsin S
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:185,775,316...185,803,440
Ensembl chr 2:183,086,437...183,114,483
|
|
G
|
Cubn
|
cubilin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231
|
|
G
|
Cx3cr1
|
C-X3-C motif chemokine receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G
|
Cxadr
|
CXADR, Ig-like cell adhesion molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:30,469,778...30,516,990
Ensembl chr11:16,982,860...17,030,046
|
|
G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]
|
CTD |
PMID:25026504 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CXCL12 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168
|
|
G
|
Cxcl13
|
C-X-C motif chemokine ligand 13
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CXCL13 mRNA
|
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G
|
Cxcl14
|
C-X-C motif chemokine ligand 14
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
multiple interactions increases expression
|
ISO
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein] Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein
|
CTD |
PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
multiple interactions increases expression increases secretion
|
ISO
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein] Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein
|
CTD |
PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 PMID:31807802 PMID:34273909 PMID:34998820 PMID:36519841 More...
|
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G
|
Cxcl6
|
C-X-C motif chemokine ligand 6
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA Dextran Sulfate results in increased expression of CXCL5 mRNA
|
CTD |
PMID:19645018 PMID:29950665 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G
|
Cxcl9
|
C-X-C motif chemokine ligand 9
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CXCL9 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G
|
Cxcr2
|
C-X-C motif chemokine receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G
|
Cyba
|
cytochrome b-245 alpha chain
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CYBA protein
|
CTD |
PMID:20637373 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G
|
Cybb
|
cytochrome b-245 beta chain
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein
|
CTD |
PMID:20637373 PMID:23894361 |
|
NCBI chr X:16,030,596...16,065,065
Ensembl chr X:13,359,430...13,392,586
|
|
G
|
Cyfip1
|
cytoplasmic FMR1 interacting protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386
|
|
G
|
Cyfip2
|
cytoplasmic FMR1 interacting protein 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
|
|
G
|
Cygb
|
cytoglobin
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of CYGB protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CYGB protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:102,376,506...102,386,272
Ensembl chr10:101,877,676...101,887,442
|
|
G
|
Cyp11a1
|
cytochrome P450, family 11, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CYP11A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G
|
Cyp17a1
|
cytochrome P450, family 17, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CYP17A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions decreases expression
|
ISO
|
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein
|
CTD |
PMID:29680209 PMID:34998820 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions decreases activity
|
EXP
|
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen
|
CTD |
PMID:28438436 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G
|
Cyp24a1
|
cytochrome P450, family 24, subfamily a, polypeptide 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of CYP24A1 protein
|
CTD |
PMID:38588969 |
|
NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:159,275,947...159,290,383
|
|
G
|
Cyp26b1
|
cytochrome P450, family 26, subfamily b, polypeptide 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CYP26B1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:117,041,808...117,058,628
|
|
G
|
Cyp27b1
|
cytochrome P450, family 27, subfamily b, polypeptide 1
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA Dextran Sulfate results in decreased expression of CYP27B1 protein
|
CTD |
PMID:29950665 PMID:38588969 |
|
NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:62,871,297...62,876,241
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
decreases activity multiple interactions
|
EXP
|
Dextran Sulfate results in decreased activity of CYP2B1 protein [Dextran Sulfate results in decreased activity of CYP2B1 protein] which results in decreased chemical synthesis of hydroxybupropion
|
CTD |
PMID:28438436 |
|
NCBI chr 1:90,646,098...90,669,762
Ensembl chr 1:81,518,408...81,542,052
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:90,722,243...90,736,272
Ensembl chr 1:81,594,555...81,608,566
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G
|
Cyp2c24
|
cytochrome P450, family 2, subfamily c, polypeptide 24
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G
|
Cyp2c66
|
cytochrome P450, family 2, subfamily c, polypeptide 66
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
decreases activity multiple interactions
|
EXP
|
Dextran Sulfate results in decreased activity of CYP2E1 protein [Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone
|
CTD |
PMID:28438436 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G
|
Cyp2j4
|
cytochrome P450, family 2, subfamily j, polypeptide 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:111,178,703...111,244,794
|
|
G
|
Cyp2r1
|
cytochrome P450, family 2, subfamily r, polypeptide 1
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein]
|
CTD |
PMID:29950665 PMID:38588969 |
|
NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759
|
|
G
|
Cyp2s1
|
cytochrome P450, family 2, subfamily s, polypeptide 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422
|
|
G
|
Cyp4b1
|
cytochrome P450, family 4, subfamily b, polypeptide 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G
|
Cyp4f1
|
cytochrome P450, family 4, subfamily f, polypeptide 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:12,661,357...12,672,952
Ensembl chr 7:12,010,852...12,022,046
|
|
G
|
Cyp4f39
|
cytochrome P450, family 4, subfamily f, polypeptide 39
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of CYP7A1 mRNA
|
CTD |
PMID:27580383 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G
|
Cyp7b1
|
cytochrome P450 family 7 subfamily B member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G
|
Dapk3
|
death-associated protein kinase 3
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DAPK3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:8,524,182...8,532,552
Ensembl chr 7:8,524,183...8,532,558
|
|
G
|
Dbt
|
dihydrolipoamide branched chain transacylase E2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of DBT protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609
|
|
G
|
Dcn
|
decorin
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:32,281,252...32,321,270
|
|
G
|
Dctn3
|
dynactin subunit 3
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DCTN3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:61,676,950...61,684,958
Ensembl chr 5:56,881,085...56,889,102
|
|
G
|
Ddr2
|
discoidin domain receptor tyrosine kinase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:84,726,412...84,851,032
Ensembl chr13:82,195,463...82,317,363
|
|
G
|
Ddx23
|
DEAD-box helicase 23
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of DDX23 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of DDX23 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:129,797,620...129,814,909
Ensembl chr 7:129,797,614...129,814,949
|
|
G
|
Depp1
|
DEPP autophagy regulator 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of DEPP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G
|
Dgkb
|
diacylglycerol kinase, beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:60,368,101...61,124,420
Ensembl chr 6:54,641,614...55,397,043
|
|
G
|
Dgki
|
diacylglycerol kinase, iota
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733
|
|
G
|
Dhcr24
|
24-dehydrocholesterol reductase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of DHCR24 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:121,344,575...121,371,137
|
|
G
|
Dhdh
|
dihydrodiol dehydrogenase
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of DHDH protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DHDH protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:95,954,361...95,965,262
Ensembl chr 1:95,953,092...95,965,197
|
|
G
|
Dhodh
|
dihydroorotate dehydrogenase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of DHODH protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of DHODH protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
|
|
G
|
Dhrs9
|
dehydrogenase/reductase 9
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of DHRS9 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 3:74,553,357...74,579,535
Ensembl chr 3:54,147,803...54,220,241
|
|
G
|
Dhrsx
|
dehydrogenase/reductase X-linked
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of DHRSX mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr12:16,299,768...16,304,553
Ensembl chr12:16,299,808...16,304,552
|
|
G
|
Diaph1
|
diaphanous-related formin 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of DIAPH1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:29,669,659...29,769,070
Ensembl chr18:29,669,659...29,769,172
|
|
G
|
Dkk2
|
dickkopf WNT signaling pathway inhibitor 2
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225
|
|
G
|
Dlk1
|
delta like non-canonical Notch ligand 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:128,410,316...128,417,522
|
|
G
|
Dmpk
|
DM1 protein kinase
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593
|
|
G
|
Dmrta1
|
DMRT-like family A1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of DMRTA1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:104,415,893...104,422,433
Ensembl chr 5:104,415,893...104,422,433
|
|
G
|
Dmwd
|
DM1 locus, WD repeat containing
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of DMWD mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:78,722,436...78,729,224
Ensembl chr 1:78,722,330...78,740,593
|
|
G
|
Dnajb4
|
DnaJ heat shock protein family (Hsp40) member B4
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of DNAJB4 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DNAJB4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G
|
Dnajc10
|
DnaJ heat shock protein family (Hsp40) member C10
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of DNAJC10 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719
|
|
G
|
Dnm1
|
dynamin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:36,002,535...36,055,220
Ensembl chr 3:15,604,784...15,648,538
|
|
G
|
Dnm3
|
dynamin 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:76,892,381...77,371,346
Ensembl chr13:74,359,213...74,838,108
|
|
G
|
Dock1
|
dedicator of cyto-kinesis 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of DOCK1 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DOCK1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:189,467,143...189,983,777
Ensembl chr 1:189,467,143...189,983,768
|
|
G
|
Dok2
|
docking protein 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:45,826,984...45,841,409
Ensembl chr15:45,827,398...45,841,402
|
|
G
|
Dpep1
|
dipeptidase 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of DPEP1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]
|
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257
|
|
G
|
Dpep2
|
dipeptidase 2
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA
|
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954
|
|
G
|
Dpyd
|
dihydropyrimidine dehydrogenase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G
|
Drap1
|
Dr1 associated protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of DRAP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:202,731,775...202,734,468
Ensembl chr 1:202,731,788...202,734,425
|
|
G
|
Drd4
|
dopamine receptor D4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:196,396,366...196,399,553
|
|
G
|
Drd5
|
dopamine receptor D5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774
|
|
G
|
Dtx1
|
deltex E3 ubiquitin ligase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:41,510,252...41,541,433
Ensembl chr12:35,849,617...35,880,838
|
|
G
|
Duoxa2
|
dual oxidase maturation factor 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of DUOXA2 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 3:109,245,337...109,249,055
Ensembl chr 3:109,245,476...109,248,968
|
|
G
|
Dusp1
|
dual specificity phosphatase 1
|
multiple interactions increases expression
|
ISO
|
DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate] Dextran Sulfate results in increased expression of DUSP1 mRNA
|
CTD |
PMID:30844440 PMID:35093514 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G
|
Eci1
|
enoyl-CoA delta isomerase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G
|
Ecpas
|
Ecm29 proteasome adaptor and scaffold
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ECPAS protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ECPAS protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860
|
|
G
|
Eda
|
ectodysplasin-A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172
|
|
G
|
Eda2r
|
ectodysplasin A2 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268
|
|
G
|
Edf1
|
endothelial differentiation-related factor 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of EDF1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:8,377,058...8,381,363
Ensembl chr 3:8,366,613...8,381,363
|
|
G
|
Edn1
|
endothelin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885
|
|
G
|
Edn2
|
endothelin 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of EDN2 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA
|
CTD |
PMID:16216902 PMID:29950665 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G
|
Ednra
|
endothelin receptor type A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:47,137,360...47,207,961
Ensembl chr19:30,233,571...30,297,049
|
|
G
|
Eef1g
|
eukaryotic translation elongation factor 1 gamma
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of EEF1G protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G
|
Efemp2
|
EGF containing fibulin extracellular matrix protein 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414
|
|
G
|
Efhd2
|
EF-hand domain family, member D2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of EFHD2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980
|
|
G
|
Efna1
|
ephrin A1
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:174,681,682...174,690,866
|
|
G
|
Egln2
|
egl-9 family hypoxia-inducible factor 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of EGLN2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:82,451,554...82,459,809
Ensembl chr 1:82,451,555...82,459,751
|
|
G
|
Ehd1
|
EH-domain containing 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of EHD1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212
|
|
G
|
Ehd4
|
EH-domain containing 4
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein Dextran Sulfate results in decreased expression of EHD4 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:127,511,973...127,575,856
Ensembl chr 3:107,058,958...107,122,002
|
|
G
|
Ehhadh
|
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:92,746,409...92,779,647
Ensembl chr11:79,241,938...79,275,188
|
|
G
|
Ehmt2
|
euchromatic histone lysine methyltransferase 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of EHMT2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G
|
Eif2ak2
|
eukaryotic translation initiation factor 2-alpha kinase 2
|
multiple interactions increases phosphorylation
|
ISO
|
EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]
|
CTD |
PMID:27920257 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G
|
Eif2b5
|
eukaryotic translation initiation factor 2B subunit epsilon
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of EIF2B5 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of EIF2B5 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr11:93,898,814...93,909,431
Ensembl chr11:80,394,433...80,404,419
|
|
G
|
Eif3a
|
eukaryotic translation initiation factor 3, subunit A
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976
|
|
G
|
Eif5a
|
eukaryotic translation initiation factor 5A
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of EIF5A protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:55,138,821...55,143,272
Ensembl chr10:54,640,024...54,644,656
|
|
G
|
Eif5b
|
eukaryotic translation initiation factor 5B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of EIF5B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G
|
Elane
|
elastase, neutrophil expressed
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G
|
Elmo2
|
engulfment and cell motility 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185
|
|
G
|
Emc2
|
ER membrane protein complex subunit 2
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 7:74,587,196...74,624,163
Ensembl chr 7:74,587,175...74,625,189
|
|
G
|
Emp2
|
epithelial membrane protein 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of EMP2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733
|
|
G
|
Eng
|
endoglin
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ENG mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:15,934,518...15,973,230
|
|
G
|
Eno1
|
enolase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ENO1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 5:166,002,867...166,014,252
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G
|
Eno2
|
enolase 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ENO2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:157,572,088...157,580,980
|
|
G
|
Eno3
|
enolase 3
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]
|
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr10:55,868,880...55,876,099
Ensembl chr10:55,366,975...55,375,921
|
|
G
|
Enpep
|
glutamyl aminopeptidase
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:217,781,985...217,851,947
Ensembl chr 2:217,782,005...217,851,947
|
|
G
|
Entpd5
|
ectonucleoside triphosphate diphosphohydrolase 5
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530
|
|
G
|
Ep300
|
E1A binding protein p300
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G
|
Ephx1
|
epoxide hydrolase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of EPHX1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr13:95,246,079...95,275,852
Ensembl chr13:92,714,315...92,790,235
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,411,313...83,435,078
|
|
G
|
Erbb3
|
erb-b2 receptor tyrosine kinase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:996,225...1,015,525
|
|
G
|
Erbb4
|
erb-b2 receptor tyrosine kinase 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G
|
Ereg
|
epiregulin
|
decreases response to substance increases expression
|
ISO
|
EREG protein results in decreased susceptibility to Dextran Sulfate dextran sodium sulfate increases expression of Ereg protein in colonic mucosa
|
CTD RGD |
PMID:15456865 PMID:20498653 |
RGD:39457688 |
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,027,287...17,041,062
|
|
G
|
Ermp1
|
endoplasmic reticulum metallopeptidase 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ERMP1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:227,383,992...227,422,120
Ensembl chr 1:227,387,920...227,436,909
|
|
G
|
Ero1a
|
endoplasmic reticulum oxidoreductase 1 alpha
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ERO1A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G
|
Errfi1
|
ERBB receptor feedback inhibitor 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of ERRFI1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G
|
Esam
|
endothelial cell adhesion molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:45,426,985...45,437,976
Ensembl chr 8:37,238,287...37,249,215
|
|
G
|
Esr1
|
estrogen receptor 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ESR1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA
|
CTD |
PMID:29950665 PMID:30270565 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G
|
Esr2
|
estrogen receptor 2
|
multiple interactions
|
ISO
|
Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]
|
CTD |
PMID:30270565 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G
|
Evl
|
Enah/Vasp-like
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:127,473,119...127,594,342
Ensembl chr 6:127,474,543...127,594,344
|
|
G
|
Ewsr1
|
EWS RNA-binding protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of EWSR1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544
|
|
G
|
F10
|
coagulation factor X
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:83,170,973...83,190,280
Ensembl chr16:76,468,838...76,488,141
|
|
G
|
F11
|
coagulation factor XI
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein
|
CTD |
PMID:35999755 |
|
NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437
|
|
G
|
F11r
|
F11 receptor
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of F11R protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of F11R protein]
|
CTD |
PMID:35362542 |
|
NCBI chr13:86,406,229...86,429,819
Ensembl chr13:83,873,797...83,897,402
|
|
G
|
F13a1
|
coagulation factor XIII A1 chain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:28,021,197...28,197,960
Ensembl chr17:27,815,702...27,992,700
|
|
G
|
F2r
|
coagulation factor II (thrombin) receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:26,868,404...26,885,870
|
|
G
|
F2rl1
|
F2R like trypsin receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:26,772,278...26,785,226
|
|
G
|
F5
|
coagulation factor V
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:79,046,657...79,116,247
Ensembl chr13:76,513,255...76,582,317
|
|
G
|
Faah
|
fatty acid amide hydrolase
|
multiple interactions
|
ISO
|
[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein
|
CTD |
PMID:30611738 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G
|
Fabp4
|
fatty acid binding protein 4
|
multiple interactions increases expression
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]
|
CTD |
PMID:26271895 PMID:32272095 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G
|
Fabp5
|
fatty acid binding protein 5
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of FABP5 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:91,765,056...91,853,773
|
|
G
|
Fabp6
|
fatty acid binding protein 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G
|
Fads1
|
fatty acid desaturase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of FADS1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:206,827,765...206,842,734
|
|
G
|
Fads2
|
fatty acid desaturase 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of FADS2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:206,708,783...206,748,789
|
|
G
|
Fam136a
|
family with sequence similarity 136, member A
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of FAM136A protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of FAM136A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:118,805,129...118,811,046
Ensembl chr 4:118,805,127...118,811,047
|
|
G
|
Fam229a
|
family with sequence similarity 229, member A
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FAM229A mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:141,829,716...141,830,705
Ensembl chr 5:141,828,664...141,830,705
|
|
G
|
Fam234a
|
family with sequence similarity 234, member A
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of FAM234A protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of FAM234A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:15,232,267...15,263,529
Ensembl chr10:15,232,278...15,263,488
|
|
G
|
Fam50b
|
family with sequence similarity 50, member B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FAM50B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr17:30,174,431...30,193,627
Ensembl chr17:30,174,411...30,193,615
|
|
G
|
Fam98b
|
family with sequence similarity 98, member B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FAM98B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:104,134,803...104,164,249
Ensembl chr 3:104,134,824...104,163,704
|
|
G
|
Fau
|
FAU ubiquitin like and ribosomal protein S30 fusion
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742 Ensembl chr 1:203,350,189...203,351,742 Ensembl chr 6:203,350,189...203,351,742
|
|
G
|
Fblim1
|
filamin binding LIM protein 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of FBLIM1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:153,883,945...153,915,524
Ensembl chr 5:153,883,960...153,913,757
|
|
G
|
Fbln2
|
fibulin 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
|
|
G
|
Fbln5
|
fibulin 5
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA Dextran Sulfate results in decreased expression of FBLN5 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755
|
|
G
|
Fbn1
|
fibrillin 1
|
multiple interactions decreases expression increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of FBN1 protein]
|
CTD |
PMID:29950665 PMID:32272095 PMID:35362542 |
|
NCBI chr 3:133,007,693...133,204,277
Ensembl chr 3:112,554,925...112,750,889
|
|
G
|
Fbxo2
|
F-box protein 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FBXO2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:158,592,925...158,598,355
|
|
G
|
Fcer1g
|
Fc epsilon receptor Ig
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:86,181,908...86,186,766
Ensembl chr13:83,649,449...83,671,443
|
|
G
|
Fcgr1a
|
Fc gamma receptor 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:186,539,941...186,548,941
Ensembl chr 2:183,851,077...183,859,994
|
|
G
|
Fcgr2a
|
Fc gamma receptor 2A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:85,813,516...85,830,269
Ensembl chr13:83,280,784...83,295,967
|
|
G
|
Fcgr2b
|
Fc gamma receptor 2B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:85,725,897...85,740,517
Ensembl chr13:83,193,163...83,207,778
|
|
G
|
Fcgr3a
|
Fc gamma receptor 3A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921
|
|
G
|
Fcsk
|
fucose kinase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FCSK mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:38,849,130...38,874,497
Ensembl chr19:38,854,762...38,874,418
|
|
G
|
Fdx1
|
ferredoxin 1
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of FDX1 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 8:61,164,839...61,183,645
Ensembl chr 8:52,268,536...52,287,414
|
|
G
|
Fdxr
|
ferredoxin reductase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of FDXR mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:101,006,845...101,015,582
Ensembl chr10:100,507,865...100,516,658
|
|
G
|
Fermt3
|
FERM domain containing kindlin 3
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of FERMT3 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein] Dextran Sulfate results in decreased expression of FERMT3 protein
|
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr 1:204,189,483...204,207,683
Ensembl chr 1:204,189,484...204,207,587
|
|
G
|
Ffar2
|
free fatty acid receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:86,071,855...86,075,049
Ensembl chr 1:86,072,184...86,075,033
|
|
G
|
Ffar4
|
free fatty acid receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:235,873,576...235,891,597
Ensembl chr 1:235,873,576...235,891,597
|
|
G
|
Fga
|
fibrinogen alpha chain
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of FGA protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:168,374,120...168,381,528
|
|
G
|
Fgf18
|
fibroblast growth factor 18
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:18,210,240...18,241,929
Ensembl chr10:17,706,174...17,736,818
|
|
G
|
Fgf19
|
fibroblast growth factor 19
|
multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein
|
CTD |
PMID:27580383 |
|
NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:200,056,644...200,060,287
|
|
G
|
Fgf2
|
fibroblast growth factor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G
|
Fgf23
|
fibroblast growth factor 23
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:161,600,439...161,609,991
Ensembl chr 4:159,914,272...159,923,821
|
|
G
|
Fgf8
|
fibroblast growth factor 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:244,584,652...244,590,359
|
|
G
|
Fgf9
|
fibroblast growth factor 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:36,325,552...36,369,995
Ensembl chr15:32,210,074...32,253,309
|
|
G
|
Fgfr1
|
Fibroblast growth factor receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:73,194,631...73,249,855
Ensembl chr16:66,494,042...66,547,350
|
|
G
|
Fgfr4
|
fibroblast growth factor receptor 4
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FGFR4 mRNA
|
CTD |
PMID:27580383 |
|
NCBI chr17:9,466,686...9,481,423
Ensembl chr17:9,461,547...9,476,242
|
|
G
|
Fgl1
|
fibrinogen-like 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FGL1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093
|
|
G
|
Fhl1
|
four and a half LIM domains 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G
|
Fhl2
|
four and a half LIM domains 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of FHL2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G
|
Fhl3
|
four and a half LIM domains 3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of FHL3 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 5:136,953,947...136,961,317
Ensembl chr 5:136,950,411...136,961,317
|
|
G
|
Flna
|
filamin A
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein
|
CTD |
PMID:35999755 |
|
NCBI chr X:157,159,051...157,185,559
Ensembl chr X:152,007,758...152,031,052
|
|
G
|
Flot2
|
flotillin 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of FLOT2 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr10:63,424,084...63,445,811
Ensembl chr10:62,920,665...62,947,756
|
|
G
|
Flt1
|
Fms related receptor tyrosine kinase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:7,297,292...7,468,626
|
|
G
|
Flt4
|
Fms related receptor tyrosine kinase 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G
|
Fmo1
|
flavin containing dimethylaniline monoxygenase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G
|
Fmod
|
fibromodulin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133
|
|
G
|
Fn1
|
fibronectin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:73,196,044...73,264,678
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO
|
Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]] Dextran Sulfate results in increased expression of FOS mRNA
|
CTD |
PMID:18687398 PMID:35093514 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G
|
Fosl1
|
FOS like 1, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FOSL1 protein
|
CTD |
PMID:20025956 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:202,754,529...202,764,930
|
|
G
|
Foxa2
|
forkhead box A2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:155,923,305...155,927,508
Ensembl chr 3:135,470,131...135,474,326
|
|
G
|
Foxa3
|
forkhead box A3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:78,662,431...78,672,155
|
|
G
|
Foxo1
|
forkhead box O1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein
|
CTD |
PMID:35670535 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790
|
|
G
|
Foxo3
|
forkhead box O3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561
|
|
G
|
Foxo4
|
forkhead box O4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:70,425,218...70,432,120
Ensembl chr X:66,385,558...66,392,115
|
|
G
|
Foxp3
|
forkhead box P3
|
increases methylation multiple interactions increases expression
|
ISO EXP
|
Dextran Sulfate results in increased methylation of FOXP3 gene Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene] kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]
|
CTD |
PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820 |
|
NCBI chr X:17,580,380...17,601,181
Ensembl chr X:14,908,494...14,923,838
|
|
G
|
Fpgt
|
fucose-1-phosphate guanylyltransferase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899
|
|
G
|
Fpr1
|
formyl peptide receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:67,417,991...67,429,813
Ensembl chr 1:58,747,246...58,756,559
|
|
G
|
Fpr2
|
formyl peptide receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:67,449,637...67,458,272
Ensembl chr 1:58,776,752...58,786,019
|
|
G
|
Fpr3
|
formyl peptide receptor 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:58,884,427...58,893,472
Ensembl chr 1:58,845,118...58,893,467
|
|
G
|
Frat2
|
FRAT regulator of WNT signaling pathway 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FRAT2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:250,603,450...250,605,779
Ensembl chr 1:240,654,137...240,656,517
|
|
G
|
Fshb
|
follicle stimulating hormone subunit beta
|
multiple interactions decreases expression
|
ISO
|
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]
|
CTD |
PMID:28421826 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G
|
Fshr
|
follicle stimulating hormone receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G
|
Fst
|
follistatin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:46,123,439...46,130,571
|
|
G
|
Fstl3
|
follistatin like 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:10,574,195...10,579,844
Ensembl chr 7:9,923,576...9,939,639
|
|
G
|
Fuca1
|
alpha-L-fucosidase 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of FUCA1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:148,152,718...148,169,972
Ensembl chr 5:148,152,700...148,169,972
|
|
G
|
Fus
|
Fus RNA binding protein
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of FUS mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414
|
|
G
|
Fxyd1
|
FXYD domain-containing ion transport regulator 1
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA Dextran Sulfate results in decreased expression of FXYD1 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278
|
|
G
|
Fxyd3
|
FXYD domain-containing ion transport regulator 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:86,305,531...86,312,455
|
|
G
|
Fxyd4
|
FXYD domain-containing ion transport regulator 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637
|
|
G
|
Fyn
|
FYN proto-oncogene, Src family tyrosine kinase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:44,322,635...44,514,498
Ensembl chr20:42,766,369...42,959,911
|
|
G
|
Fzd1
|
frizzled class receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:30,265,074...30,269,472
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G
|
Fzd4
|
frizzled class receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:143,279,934...143,288,799
Ensembl chr 1:143,280,065...143,285,724
|
|
G
|
Fzd5
|
frizzled class receptor 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:66,113,112...66,121,457
|
|
G
|
Fzd6
|
frizzled class receptor 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:70,055,012...70,086,781
Ensembl chr 7:70,055,068...70,086,776
|
|
G
|
Fzd7
|
frizzled class receptor 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:60,930,875...60,935,781
|
|
G
|
Fzd8
|
frizzled class receptor 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:62,007,849...62,015,485
Ensembl chr17:57,314,450...57,320,650
|
|
G
|
G6pc1
|
glucose-6-phosphatase catalytic subunit 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G
|
Gabbr1
|
gamma-aminobutyric acid type B receptor subunit 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994
|
|
G
|
Gabra2
|
gamma-aminobutyric acid type A receptor subunit alpha 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944
|
|
G
|
Gabra5
|
gamma-aminobutyric acid type A receptor subunit alpha 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917
|
|
G
|
Gabrb2
|
gamma-aminobutyric acid type A receptor subunit beta 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G
|
Gabrd
|
gamma-aminobutyric acid type A receptor subunit delta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411
|
|
G
|
Gad1
|
glutamate decarboxylase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G
|
Gale
|
UDP-galactose-4-epimerase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G
|
Galk1
|
galactokinase 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of GALK1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GALK1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:101,243,146...101,247,323
Ensembl chr10:101,235,994...101,247,337
|
|
G
|
Galk2
|
galactokinase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:113,110,057...113,243,014
Ensembl chr 3:113,110,030...113,233,306
|
|
G
|
Galm
|
galactose mutarotase
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GALM mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 6:14,837,540...14,889,484
Ensembl chr 6:14,837,548...14,889,310
|
|
G
|
Galnt1
|
polypeptide N-acetylgalactosaminyltransferase 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GALNT1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G
|
Galnt10
|
polypeptide N-acetylgalactosaminyltransferase 10
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:42,321,691...42,468,087
Ensembl chr10:41,820,158...41,967,013
|
|
G
|
Galnt12
|
polypeptide N-acetylgalactosaminyltransferase 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:61,384,575...61,413,346
Ensembl chr 5:61,384,571...61,413,354
|
|
G
|
Galnt15
|
polypeptide N-acetylgalactosaminyltransferase 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
|
|
G
|
Galnt16
|
polypeptide N-acetylgalactosaminyltransferase 16
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705
|
|
G
|
Galnt18
|
polypeptide N-acetylgalactosaminyltransferase 18
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:165,593,180...165,904,268
Ensembl chr 1:165,593,187...165,904,268
|
|
G
|
Galnt2
|
polypeptide N-acetylgalactosaminyltransferase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G
|
Galnt3
|
polypeptide N-acetylgalactosaminyltransferase 3
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of GALNT3 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of GALNT3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
|
|
G
|
Galnt4
|
polypeptide N-acetylgalactosaminyltransferase 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:33,925,229...33,927,770
|
|
G
|
Galnt5
|
polypeptide N-acetylgalactosaminyltransferase 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:42,573,622...42,619,881
Ensembl chr 3:42,573,622...42,619,881
|
|
G
|
Galnt6
|
polypeptide N-acetylgalactosaminyltransferase 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:131,789,836...131,828,077
Ensembl chr 7:131,789,839...131,819,661
|
|
G
|
Galnt7
|
polypeptide N-acetylgalactosaminyltransferase 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690
|
|
G
|
Galntl6
|
polypeptide N-acetylgalactosaminyltransferase-like 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:31,192,880...32,443,979
Ensembl chr16:31,186,462...32,441,960
|
|
G
|
Gar1
|
GAR1 ribonucleoprotein
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GAR1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524
|
|
G
|
Gas8
|
growth arrest specific 8
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GAS8 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr19:51,552,770...51,572,323
Ensembl chr19:51,552,816...51,572,305
|
|
G
|
Gast
|
gastrin
|
decreases response to substance multiple interactions
|
ISO
|
GAST protein modified form results in decreased susceptibility to Dextran Sulfate [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA
|
CTD |
PMID:16618411 PMID:29950665 |
|
NCBI chr10:85,765,216...85,767,881
Ensembl chr10:85,264,832...85,267,496
|
|
G
|
Gata2
|
GATA binding protein 2
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:120,658,986...120,667,761
|
|
G
|
Gbp4
|
guanylate binding protein 4
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of GBP4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G
|
Gbp6
|
guanylate binding protein family member 6
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of GBP9 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GBP9 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062 Ensembl chr14:4,730,453...4,839,062
|
|
G
|
Gbp7
|
guanylate binding protein 7
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of GBP7 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:231,275,521...231,297,289
Ensembl chr 2:231,275,640...231,297,278
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G
|
Gcnt3
|
glucosaminyl (N-acetyl) transferase 3, mucin type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:79,570,081...79,577,389
Ensembl chr 8:70,686,844...70,699,562
|
|
G
|
Gda
|
guanine deaminase
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of GDA protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of GDA protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G
|
Gdi1
|
GDP dissociation inhibitor 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GDI1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr X:152,087,611...152,094,274
Ensembl chr X:152,087,444...152,094,272
|
|
G
|
Gdpd1
|
glycerophosphodiester phosphodiesterase domain containing 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GDPD1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:71,840,497...71,883,936
Ensembl chr10:71,840,497...71,883,850
|
|
G
|
Gfpt1
|
glutamine fructose-6-phosphate transaminase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G
|
Gfpt2
|
glutamine-fructose-6-phosphate transaminase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,115,052...34,161,329
|
|
G
|
Gfus
|
GDP-L-fucose synthase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948
|
|
G
|
Gfy
|
golgi-associated, olfactory signaling regulator
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GFY mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:95,661,621...95,665,300
Ensembl chr 1:95,661,773...95,665,893
|
|
G
|
Ggct
|
gamma-glutamyl cyclotransferase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GGCT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277
|
|
G
|
Ggh
|
gamma-glutamyl hydrolase
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GGH protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787
|
|
G
|
Ggnbp1
|
gametogenetin binding protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GGNBP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr20:5,109,849...5,116,185
Ensembl chr20:5,099,311...5,116,183
|
|
G
|
Gh1
|
growth hormone 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GH mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,228,103...91,230,078
|
|
G
|
Ghrl
|
ghrelin and obestatin prepropeptide
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GHRL mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:146,865,712...146,869,621
|
|
G
|
Gipc2
|
GIPC PDZ domain containing family, member 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GIPC2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:241,030,764...241,110,236
Ensembl chr 2:241,030,770...241,110,236
|
|
G
|
Glb1
|
galactosidase, beta 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of GLB1 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GLB1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G
|
Glb1l2
|
galactosidase, beta 1-like 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of GLB1L2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:25,115,462...25,166,843
Ensembl chr 8:25,115,462...25,166,783
|
|
G
|
Gli1
|
GLI family zinc finger 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of GLI1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:65,042,237...65,054,888
Ensembl chr 7:63,156,926...63,169,251
|
|
G
|
Gli3
|
GLI family zinc finger 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLI3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:54,134,064...54,405,198
Ensembl chr17:49,438,567...49,709,712
|
|
G
|
Glp1r
|
glucagon-like peptide 1 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLP1R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241
|
|
G
|
Glrx5
|
glutaredoxin 5
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GLRX5 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:129,752,902...129,763,278
Ensembl chr 6:123,988,134...123,998,545
|
|
G
|
Gls
|
glutaminase
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of GLS protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GLS protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:49,344,781...49,416,900
|
|
G
|
Gmds
|
GDP-mannose 4, 6-dehydratase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GMDS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,095,386...32,621,961
|
|
G
|
Gmpr
|
guanosine monophosphate reductase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of GMPR protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GMPR protein]
|
CTD |
PMID:35362542 |
|
NCBI chr17:19,151,820...19,189,626
Ensembl chr17:19,151,815...19,189,621
|
|
G
|
Gna11
|
G protein subunit alpha 11
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA11 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:8,814,285...8,828,628
Ensembl chr 7:8,162,750...8,179,812
|
|
G
|
Gna12
|
G protein subunit alpha 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:18,919,629...19,000,185
Ensembl chr12:13,805,698...13,886,255
|
|
G
|
Gna14
|
G protein subunit alpha 14
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G
|
Gna15
|
G protein subunit alpha 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508
|
|
G
|
Gnao1
|
G protein subunit alpha o1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GNAO1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:11,040,788...11,198,437
Ensembl chr19:11,035,956...11,192,493
|
|
G
|
Gnaz
|
G protein subunit alpha z
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNAZ mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:13,642,853...13,693,616
Ensembl chr20:13,644,640...13,669,907
|
|
G
|
Gnb3
|
G protein subunit beta 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNB3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:157,639,468...157,645,171
Ensembl chr 4:157,639,469...157,645,173
|
|
G
|
Gne
|
glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNE mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:63,062,953...63,103,320
Ensembl chr 5:58,267,210...58,307,499
|
|
G
|
Gng12
|
G protein subunit gamma 12
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of GNG12 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of GNG12 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:97,340,830...97,464,422
Ensembl chr 4:96,010,952...96,134,712
|
|
G
|
Gng4
|
G protein subunit gamma 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:86,448,708...86,497,560
Ensembl chr17:86,449,022...86,495,254
|
|
G
|
Gng7
|
G protein subunit gamma 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:9,348,148...9,411,924
Ensembl chr 7:8,697,521...8,761,240
|
|
G
|
Gng8
|
G protein subunit gamma 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371
|
|
G
|
Gngt2
|
G protein subunit gamma transducin 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNGT2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:80,776,003...80,784,235
|
|
G
|
Gnl1
|
G protein nucleolar 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GNL1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr20:2,783,130...2,792,115
Ensembl chr20:2,778,985...2,792,115
|
|
G
|
Gnpnat1
|
glucosamine-phosphate N-acetyltransferase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNPNAT1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739
|
|
G
|
Golga3
|
golgin A3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of GOLGA3 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GOLGA3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr12:46,452,409...46,500,509
Ensembl chr12:46,454,870...46,500,509 Ensembl chr 4:46,454,870...46,500,509
|
|
G
|
Golga4
|
golgin A4
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of GOLGA4 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GOLGA4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 8:118,208,200...118,285,003
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
multiple interactions increases activity
|
ISO
|
Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of GOT1 protein]
|
CTD |
PMID:30489199 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:242,357,306...242,380,633
|
|
G
|
Gp1bb
|
glycoprotein Ib platelet subunit beta
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GP1BB mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr11:95,882,561...95,883,738
Ensembl chr11:82,378,199...82,379,392
|
|
G
|
Gp6
|
glycoprotein VI
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GP6 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:69,429,232...69,492,709
Ensembl chr 1:69,465,789...69,491,326
|
|
G
|
Gpbar1
|
G protein-coupled bile acid receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPBAR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:83,309,895...83,312,397
Ensembl chr 9:75,860,677...75,863,168
|
|
G
|
Gpc4
|
glypican 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPC4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:136,565,536...136,676,142
Ensembl chr X:131,644,704...131,755,284
|
|
G
|
Gpi
|
glucose-6-phosphate isomerase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of GPI protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G
|
Gpnmb
|
glycoprotein nmb
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GPNMB mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G
|
Gpr119
|
G protein-coupled receptor 119
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of GPR119 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:127,852,145...127,858,198
Ensembl chr X:127,852,145...127,858,198
|
|
G
|
Gpr137b
|
G protein-coupled receptor 137B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR137B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:92,987,792...93,026,003
Ensembl chr17:85,966,921...86,041,835
|
|
G
|
Gpr149
|
G protein-coupled receptor 149
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR149 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:146,909,710...146,981,924
Ensembl chr 2:146,909,713...146,981,167
|
|
G
|
Gpr15
|
G protein-coupled receptor 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:41,898,300...41,899,646
Ensembl chr11:41,898,356...41,900,441
|
|
G
|
Gpr152
|
G protein-coupled receptor 152
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR152 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:201,435,878...201,438,373
Ensembl chr 1:201,435,884...201,437,443
|
|
G
|
Gpr17
|
G protein-coupled receptor 17
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR17 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966
|
|
G
|
Gpr176
|
G protein-coupled receptor 176
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:105,236,795...105,337,226
|
|
G
|
Gpr20
|
G protein-coupled receptor 20
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR20 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:105,601,761...105,611,959
Ensembl chr 7:105,602,368...105,603,430
|
|
G
|
Gpr27
|
G protein-coupled receptor 27
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR27 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497
|
|
G
|
Gpr37l1
|
G protein-coupled receptor 37-like 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR37L1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:49,150,355...49,157,204
Ensembl chr13:46,598,578...46,605,421
|
|
G
|
Gpr39
|
G protein-coupled receptor 39
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR39 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:37,115,258...37,327,312
Ensembl chr13:37,115,102...37,328,267
|
|
G
|
Gpr4
|
G protein-coupled receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599
|
|
G
|
Gpr50
|
G protein-coupled receptor 50
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR50 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:149,368,900...149,373,486
Ensembl chr X:149,368,900...149,373,486
|
|
G
|
Gpr68
|
G protein-coupled receptor 68
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR68 mRNA
|
CTD |
PMID:28174749 |
|
NCBI chr 6:125,865,205...125,895,674
Ensembl chr 6:120,135,436...120,166,089
|
|
G
|
Gpr83
|
G protein-coupled receptor 83
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR83 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028
|
|
G
|
Gpr85
|
G protein-coupled receptor 85
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR85 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566
|
|
G
|
Gpr88
|
G-protein coupled receptor 88
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR88 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:204,191,443...204,199,576
Ensembl chr 2:204,191,427...204,199,733
|
|
G
|
Gprc5b
|
G protein-coupled receptor, class C, group 5, member B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932
|
|
G
|
Gprc5d
|
G protein-coupled receptor, class C, group 5, member D
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5D mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:167,943,523...167,955,616
Ensembl chr 4:167,943,523...167,955,616
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
decreases activity
|
ISO
|
Dextran Sulfate results in decreased activity of GPT protein
|
CTD |
PMID:30489199 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G
|
Gpt2
|
glutamic--pyruvic transaminase 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of GPT2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610
|
|
G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GPX2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:95,493,589...95,496,877
|
|
G
|
Gpx3
|
glutathione peroxidase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,028,570...39,037,035
|
|
G
|
Gpx4
|
glutathione peroxidase 4
|
decreases expression multiple interactions decreases activity
|
ISO
|
Dextran Sulfate results in decreased expression of GPX4 mRNA; Dextran Sulfate results in decreased expression of GPX4 protein gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 mRNA]; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 protein] Dextran Sulfate results in decreased activity of GPX4 protein
|
CTD |
PMID:36135333 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G
|
Gpx6
|
glutathione peroxidase 6
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of GPX6 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr17:48,104,197...48,111,816
Ensembl chr17:43,408,472...43,416,091
|
|
G
|
Gpx7
|
glutathione peroxidase 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:128,373,881...128,381,866
Ensembl chr 5:123,144,331...123,153,004
|
|
G
|
Gpx8
|
glutathione peroxidase 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:46,409,646...46,413,401
Ensembl chr 2:44,676,454...44,680,195
|
|
G
|
Grb2
|
growth factor receptor bound protein 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:101,380,354...101,448,138
Ensembl chr10:100,869,718...100,949,309
|
|
G
|
Grb7
|
growth factor receptor bound protein 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRB7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:83,443,387...83,453,057
Ensembl chr10:83,444,004...83,453,052
|
|
G
|
Grem1
|
gremlin 1, DAN family BMP antagonist
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GREM1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G
|
Grik4
|
glutamate ionotropic receptor kainate type subunit 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIK4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
|
|
G
|
Grin2b
|
glutamate ionotropic receptor NMDA type subunit 2B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRIN2B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:168,599,546...169,042,279
|
|
G
|
Grin2d
|
glutamate ionotropic receptor NMDA type subunit 2D
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIN2D mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:105,443,317...105,483,400
Ensembl chr 1:96,308,365...96,344,793
|
|
G
|
Grk3
|
G protein-coupled receptor kinase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRK3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:49,285,228...49,395,803
Ensembl chr12:43,624,897...43,731,262
|
|
G
|
Grk6
|
G protein-coupled receptor kinase 6
|
multiple interactions decreases response to substance
|
ISO
|
GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]] GRK6 results in decreased susceptibility to Dextran Sulfate
|
CTD |
PMID:18687398 |
|
NCBI chr17:9,182,160...9,198,380
Ensembl chr17:9,177,019...9,192,644
|
|
G
|
Grm4
|
glutamate metabotropic receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRM4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,481,124...5,572,821
|
|
G
|
Grpr
|
gastrin releasing peptide receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRPR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:30,998,425...31,038,442
Ensembl chr X:30,998,416...31,038,442
|
|
G
|
Gsdmd
|
gasdermin D
|
multiple interactions increases cleavage
|
ISO
|
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]
|
CTD |
PMID:37001609 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G
|
Gsn
|
gelsolin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GSN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:18,585,172...18,638,402
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
decreases activity multiple interactions
|
ISO
|
Dextran Sulfate results in decreased activity of GSR protein Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in decreased activity of GSR protein]
|
CTD |
PMID:30489199 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G
|
Gss
|
glutathione synthetase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G
|
Gstk1
|
glutathione S-transferase kappa 1
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTK1 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GSTK1 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr 4:72,085,532...72,089,934
Ensembl chr 4:71,118,896...71,123,292
|
|
G
|
Gstm1
|
glutathione S-transferase mu 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of GSTM1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G
|
Gstm2
|
glutathione S-transferase mu 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of GSTM2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G
|
Gstm5
|
glutathione S-transferase, mu 5
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GSTM3 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GSTM3 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G
|
Gsto1
|
glutathione S-transferase omega 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:246,721,221...246,731,468
|
|
G
|
Gsto2
|
glutathione S-transferase omega 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:246,731,314...246,757,592
Ensembl chr 1:246,732,089...246,753,866
|
|
G
|
Gtf2f1
|
general transcription factor IIF subunit 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GTF2F1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:1,844,027...1,853,455
Ensembl chr 9:1,843,901...1,853,423
|
|
G
|
Guca1a
|
guanylate cyclase activator 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GUCA1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:13,588,988...13,598,566
Ensembl chr 9:13,588,525...13,598,565
|
|
G
|
Guca1b
|
guanylate cyclase activator 1B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCA1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:13,599,619...13,607,455
Ensembl chr 9:13,599,619...13,607,455
|
|
G
|
Guca2b
|
guanylate cyclase activator 2B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of GUCA2B protein
|
CTD |
PMID:35999755 |
|
NCBI chr 5:133,246,891...133,248,941
Ensembl chr 5:133,246,909...133,248,966
|
|
G
|
Gucy2f
|
guanylate cyclase 2F
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCY2F mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:105,710,356...105,808,183
Ensembl chr X:105,710,356...105,808,183
|
|
G
|
Guk1
|
guanylate kinase 1
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GUK1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of GUK1 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107
|
|
G
|
Gyg1
|
glycogenin 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of GYG1 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of GYG1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:102,611,888...102,653,916
Ensembl chr 2:102,598,496...102,653,797
|
|
G
|
Gzma
|
granzyme A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GZMA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493
|
|
G
|
H1f1
|
H1.1 linker histone, cluster member
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of H1F1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of H1F1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011
|
|
G
|
H1f10
|
H1.10 linker histone
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of H1F10 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:120,440,515...120,441,578
Ensembl chr 4:120,440,870...120,441,448
|
|
G
|
H6pd
|
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of H6PD protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of H6PD protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171
|
|
G
|
Hadh
|
hydroxyacyl-CoA dehydrogenase
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of HADH protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of HADH protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:222,462,049...222,504,446
Ensembl chr 2:219,787,927...219,830,353
|
|
G
|
Hadhb
|
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HADHB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:31,873,404...31,907,557
Ensembl chr 6:26,153,578...26,184,869
|
|
G
|
Hba-a1
|
hemoglobin alpha, adult chain 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of HBA-A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392
|
|
G
|
Hbb
|
hemoglobin subunit beta
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of HBB-B1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:158,120,200...158,252,012
|
|
G
|
Hbb-b2
|
hemoglobin, beta adult minor chain
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of HBB-B2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:158,243,696...158,245,076
Ensembl chr 1:158,120,200...158,252,012
|
|
G
|
Hcls1
|
hematopoietic cell specific Lyn substrate 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of HCLS1 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of HCLS1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr11:77,322,873...77,346,333
Ensembl chr11:63,817,476...63,841,014
|
|
G
|
Hcn2
|
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841
|
|
G
|
Hcn3
|
hyperpolarization-activated cyclic nucleotide-gated potassium channel 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:174,551,861...174,567,459
Ensembl chr 2:174,551,680...174,565,966
|
|
G
|
Hcn4
|
hyperpolarization activated cyclic nucleotide-gated potassium channel 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:59,222,206...59,259,626
Ensembl chr 8:59,221,653...59,259,639
|
|
G
|
Hdgfl2
|
HDGF like 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of HDGFL2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:909,581...929,195
Ensembl chr 9:909,614...929,186
|
|
G
|
Heph
|
hephaestin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HEPH mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980
|
|
G
|
Hes1
|
hes family bHLH transcription factor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HES1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:70,705,764...70,708,192
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of HIF1A mRNA; Dextran Sulfate results in increased expression of HIF1A protein Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of HIF1A protein]; xianglian pill inhibits the reaction [Dextran Sulfate results in increased expression of HIF1A mRNA]
|
CTD |
PMID:26074695 PMID:33486267 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G
|
Hint2
|
histidine triad nucleotide binding protein 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of HINT2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:62,700,383...62,702,638
Ensembl chr 5:57,904,614...57,907,097
|
|
G
|
Hirip3
|
HIRA interacting protein 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of HIRIP3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:181,472,537...181,475,082
Ensembl chr 1:181,472,056...181,475,079
|
|
G
|
Hk1
|
hexokinase 1
|
multiple interactions increases expression
|
ISO
|
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of HK1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of HK1 protein]
|
CTD |
PMID:37001609 |
|
NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,230,486...30,332,131
|
|
G
|
Hk3
|
hexokinase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HK3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:9,602,119...9,620,038
Ensembl chr17:9,599,865...9,614,863
|
|
G
|
Hmgb1
|
high mobility group box 1
|
multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein]
|
CTD |
PMID:29496522 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G
|
Hmgb3
|
high mobility group box 3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of HMGB3 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of HMGB3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr X:154,341,106...154,346,087
Ensembl chr X:149,296,375...149,301,292
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HMOX1 mRNA; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein] Dextran Sulfate results in decreased expression of HMOX1 mRNA; Dextran Sulfate results in decreased expression of HMOX1 protein
|
CTD |
PMID:29950665 PMID:30142311 PMID:33974900 PMID:36135333 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G
|
Hnf1a
|
HNF1 homeobox A
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of HNF1A protein 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of HNF1A protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1A mRNA
|
CTD |
PMID:29680209 PMID:29950665 |
|
NCBI chr12:47,299,171...47,333,457
Ensembl chr12:41,645,587...41,672,104
|
|
G
|
Hnf1b
|
HNF1 homeobox B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:68,735,894...68,789,888
Ensembl chr10:68,735,894...68,789,888
|
|
G
|
Hnf4a
|
hepatocyte nuclear factor 4, alpha
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4A mRNA Dextran Sulfate results in decreased expression of HNF4A mRNA
|
CTD |
PMID:29950665 PMID:38844255 |
|
NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:152,186,787...152,248,320
|
|
G
|
Hnf4g
|
hepatocyte nuclear factor 4, gamma
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4G mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:97,885,773...98,036,650
Ensembl chr 2:97,887,432...98,036,592
|
|
G
|
Hnrnpa0
|
heterogeneous nuclear ribonucleoprotein A0
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of HNRNPA0 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr17:6,507,728...6,510,385
Ensembl chr17:6,507,275...6,509,375
|
|
G
|
Hnrnpul1
|
heterogeneous nuclear ribonucleoprotein U-like 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of HNRNPUL1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of HNRNPUL1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:81,228,404...81,264,121
Ensembl chr 1:81,228,404...81,262,592
|
|
G
|
Hook2
|
hook microtubule-tethering protein 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of HOOK2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr19:23,151,869...23,170,139
Ensembl chr19:23,151,870...23,164,181
|
|
G
|
Hp
|
haptoglobin
|
multiple interactions increases expression decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of HP protein; Chlorpyrifos promotes the reaction [Dextran Sulfate results in increased expression of HP protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of HP protein]
|
CTD |
PMID:31807802 PMID:35362542 PMID:35999755 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G
|
Hpgd
|
15-hydroxyprostaglandin dehydrogenase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HPGD mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G
|
Hpse
|
heparanase
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of HPSE protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G
|
Hrh3
|
histamine receptor H3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HRH3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:187,569,174...187,575,263
Ensembl chr 3:167,191,558...167,196,642
|
|
G
|
Hsd11b1
|
hydroxysteroid 11-beta dehydrogenase 1
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD11B1 mRNA Dextran Sulfate results in increased expression of HSD11B1 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD11B2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:33,397,656...33,402,899
|
|
G
|
Hsd17b1
|
hydroxysteroid (17-beta) dehydrogenase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD17B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,009,728...86,011,927
|
|
G
|
Hsd17b3
|
hydroxysteroid (17-beta) dehydrogenase 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of HSD17B3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,027,229...1,058,554
|
|
G
|
Hsd17b6
|
hydroxysteroid (17-beta) dehydrogenase 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD17B6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425
|
|
G
|
Hsd3b1
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of HSD3B1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
multiple interactions increases expression
|
EXP ISO
|
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AA1 mRNA] xianglian pill inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AA1 mRNA]
|
CTD |
PMID:32470352 PMID:33486267 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268
|
|
G
|
Hsp90ab1
|
heat shock protein 90 alpha family class B member 1
|
multiple interactions increases expression
|
EXP
|
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AB1 protein]
|
CTD |
PMID:32470352 |
|
NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:15,433,691...15,438,488
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1A mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,856,006...3,873,227
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1B mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of HSPA8 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259
|
|
G
|
Hspb1
|
heat shock protein family B (small) member 1
|
multiple interactions increases expression
|
ISO
|
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of HSPB1 mRNA]
|
CTD |
PMID:32033881 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:20,794,028...20,795,743
|
|
G
|
Hspg2
|
heparan sulfate proteoglycan 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSPG2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:154,960,818...155,061,971
Ensembl chr 5:149,677,476...149,778,594
|
|
G
|
Htr1b
|
5-hydroxytryptamine receptor 1B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:91,395,405...91,414,815
Ensembl chr 8:82,517,360...82,534,549
|
|
G
|
Htr1d
|
5-hydroxytryptamine receptor 1D
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HTR1D mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:148,656,252...148,676,532
Ensembl chr 5:148,674,495...148,675,619
|
|
G
|
Htr4
|
5-hydroxytryptamine receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HTR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321
|
|
G
|
Htr7
|
5-hydroxytryptamine receptor 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:243,049,064...243,173,636
Ensembl chr 1:233,636,452...233,760,626
|
|
G
|
Htra1
|
HtrA serine peptidase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of HTRA1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions increases expression
|
ISO
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM1 mRNA; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]
|
CTD |
PMID:21724996 PMID:24038091 PMID:25448682 PMID:25472953 PMID:29950665 PMID:38583725 More...
|
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G
|
Icam4
|
intercellular adhesion molecule 4, Landsteiner-Wiener blood group
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:19,566,075...19,567,171
Ensembl chr 8:19,566,075...19,567,171
|
|
G
|
Icoslg
|
inducible T-cell co-stimulator ligand
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICOSL mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:10,600,078...10,610,385
Ensembl chr20:10,600,420...10,610,703
|
|
G
|
Idh1
|
isocitrate dehydrogenase (NADP(+)) 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of IDH1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:74,027,887...74,057,442
Ensembl chr 9:66,534,146...66,563,708
|
|
G
|
Ido1
|
indoleamine 2,3-dioxygenase 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of IDO1 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G
|
Ier3
|
immediate early response 3
|
multiple interactions increases expression
|
ISO
|
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IER3 mRNA]
|
CTD |
PMID:32033881 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,928,378...2,929,583
|
|
G
|
Ifitm3
|
interferon induced transmembrane protein 3
|
multiple interactions increases expression
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of IFITM3 mRNA; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of IFITM3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IFITM3 protein]
|
CTD |
PMID:26271895 PMID:32272095 |
|
NCBI chr 1:196,111,026...196,112,135
Ensembl chr 1:196,111,043...196,112,203
|
|
G
|
Ifnar2
|
interferon alpha and beta receptor subunit 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNAR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:44,099,574...44,131,941
Ensembl chr11:30,613,767...30,668,124
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions increases secretion increases expression
|
ISO
|
2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNG protein; [Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IFNG protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of IFNG protein] Dextran Sulfate results in increased expression of IFNG mRNA; Dextran Sulfate results in increased expression of IFNG protein
|
CTD |
PMID:12105854 PMID:19940103 PMID:20637373 PMID:21068411 PMID:21359540 PMID:21858153 PMID:24038091 PMID:24384223 PMID:24548422 PMID:25026504 PMID:25231984 PMID:25472953 PMID:25837923 PMID:26973525 PMID:28411859 PMID:29672155 PMID:31737179 PMID:32272095 PMID:34273909 PMID:35889507 More...
|
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G
|
Ifnk
|
interferon kappa
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNK mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:54,528,304...54,530,511
Ensembl chr 5:49,732,073...49,734,281
|
|
G
|
Igf1
|
insulin-like growth factor 1
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IGF1 protein
|
CTD |
PMID:19931517 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G
|
Igf2bp3
|
insulin-like growth factor 2 mRNA binding protein 3
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein; Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein]
|
CTD |
PMID:36822301 |
|
NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865
|
|
G
|
Igf2r
|
insulin-like growth factor 2 receptor
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of IGF2R protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G
|
Igfbp2
|
insulin-like growth factor binding protein 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G
|
Igfbp4
|
insulin-like growth factor binding protein 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:84,491,471...84,503,487
Ensembl chr10:83,989,591...84,007,225
|
|
G
|
Igfbp6
|
insulin-like growth factor binding protein 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
|
|
G
|
Igfbp7
|
insulin-like growth factor binding protein 7
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of IGFBP7 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of IGFBP7 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr14:31,091,681...31,151,623
Ensembl chr14:30,737,164...30,797,314
|
|
G
|
Ihh
|
Indian hedgehog signaling molecule
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IHH mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:83,952,986...83,959,203
Ensembl chr 9:76,504,315...76,510,532
|
|
G
|
Ik
|
IK cytokine
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of IK protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of IK protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:28,632,025...28,646,829
Ensembl chr18:28,357,977...28,378,832
|
|
G
|
Ikbkb
|
inhibitor of nuclear factor kappa B kinase subunit beta
|
multiple interactions increases activity increases expression
|
ISO
|
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of IKBKB protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IKBKB mRNA; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IKBKB protein modified form]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of IKBKB protein]
|
CTD |
PMID:20155626 PMID:25472953 PMID:29950665 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:69,319,554...69,373,250
|
|
G
|
Ikbke
|
inhibitor of nuclear factor kappa B kinase subunit epsilon
|
increases phosphorylation multiple interactions
|
ISO
|
Dextran Sulfate results in increased phosphorylation of IKBKE protein GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of IKBKE protein]
|
CTD |
PMID:27920257 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G
|
Ikzf3
|
IKAROS family zinc finger 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of IKZF3 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr10:83,956,850...84,049,861
Ensembl chr10:83,465,745...83,553,591
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester promotes the reaction [Dextran Sulfate results in increased expression of IL10 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; celastrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Coumarins inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL10 protein]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein]; isomaltulose inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 mRNA]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Resveratrol promotes the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of IL10 mRNA] Dextran Sulfate results in increased expression of IL10 mRNA; Dextran Sulfate results in increased expression of IL10 protein kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA] Dextran Sulfate results in decreased expression of IL10 mRNA; Dextran Sulfate results in decreased expression of IL10 protein
|
CTD |
PMID:20132809 PMID:20881082 PMID:21068411 PMID:21359540 PMID:21724996 PMID:24384223 PMID:25026504 PMID:25231984 PMID:25777935 PMID:26074695 PMID:26973525 PMID:28438436 PMID:29672155 PMID:31442584 PMID:31807802 PMID:31926917 PMID:33974900 PMID:35894244 PMID:37263316 PMID:38164749 PMID:38437956 PMID:38583725 PMID:38648921 More...
|
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G
|
Il11
|
interleukin 11
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11 mRNA; Melatonin inhibits the reaction [Dextran Sulfate results in decreased expression of IL11 protein]
|
CTD |
PMID:29950665 PMID:36265525 |
|
NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:69,068,137...69,076,129
|
|
G
|
Il11ra1
|
interleukin 11 receptor subunit alpha 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11RA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:61,727,650...61,737,265
Ensembl chr 5:56,935,516...56,941,408
|
|
G
|
Il12a
|
interleukin 12A
|
affects response to substance
|
ISO
|
IL12A protein affects the susceptibility to Dextran Sulfate
|
CTD |
PMID:12940437 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:152,965,769...152,972,734
|
|
G
|
Il12b
|
interleukin 12B
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of IL12B mRNA ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL12B mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL12B mRNA]
|
CTD |
PMID:33130971 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903
|
|
G
|
Il15
|
interleukin 15
|
increases response to substance decreases expression multiple interactions
|
ISO EXP
|
IL15 protein results in increased susceptibility to Dextran Sulfate Dextran Sulfate results in decreased expression of IL15 mRNA Oligosaccharides inhibits the reaction [Dextran Sulfate results in decreased expression of IL15 mRNA] [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL15 mRNA
|
CTD |
PMID:16162679 PMID:16375993 PMID:29950665 |
|
NCBI chr19:42,536,160...42,611,349
Ensembl chr19:25,640,251...25,706,820
|
|
G
|
Il17a
|
interleukin 17A
|
multiple interactions increases expression affects response to substance
|
ISO EXP
|
2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IFNG protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL17A mRNA; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; isomaltulose inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]]; xianglian pill inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein] kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA] Dextran Sulfate results in increased expression of IL17A mRNA; Dextran Sulfate results in increased expression of IL17A protein
|
CTD |
PMID:20881082 PMID:21068411 PMID:24384223 PMID:24548422 PMID:26074695 PMID:26973525 PMID:27995407 PMID:29672155 PMID:29950665 PMID:31737179 PMID:31807802 PMID:33130971 PMID:33486267 PMID:34998820 PMID:35889507 PMID:35894244 PMID:36519841 PMID:38663798 More...
|
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889
|
|
G
|
Il18
|
interleukin 18
|
affects response to substance increases expression multiple interactions increases secretion
|
ISO EXP
|
IL18 protein affects the susceptibility to Dextran Sulfate Dextran Sulfate results in increased expression of IL18 mRNA; Dextran Sulfate results in increased expression of IL18 protein [Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL18 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of IL18 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL18 mRNA; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; Dextran Sulfate inhibits the reaction [Zearalenone results in increased secretion of IL18 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]; nuciferine inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]
|
CTD |
PMID:12940437 PMID:25448682 PMID:29950665 PMID:30270565 PMID:32470352 PMID:36577154 PMID:37001609 More...
|
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887
|
|
G
|
Il18r1
|
interleukin 18 receptor 1
|
affects response to substance
|
ISO
|
IL18R1 protein affects the susceptibility to Dextran Sulfate
|
CTD |
PMID:12940437 |
|
NCBI chr 9:50,223,274...50,257,370
Ensembl chr 9:42,727,869...42,760,715
|
|
G
|
Il18rap
|
interleukin 18 receptor accessory protein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL18RAP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959
|
|
G
|
Il19
|
interleukin 19
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL19 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:44,949,989...44,958,714
Ensembl chr13:42,399,138...42,405,473
|
|
G
|
Il1a
|
interleukin 1 alpha
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of IL1A mRNA; Dextran Sulfate results in increased expression of IL1A protein 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL1A protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1A protein; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1A protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1A mRNA]
|
CTD |
PMID:23894361 PMID:25472953 PMID:29672155 PMID:34273909 PMID:36265525 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression increases secretion increases cleavage
|
ISO EXP
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; [ABTB1 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of IL1B protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of IL1B protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1B mRNA; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; biochanin A inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; isomaltulose inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased cleavage of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; nuciferine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; oxymatrine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; phenethyl isothiocyanate inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Quercetin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein] [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein] Dextran Sulfate results in increased expression of IL1B mRNA; Dextran Sulfate results in increased expression of IL1B protein
|
CTD |
PMID:15652231 PMID:16774945 PMID:19028472 PMID:19285099 PMID:19645018 PMID:19940103 PMID:20079348 PMID:20132809 PMID:20423518 PMID:20824662 PMID:20881082 PMID:21068411 PMID:21724996 PMID:21893696 PMID:22334590 PMID:23568217 PMID:23894361 PMID:24038091 PMID:24384223 PMID:24548422 PMID:25231984 PMID:25448682 PMID:25472953 PMID:25777935 PMID:25837923 PMID:26190278 PMID:26631293 PMID:26973525 PMID:27125760 PMID:27611972 PMID:27920257 PMID:27995407 PMID:28421826 PMID:28438436 PMID:29496522 PMID:29672155 PMID:29950665 PMID:30270565 PMID:30611738 PMID:30972795 PMID:31715269 PMID:31737179 PMID:31926917 PMID:32033881 PMID:32272095 PMID:32470352 PMID:33130971 PMID:34273909 PMID:34964214 PMID:34998820 PMID:35362542 PMID:35670535 PMID:35894244 PMID:36135333 PMID:36265525 PMID:36281492 PMID:36519841 PMID:36543318 PMID:36577154 PMID:36806191 PMID:37001609 PMID:37209277 PMID:37263316 PMID:37263555 PMID:38164749 PMID:38423481 PMID:38437956 PMID:38583725 PMID:38648921 PMID:38866194 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G
|
Il1r1
|
interleukin 1 receptor type 1
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R1 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1R1 mRNA]
|
CTD |
PMID:29950665 PMID:32033881 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:42,504,735...42,579,937
|
|
G
|
Il1r2
|
interleukin 1 receptor type 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:42,384,433...42,424,725
|
|
G
|
Il1rn
|
interleukin 1 receptor antagonist
|
multiple interactions decreases expression
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of IL1RN protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein]
|
CTD |
PMID:25026504 PMID:35362542 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:7,111,550...7,127,445
|
|
G
|
Il2
|
interleukin 2
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of IL2 mRNA; Dextran Sulfate results in increased expression of IL2 protein 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of IL2 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of IL2 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL2 protein]
|
CTD |
PMID:21068411 PMID:25472953 PMID:32272095 PMID:35362542 PMID:35889507 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G
|
Il20ra
|
interleukin 20 receptor subunit alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:16,243,683...16,313,229
Ensembl chr 1:14,451,228...14,493,602
|
|
G
|
Il20rb
|
interleukin 20 receptor subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:109,858,108...109,896,066
Ensembl chr 8:100,980,383...101,009,942
|
|
G
|
Il22ra1
|
interleukin 22 receptor subunit alpha 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL22RA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:153,245,067...153,269,865
Ensembl chr 5:147,961,349...147,986,296
|
|
G
|
Il22ra2
|
interleukin 22 receptor subunit alpha 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of IL22RA2 mRNA
|
CTD |
PMID:27920257 |
|
NCBI chr 1:16,172,238...16,228,009
Ensembl chr 1:14,364,489...14,377,844
|
|
G
|
Il23a
|
interleukin 23 subunit alpha
|
increases expression multiple interactions
|
ISO EXP
|
Dextran Sulfate results in increased expression of IL23A protein celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein] Dextran Sulfate results in increased expression of IL23A mRNA kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL23A mRNA]
|
CTD |
PMID:20881082 PMID:24384223 PMID:36265525 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:721,809...723,923
|
|
G
|
Il27ra
|
interleukin 27 receptor subunit alpha
|
decreases response to substance
|
ISO
|
IL27RA protein results in decreased susceptibility to Dextran Sulfate
|
CTD |
PMID:16306766 |
|
NCBI chr19:24,109,963...24,121,977
Ensembl chr19:24,109,972...24,121,938
|
|
G
|
Il2rg
|
interleukin 2 receptor subunit gamma
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of IL2RG mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr X:70,435,340...70,439,052
Ensembl chr X:66,392,542...66,399,823
|
|
G
|
Il33
|
interleukin 33
|
multiple interactions increases expression
|
ISO
|
flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL33 mRNA]
|
CTD |
PMID:38583725 |
|
NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:227,721,435...227,736,373
|
|
G
|
Il3ra
|
interleukin 3 receptor subunit alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL3RA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:21,431,848...21,437,336
Ensembl chr12:16,318,081...16,323,484
|
|
G
|
Il4
|
interleukin 4
|
decreases expression multiple interactions increases expression
|
ISO EXP
|
Dextran Sulfate results in decreased expression of IL4 mRNA [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein; MIF protein affects the reaction [Dextran Sulfate results in decreased expression of IL4 mRNA] Dextran Sulfate results in increased expression of IL4 protein
|
CTD |
PMID:12105854 PMID:21068411 PMID:25777935 PMID:28438436 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G
|
Il4r
|
interleukin 4 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL4RA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:180,115,120...180,139,980
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions increases expression affects expression increases secretion
|
ISO EXP
|
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 4-methylesculetin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of IL6 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of IL6 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of IL6 protein]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein]; Dextran Sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Dextran Sulfate inhibits the reaction [Polymyxin B results in decreased expression of IL6 protein]; Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Fenofibrate promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein]; isomaltulose inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Lipopolysaccharides promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; oxymatrine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein] banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein] Dextran Sulfate results in increased expression of IL6 mRNA; Dextran Sulfate results in increased expression of IL6 protein
|
CTD |
PMID:15652231 PMID:16774945 PMID:19285099 PMID:19940103 PMID:20079348 PMID:20881082 PMID:21068411 PMID:21359540 PMID:21893696 PMID:22334590 PMID:23261717 PMID:23568217 PMID:24038091 PMID:24146755 PMID:24548422 PMID:25026504 PMID:25035112 PMID:25231984 PMID:25448682 PMID:25472953 PMID:25777935 PMID:25837923 PMID:26074695 PMID:26190278 PMID:26631293 PMID:26973525 PMID:27580383 PMID:27611972 PMID:27920257 PMID:27920472 PMID:27995407 PMID:28438436 PMID:29217385 PMID:29496522 PMID:29672155 PMID:29680209 PMID:30142311 PMID:30611738 PMID:30844440 PMID:30972795 PMID:31442584 PMID:31715269 PMID:31926917 PMID:32033881 PMID:32272095 PMID:32470352 PMID:33130971 PMID:33974900 PMID:34273909 PMID:34964214 PMID:34998820 PMID:35362542 PMID:35670535 PMID:35894244 PMID:36135333 PMID:36265525 PMID:36281492 PMID:36519841 PMID:36543318 PMID:36806191 PMID:37001609 PMID:37209277 PMID:37263316 PMID:37385329 PMID:38164749 PMID:38437956 PMID:38583725 PMID:38588969 PMID:38663798 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G
|
Il6st
|
interleukin 6 cytokine family signal transducer
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL6ST mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:44,066,130...44,109,936
|
|
G
|
Il7r
|
interleukin 7 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL7R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:58,454,217...58,477,757
|
|
G
|
Ilk
|
integrin-linked kinase
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ILK protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ILK protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G
|
Inhba
|
inhibin subunit beta A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:53,787,159...53,810,942
Ensembl chr17:49,095,920...49,108,982
|
|
G
|
Inhbb
|
inhibin subunit beta B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G
|
Ino80b
|
INO80 complex subunit B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of INO80B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456
|
|
G
|
Inpp5d
|
inositol polyphosphate-5-phosphatase D
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INPP5D mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:88,287,677...88,392,746
|
|
G
|
Insl5
|
insulin like 5
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INSL5 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of INSL5 protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 5:117,773,104...117,777,376
|
|
G
|
Iqank1
|
IQ motif and ankyrin repeat containing 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of IQANK1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:107,724,962...107,759,163
Ensembl chr 7:107,724,997...107,759,162
|
|
G
|
Iqcd
|
IQ motif containing D
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of IQCD mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr12:35,955,522...35,972,420
Ensembl chr12:35,934,716...35,972,523
|
|
G
|
Irag1
|
inositol 1,4,5-triphosphate receptor associated 1
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IRAG1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:164,981,716...165,094,232
Ensembl chr 1:164,981,716...165,094,176
|
|
G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK1 protein
|
CTD |
PMID:34273909 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G
|
Irak2
|
interleukin-1 receptor-associated kinase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRAK2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:148,341,704...148,398,211
Ensembl chr 4:146,786,100...146,842,602
|
|
G
|
Irak4
|
interleukin-1 receptor-associated kinase 4
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK4 protein
|
CTD |
PMID:34273909 |
|
NCBI chr 7:125,682,502...125,708,294
Ensembl chr 7:125,682,488...125,717,837
|
|
G
|
Irf4
|
interferon regulatory factor 4
|
multiple interactions
|
ISO
|
IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]
|
CTD |
PMID:38164749 |
|
NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,721,811...33,740,070
|
|
G
|
Irs1
|
insulin receptor substrate 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRS1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:83,548,944...83,606,122
|
|
G
|
Irx6
|
iroquois homeobox 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRX6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:14,330,440...14,336,403
Ensembl chr19:14,330,440...14,336,403
|
|
G
|
Itga10
|
integrin subunit alpha 10
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGA10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:184,182,869...184,202,172
Ensembl chr 2:184,182,869...184,202,172
|
|
G
|
Itga2b
|
integrin subunit alpha 2b
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA2B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G
|
Itga4
|
integrin subunit alpha 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:84,569,487...84,646,276
Ensembl chr 3:64,163,085...64,233,715
|
|
G
|
Itga5
|
integrin subunit alpha 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:136,358,097...136,381,305
Ensembl chr 7:134,478,968...134,502,837
|
|
G
|
Itga6
|
integrin subunit alpha 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
|
|
G
|
Itgal
|
integrin subunit alpha L
|
multiple interactions increases expression
|
ISO
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]
|
CTD |
PMID:21724996 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G
|
Itgb1
|
integrin subunit beta 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195
|
|
G
|
Itgb2
|
integrin subunit beta 2
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITGB2 protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,061,430...11,097,600
|
|
G
|
Itgb3
|
integrin subunit beta 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:89,509,989...89,564,679
|
|
G
|
Itgb6
|
integrin subunit beta 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGB6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:45,048,044...45,121,671
|
|
G
|
Itgb8
|
integrin subunit beta 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:146,267,982...146,351,245
Ensembl chr 6:140,127,203...140,208,476
|
|
G
|
Itih1
|
inter-alpha trypsin inhibitor, heavy chain 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ITIH1 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITIH1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363
|
|
G
|
Itih3
|
inter-alpha trypsin inhibitor, heavy chain 3
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ITIH3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924
|
|
G
|
Itih4
|
inter-alpha-trypsin inhibitor heavy chain 4
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of ITIH4 protein [Dextran Sulfate co-treated with bisphenol A] results in increased expression of ITIH4 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITIH4 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ITIH4 protein]
|
CTD |
PMID:32272095 PMID:35362542 PMID:35999755 |
|
NCBI chr16:6,080,539...6,095,710
Ensembl chr16:6,080,539...6,095,708
|
|
G
|
Itih5
|
inter-alpha-trypsin inhibitor heavy chain 5
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of ITIH5 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207
|
|
G
|
Itpka
|
inositol-trisphosphate 3-kinase A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPKA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:106,726,036...106,734,601
Ensembl chr 3:106,726,036...106,734,600
|
|
G
|
Itpr3
|
inositol 1,4,5-trisphosphate receptor, type 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPR3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337
|
|
G
|
Jak2
|
Janus kinase 2
|
increases phosphorylation multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in increased phosphorylation of JAK2 protein BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of JAK2 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of JAK2 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; xianglian pill inhibits the reaction [Dextran Sulfate results in increased expression of JAK2 mRNA]
|
CTD |
PMID:32272095 PMID:33486267 PMID:38164749 PMID:38437956 PMID:38663798 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189
|
|
G
|
Jam2
|
junctional adhesion molecule 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:23,830,820...23,880,071
Ensembl chr11:23,831,106...23,880,063
|
|
G
|
Jam3
|
junctional adhesion molecule 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:33,767,606...33,828,451
Ensembl chr 8:25,507,057...25,569,355
|
|
G
|
Jaml
|
junction adhesion molecule like
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAML mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:45,384,836...45,415,459
Ensembl chr 8:45,383,495...45,416,565
|
|
G
|
Jchain
|
joining chain of multimeric IgA and IgM
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of JCHAIN mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr14:19,822,976...19,831,072
Ensembl chr14:19,538,952...19,546,298
|
|
G
|
Josd2
|
Josephin domain containing 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of JOSD2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:94,960,867...94,964,751
Ensembl chr 1:94,961,107...94,964,749
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of and affects the localization of JUN protein; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of JUN protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of JUN protein]
|
CTD |
PMID:33130971 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G
|
Kalrn
|
kalirin, RhoGEF kinase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of KALRN protein
|
CTD |
PMID:35999755 |
|
NCBI chr11:66,198,155...66,803,166
Ensembl chr11:66,198,173...66,797,610
|
|
G
|
Kash5
|
KASH domain containing 5
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of KASH5 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:95,668,918...95,691,353
Ensembl chr 1:95,668,886...95,691,368
|
|
G
|
Kcnab1
|
potassium voltage-gated channel subfamily A regulatory beta subunit 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNAB1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:149,137,025...149,603,540
Ensembl chr 2:149,137,041...149,603,534
|
|
G
|
Kcne3
|
potassium voltage-gated channel subfamily E regulatory subunit 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNE3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNH2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G
|
Kcnj9
|
potassium inwardly-rectifying channel, subfamily J, member 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNJ9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:84,780,826...84,787,928
Ensembl chr13:84,779,741...84,787,928
|
|
G
|
Kcnk4
|
potassium two pore domain channel subfamily K member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNK4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:204,117,941...204,129,494
Ensembl chr 1:204,114,572...204,125,925
|
|
G
|
Kcnk5
|
potassium two pore domain channel subfamily K member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNK5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:4,122,442...4,164,718
Ensembl chr15:4,122,442...4,164,718
|
|
G
|
Kdm1a
|
lysine demethylase 1A
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of KDM1A protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of KDM1A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G
|
Kiss1
|
KiSS-1 metastasis-suppressor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KISS1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:44,775,106...44,780,707
Ensembl chr13:44,774,823...44,780,612
|
|
G
|
Kit
|
KIT proto-oncogene receptor tyrosine kinase
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KIT mRNA Dextran Sulfate results in decreased expression of KIT mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,548,877...32,624,652
|
|
G
|
Kitlg
|
KIT ligand
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KITL mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G
|
Klb
|
klotho beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KLB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:42,899,050...42,950,788
Ensembl chr14:42,899,510...42,950,799
|
|
G
|
Klc3
|
kinesin light chain 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of KLC3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:79,045,842...79,055,809
Ensembl chr 1:79,045,844...79,055,416
|
|
G
|
Klk1
|
kallikrein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:103,779,152...103,783,270
Ensembl chr 1:94,642,687...94,646,754
|
|
G
|
Klk1b3
|
kallikrein 1-related peptidase B3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:94,709,105...94,713,308
Ensembl chr 1:94,709,105...94,713,308
|
|
G
|
Klk1c10
|
kallikrein 1-related peptidase C10
|
multiple interactions
|
ISO
|
Dextran Sulfate affects the reaction [SEMG2 protein binds to KLK3 protein]
|
CTD |
PMID:17253189 |
|
NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:94,402,993...94,407,052
|
|
G
|
Kpna1
|
karyopherin subunit alpha 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of KPNA1 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of KPNA1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr11:64,715,844...64,774,647
Ensembl chr11:64,717,563...64,774,623
|
|
G
|
Kras
|
KRAS proto-oncogene, GTPase
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KRAS mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of KRAS protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 4:179,916,255...179,949,613
|
|
G
|
Krt16
|
keratin 16
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of KRT16 protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799
|
|
G
|
L1cam
|
L1 cell adhesion molecule
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of L1CAM mRNA Dextran Sulfate results in decreased expression of L1CAM protein
|
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857
|
|
G
|
Lama5
|
laminin subunit alpha 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMA5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451
|
|
G
|
Lamb2
|
laminin subunit beta 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:109,178,409...109,190,549
|
|
G
|
Lamb3
|
laminin subunit beta 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LAMB3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G
|
Lamc1
|
laminin subunit gamma 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMC1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G
|
Lamc3
|
laminin subunit gamma 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of LAMC3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:15,165,220...15,226,697
Ensembl chr 3:15,165,220...15,226,697
|
|
G
|
Lamp2
|
lysosomal-associated membrane protein 2
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of LAMP2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr X:122,038,734...122,087,745
Ensembl chr X:117,057,606...117,260,522
|
|
G
|
Lamtor2
|
late endosomal/lysosomal adaptor, MAPK and MTOR activator 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of LAMTOR2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of LAMTOR2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:174,008,556...174,011,950
Ensembl chr 2:174,008,548...174,013,013
|
|
G
|
Laptm5
|
lysosomal protein transmembrane 5
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LAPTM5 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 5:148,371,880...148,393,927
Ensembl chr 5:143,087,759...143,109,807
|
|
G
|
Larp1
|
La ribonucleoprotein 1, translational regulator
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of LARP1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr10:42,691,833...42,746,816
Ensembl chr10:42,191,325...42,243,371
|
|
G
|
Lasp1
|
LIM and SH3 protein 1
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of LASP1 protein Dextran Sulfate results in decreased expression of LASP1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G
|
Lat2
|
linker for activation of T cells family, member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAT2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:22,104,173...22,118,294
Ensembl chr12:22,104,219...22,118,288
|
|
G
|
Layn
|
layilin
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of LAYN protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:51,363,928...51,384,748
Ensembl chr 8:51,367,091...51,384,330
|
|
G
|
Lcn2
|
lipocalin 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of LCN2 mRNA AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]
|
CTD |
PMID:23894361 PMID:36519841 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G
|
Lct
|
lactase
|
decreases activity multiple interactions
|
ISO
|
Dextran Sulfate results in decreased activity of LCT protein Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in decreased activity of LCT protein]
|
CTD |
PMID:30489199 |
|
NCBI chr13:39,781,929...39,824,456
Ensembl chr13:39,781,929...39,824,456
|
|
G
|
Ldha
|
lactate dehydrogenase A
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of LDHA protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:97,366,021...97,433,472
|
|
G
|
Ldhal6b
|
lactate dehydrogenase A-like 6B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LDHAL6B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:45,997,845...45,999,268
Ensembl chr 1:45,991,991...45,999,272
|
|
G
|
Ldhb
|
lactate dehydrogenase B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LDHB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:177,159,389...177,177,408
Ensembl chr 4:175,428,385...175,446,403
|
|
G
|
Ldhc
|
lactate dehydrogenase C
|
increases activity multiple interactions
|
ISO
|
Dextran Sulfate results in increased activity of LDHC protein gingerol inhibits the reaction [Dextran Sulfate results in increased activity of LDHC protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of LDHC protein]
|
CTD |
PMID:28421826 |
|
NCBI chr 1:97,385,984...97,403,382
Ensembl chr 1:97,382,379...97,403,378
|
|
G
|
Lef1
|
lymphoid enhancer binding factor 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein]
|
CTD |
PMID:31715269 |
|
NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:219,666,592...219,779,794
|
|
G
|
Leng1
|
leukocyte receptor cluster member 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LENG1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:65,551,983...65,556,915
Ensembl chr 1:65,551,983...65,556,915
|
|
G
|
Lep
|
leptin
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP protein
|
CTD |
PMID:19931517 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G
|
Lgmn
|
legumain
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of LGMN protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of LGMN protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:127,308,913...127,347,355
Ensembl chr 6:121,544,053...121,582,480
|
|
G
|
Lgr4
|
leucine-rich repeat-containing G protein-coupled receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LGR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899
|
|
G
|
Lgr6
|
leucine-rich repeat-containing G protein-coupled receptor 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LGR6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:46,424,382...46,544,074
Ensembl chr13:46,424,383...46,543,945
|
|
G
|
Lhb
|
luteinizing hormone subunit beta
|
multiple interactions decreases expression
|
ISO
|
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of LHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of LHB protein]
|
CTD |
PMID:28421826 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G
|
Lhcgr
|
luteinizing hormone/choriogonadotropin receptor
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of LHCGR mRNA Dextran Sulfate results in decreased expression of LHCGR mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:5,661,871...5,724,521
|
|
G
|
Limk1
|
LIM domain kinase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LIMK1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:27,663,177...27,697,085
Ensembl chr12:22,026,672...22,060,606
|
|
G
|
Lims1
|
LIM zinc finger domain containing 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of LIMS1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr20:26,851,364...26,961,607
Ensembl chr20:26,309,895...26,418,500
|
|
G
|
Lmnb2
|
lamin B2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LMNB2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:8,792,628...8,808,665
Ensembl chr 7:8,789,314...8,808,665
|
|
G
|
Lox
|
lysyl oxidase
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOX mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of LOX mRNA]
|
CTD |
PMID:29950665 PMID:32033881 PMID:35093514 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G
|
Loxl1
|
lysyl oxidase-like 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOXL1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356
|
|
G
|
Lpar2
|
lysophosphatidic acid receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:19,592,067...19,599,998
Ensembl chr16:19,595,655...19,599,998
|
|
G
|
Lpar3
|
lysophosphatidic acid receptor 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LPAR3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
|
|
G
|
Lpar4
|
lysophosphatidic acid receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:72,033,486...72,046,978
Ensembl chr X:72,033,486...72,046,977
|
|
G
|
Lrg1
|
leucine-rich alpha-2-glycoprotein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LRG1 mRNA
|
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
|
|
G
|
Lrp1
|
LDL receptor related protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LRP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:65,265,639...65,346,196
Ensembl chr 7:63,380,356...63,460,910
|
|
G
|
Lrp2
|
LDL receptor related protein 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LRP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:54,189,308...54,346,708
|
|
G
|
Lrp5
|
LDL receptor related protein 5
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 1:210,243,499...210,346,886
Ensembl chr 1:200,814,250...200,917,581
|
|
G
|
Lrpap1
|
LDL receptor related protein associated protein 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of LRPAP1 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of LRPAP1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr14:79,876,002...79,888,011
Ensembl chr14:75,651,376...75,665,414
|
|
G
|
Lrrc61
|
leucine rich repeat containing 61
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LRRC61 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:77,503,882...77,523,909
Ensembl chr 4:77,503,857...77,524,020
|
|
G
|
Lsm3
|
LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of LSM3 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of LSM3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:124,021,023...124,027,269
Ensembl chr 4:124,021,023...124,027,269
|
|
G
|
Lsm4
|
LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated
|
increases expression decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of LSM4 mRNA Dextran Sulfate results in decreased expression of LSM4 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of LSM4 protein]
|
CTD |
PMID:35093514 PMID:35362542 |
|
NCBI chr16:18,755,481...18,761,106
Ensembl chr16:18,755,484...18,760,926
|
|
G
|
Lta
|
lymphotoxin alpha
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LTA mRNA
|
CTD |
PMID:20079348 |
|
NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859
|
|
G
|
Lta4h
|
leukotriene A4 hydrolase
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of LTA4H protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:29,856,846...29,888,642
Ensembl chr 7:27,969,789...28,001,600
|
|
G
|
Ltb4r
|
leukotriene B4 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTB4R1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G
|
Ltbp3
|
latent transforming growth factor beta binding protein 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:203,029,412...203,045,975
Ensembl chr 1:203,029,877...203,045,975
|
|
G
|
Ltbp4
|
latent transforming growth factor beta binding protein 4
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP4 mRNA Dextran Sulfate results in decreased expression of LTBP4 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 1:91,727,769...91,759,822
Ensembl chr 1:82,600,136...82,632,178
|
|
G
|
Ltf
|
lactotransferrin
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of LTF protein Dextran Sulfate results in decreased expression of LTF protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:110,999,948...111,022,795
|
|
G
|
Luc7l3
|
LUC7-like 3 pre-mRNA splicing factor
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of LUC7L3 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of LUC7L3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538
|
|
G
|
Ly6d
|
lymphocyte antigen 6 family member D
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of LY6D mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:108,532,207...108,533,943
Ensembl chr 7:106,643,232...106,644,733
|
|
G
|
Ly6e
|
lymphocyte antigen 6 family member E
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of LY6E mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
|
|
G
|
Ly86
|
lymphocyte antigen 86
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LY86 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260
|
|
G
|
Lyz2
|
lysozyme 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of LYZ2 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:52,906,811...52,912,106
|
|
G
|
Macf1
|
microtubule-actin crosslinking factor 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MACF1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905
|
|
G
|
Maff
|
MAF bZIP transcription factor F
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MAFF mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:110,912,499...110,923,851
|
|
G
|
Mag
|
myelin-associated glycoprotein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAG mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:95,275,728...95,291,133
Ensembl chr 1:86,148,228...86,163,656
|
|
G
|
Man1a1
|
mannosidase, alpha, class 1A, member 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MAN1A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824
|
|
G
|
Manf
|
mesencephalic astrocyte-derived neurotrophic factor
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of MANF protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:107,500,856...107,551,595
Ensembl chr 8:107,548,352...107,551,438
|
|
G
|
Maoa
|
monoamine oxidase A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MAOA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:6,030,795...6,099,593
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
multiple interactions
|
ISO
|
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of and results in increased lipidation of MAP1LC3B protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]
|
CTD |
PMID:31676321 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G
|
Map3k7
|
mitogen activated protein kinase kinase kinase 7
|
multiple interactions increases phosphorylation
|
ISO
|
flavokawain B inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAP3K7 protein]
|
CTD |
PMID:38583725 |
|
NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:46,357,931...46,415,597
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases activity increases phosphorylation
|
ISO EXP
|
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of MAPK1 protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK1 protein; nuciferine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MAPK1 protein] banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:19931517 PMID:20155626 PMID:35889507 PMID:36577154 PMID:36806191 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G
|
Mapk10
|
mitogen activated protein kinase 10
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAPK10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,497,707...6,786,201
|
|
G
|
Mapk13
|
mitogen activated protein kinase 13
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MAPK13 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MAPK13 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr20:6,836,979...6,847,197
Ensembl chr20:6,835,320...6,844,222
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases activity increases phosphorylation
|
ISO EXP
|
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of MAPK3 protein]; 5,7-dimethoxycoumarin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK3 protein; nuciferine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MAPK3 protein] banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:19931517 PMID:20155626 PMID:35889507 PMID:36577154 PMID:36806191 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G
|
Mapre1
|
microtubule-associated protein, RP/EB family, member 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of MAPRE1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:162,679,020...162,707,167
Ensembl chr 3:142,212,955...142,246,983
|
|
G
|
Masp1
|
MBL associated serine protease 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MASP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:90,839,081...90,909,922
Ensembl chr11:77,334,859...77,402,974
|
|
G
|
Matn4
|
matrilin 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MATN4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:153,120,605...153,135,628
Ensembl chr 3:153,120,632...153,135,865
|
|
G
|
Mavs
|
mitochondrial antiviral signaling protein
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MAVS protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 3:138,904,673...138,919,129
Ensembl chr 3:118,451,743...118,466,094
|
|
G
|
Mbd3
|
methyl-CpG binding domain protein 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MBD3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165
|
|
G
|
Mc4r
|
melanocortin 4 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MC4R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:62,689,798...62,691,685
Ensembl chr18:60,419,832...60,421,719
|
|
G
|
Mcm3
|
minichromosome maintenance complex component 3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MCM3 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MCM3 protein]
|
CTD |
PMID:20025956 PMID:35362542 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G
|
Mdh1
|
malate dehydrogenase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of MDH1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
|
|
G
|
Mdk
|
midkine
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MDK mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:98,356,789...98,358,960
Ensembl chr 3:77,901,158...77,903,130
|
|
G
|
Me1
|
malic enzyme 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ME1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G
|
Mecr
|
mitochondrial trans-2-enoyl-CoA reductase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MECR protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MECR protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:149,313,765...149,339,964
Ensembl chr 5:144,029,731...144,055,863
|
|
G
|
Memo1
|
mediator of cell motility 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MEMO1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:21,144,525...21,234,363
Ensembl chr 6:21,125,639...21,234,561
|
|
G
|
Mep1a
|
meprin A subunit alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:17,474,634...17,504,147
Ensembl chr 9:17,474,619...17,504,147
|
|
G
|
Mep1b
|
meprin A subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:12,366,126...12,392,840
Ensembl chr18:12,365,289...12,392,840
|
|
G
|
Mesp1
|
mesoderm posterior bHLH transcription factor 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MESP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:143,147,671...143,149,189
Ensembl chr 1:133,738,357...133,739,875
|
|
G
|
Mfap4
|
microfibril associated protein 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155
|
|
G
|
Mfap5
|
microfibril associated protein 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:155,727,925...155,750,458
Ensembl chr 4:155,727,925...155,750,458
|
|
G
|
Mfge8
|
milk fat globule EGF and factor V/VIII domain containing
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of MFGE8 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G
|
Mfsd2a
|
MFSD2 lysolipid transporter A, lysophospholipid
|
increases expression decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of MFSD2A mRNA Dextran Sulfate results in decreased expression of MFSD2A mRNA
|
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G
|
Mgat4c
|
MGAT4 family, member C
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MGAT4C protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:36,709,564...37,485,810
Ensembl chr 7:37,260,321...37,474,571
|
|
G
|
Mgp
|
matrix Gla protein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MGP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G
|
Mgst2
|
microsomal glutathione S-transferase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828
|
|
G
|
Mgst3
|
microsomal glutathione S-transferase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411
|
|
G
|
Micu2
|
mitochondrial calcium uptake 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MICU2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr15:32,064,872...32,146,874
Ensembl chr15:32,064,875...32,147,094
|
|
G
|
Mien1
|
migration and invasion enhancer 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MIEN1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MIEN1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:83,435,198...83,436,491
Ensembl chr10:83,434,710...83,436,488
|
|
G
|
Mif
|
macrophage migration inhibitory factor
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MIF mRNA MIF protein affects the reaction [Dextran Sulfate results in decreased expression of IL4 mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of TNF mRNA]
|
CTD |
PMID:12105854 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504 Ensembl chr 4:12,790,902...12,799,504
|
|
G
|
Miox
|
myo-inositol oxygenase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MIOX mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:120,405,031...120,407,529
Ensembl chr 7:120,405,031...120,407,537
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
multiple interactions decreases expression
|
EXP ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein] [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein; berberrubine inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of MKI67 protein]
|
CTD |
PMID:19028472 PMID:34273909 PMID:37871880 PMID:38648921 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G
|
Mlkl
|
mixed lineage kinase domain like pseudokinase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MLKL protein dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of MLKL protein]
|
CTD |
PMID:29496522 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G
|
Mme
|
membrane metallo-endopeptidase
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MME mRNA Dextran Sulfate results in decreased expression of MME mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:147,722,086...147,803,792
|
|
G
|
Mmp10
|
matrix metallopeptidase 10
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MMP10 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP10 mRNA
|
CTD |
PMID:20824662 PMID:29950665 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G
|
Mmp12
|
matrix metallopeptidase 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:4,581,785...4,599,611
|
|
G
|
Mmp13
|
matrix metallopeptidase 13
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP13 mRNA; MIF protein affects the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]
|
CTD |
PMID:12105854 PMID:19285099 PMID:20824662 PMID:23894361 PMID:29950665 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G
|
Mmp14
|
matrix metallopeptidase 14
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:27,887,727...27,899,864
|
|
G
|
Mmp15
|
matrix metallopeptidase 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMP15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:9,669,506...9,691,000
Ensembl chr19:9,663,449...9,684,943
|
|
G
|
Mmp19
|
matrix metallopeptidase 19
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP19 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:1,221,229...1,229,555
Ensembl chr 7:1,221,343...1,229,555
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MMP2 mRNA; Dextran Sulfate results in increased expression of MMP2 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP2 mRNA; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP2 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP2 protein]
|
CTD |
PMID:19285099 PMID:29950665 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G
|
Mmp23
|
matrix metallopeptidase 23
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP23 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:166,239,643...166,242,734
Ensembl chr 5:166,239,644...166,242,433
|
|
G
|
Mmp3
|
matrix metallopeptidase 3
|
multiple interactions increases expression
|
ISO
|
Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP3 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of MMP3 mRNA]
|
CTD |
PMID:19285099 PMID:20824662 PMID:32033881 |
|
NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:4,640,416...4,653,961
|
|
G
|
Mmp7
|
matrix metallopeptidase 7
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 8:13,133,043...13,140,761
Ensembl chr 8:4,848,186...4,855,902
|
|
G
|
Mmp8
|
matrix metallopeptidase 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP9 mRNA; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein] Dextran Sulfate results in increased expression of MMP9 mRNA; Dextran Sulfate results in increased expression of MMP9 protein
|
CTD |
PMID:19285099 PMID:27125760 PMID:29950665 PMID:30972795 PMID:32033881 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G
|
Mmut
|
methylmalonyl-CoA mutase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMUT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046
|
|
G
|
Mnda
|
myeloid cell nuclear differentiation antigen
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFI204 mRNA Dextran Sulfate results in increased expression of PYHIN1 mRNA
|
CTD |
PMID:23894361 PMID:29950665 |
|
NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201
|
|
G
|
Mns1
|
meiosis-specific nuclear structural 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MNS1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:73,148,877...73,169,570
Ensembl chr 8:73,148,877...73,176,925
|
|
G
|
Mob4
|
MOB family member 4, phocein
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MOB4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 9:56,617,374...56,641,336
Ensembl chr 9:56,617,368...56,641,329
|
|
G
|
Morn2
|
MORN repeat containing 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MORN2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 6:14,718,799...14,725,281
|
|
G
|
Mpeg1
|
macrophage expressed 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MPEG1 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855
|
|
G
|
Mpi
|
mannose phosphate isomerase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MPI mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:57,947,883...57,956,205
Ensembl chr 8:57,947,893...57,956,150
|
|
G
|
Mpig6b
|
megakaryocyte and platelet inhibitory receptor G6b
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of MPIG6B protein
|
CTD |
PMID:35999755 |
|
NCBI chr20:3,757,396...3,761,024
Ensembl chr20:3,757,536...3,760,735
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions increases expression increases activity increases secretion
|
EXP ISO
|
Capsaicin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; lafutidine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Oligosaccharides inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Olmesartan Medoxomil inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Rosiglitazone inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; zileuton inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; 4-methylesculetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; [APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of MPO protein; [Probenecid binds to Dextrans] inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased activity of MPO protein; [Streptozocin co-treated with Dextran Sulfate] results in increased activity of MPO protein; alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; icilin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; ligustilide inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; morphiceptin analog inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Tropisetron inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]
|
CTD |
PMID:11766996 PMID:15339030 PMID:15573930 PMID:16375993 PMID:20637373 PMID:20881082 PMID:21724996 PMID:21893696 PMID:23261679 PMID:23261717 PMID:23596210 PMID:23665423 PMID:24038091 PMID:24146755 PMID:24384223 PMID:25149976 PMID:25231984 PMID:25448682 PMID:25472953 PMID:25777935 PMID:25837923 PMID:26190278 PMID:26262998 PMID:26631293 PMID:27125760 PMID:27920472 PMID:27995407 PMID:28421826 PMID:29217385 PMID:29496522 PMID:30102254 PMID:30142311 PMID:30270565 PMID:30611738 PMID:30972795 PMID:31676321 PMID:31737179 PMID:32470352 PMID:33130971 PMID:33974900 PMID:34964214 PMID:37001609 PMID:37263555 PMID:38648921 PMID:38663798 More...
|
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G
|
Mpst
|
mercaptopyruvate sulfurtransferase
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MPST protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:111,836,079...111,843,651
Ensembl chr 7:109,955,675...109,963,141
|
|
G
|
Mrc1
|
mannose receptor, C type 1
|
multiple interactions decreases expression
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein] Dextran Sulfate results in decreased expression of MRC1 mRNA; Dextran Sulfate results in decreased expression of MRC1 protein
|
CTD |
PMID:25026504 PMID:38164749 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G
|
Mrpl20
|
mitochondrial ribosomal protein L20
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MRPL20 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:166,408,962...166,413,492
Ensembl chr 5:166,408,962...166,413,492
|
|
G
|
Mrpl22
|
mitochondrial ribosomal protein L22
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of MRPL22 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MRPL22 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:42,345,446...42,355,779
Ensembl chr10:42,342,776...42,355,779
|
|
G
|
Ms4a1
|
membrane spanning 4-domains A1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MS4A1 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 1:217,331,274...217,351,934
Ensembl chr 1:207,906,374...207,918,512
|
|
G
|
Msmo1
|
methylsterol monooxygenase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of MSMO1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G
|
Msn
|
moesin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MSN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
|
|
G
|
Msrb3
|
methionine sulfoxide reductase B3
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MSRB3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:56,260,985...56,426,004
Ensembl chr 7:56,303,308...56,425,496
|
|
G
|
Mt-nd1
|
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ND1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ND1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
|
|
G
|
Mt-nd4
|
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ND4 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ND4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537
|
|
G
|
Mt-nd6
|
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of ND6 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G
|
Mt1
|
metallothionein 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of MT1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MT1 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G
|
Mt2
|
metallothionein 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MT2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,832,002...10,832,784
|
|
G
|
Mtnr1a
|
melatonin receptor 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:47,144,461...47,163,919
Ensembl chr16:47,144,461...47,163,919
|
|
G
|
Mtnr1b
|
melatonin receptor 1B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:12,638,219...12,652,737
Ensembl chr 8:12,638,219...12,652,737
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
increases expression multiple interactions decreases phosphorylation increases phosphorylation
|
ISO EXP
|
Dextran Sulfate results in increased expression of MTOR protein biochanin A inhibits the reaction [Dextran Sulfate results in increased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein] Dextran Sulfate results in increased expression of MTOR protein modified form celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein modified form]
|
CTD |
PMID:26074695 PMID:27611972 PMID:31926917 PMID:32470352 PMID:38648921 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G
|
Mtpn
|
myotrophin
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MTPN protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 4:64,159,273...64,186,686
Ensembl chr 4:64,157,641...64,186,724
|
|
G
|
Muc13
|
mucin 13, cell surface associated
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC13 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:66,957,208...66,980,264
Ensembl chr11:66,960,595...66,984,727
|
|
G
|
Muc2
|
mucin 2, oligomeric mucus/gel-forming
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of MUC2 mRNA; Dextran Sulfate results in decreased expression of MUC2 protein biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of MUC2 protein]
|
CTD |
PMID:37385329 PMID:38648921 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G
|
Muc4
|
mucin 4, cell surface associated
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:81,513,321...81,575,200
|
|
G
|
Musk
|
muscle associated receptor tyrosine kinase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MUSK mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:73,058,427...73,169,696
Ensembl chr 5:73,058,121...73,171,932
|
|
G
|
Mvd
|
mevalonate diphosphate decarboxylase
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MVD protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G
|
Mybpc1
|
myosin binding protein C1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:24,817,770...24,903,681
Ensembl chr 7:22,930,350...23,015,957
|
|
G
|
Mybpc2
|
myosin binding protein C2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:94,994,121...95,017,584
Ensembl chr 1:94,994,104...95,017,584
|
|
G
|
Mybpc3
|
myosin binding protein C3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:77,095,165...77,113,406
Ensembl chr 3:77,095,252...77,113,405
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein]
|
CTD |
PMID:31715269 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
multiple interactions increases expression
|
ISO
|
Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of MYD88 protein]; flavokawain B inhibits the reaction [Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of MYD88 protein]
|
CTD |
PMID:35362542 PMID:38583725 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415
|
|
G
|
Myh8
|
myosin heavy chain 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYH8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:52,462,509...52,492,105
Ensembl chr10:51,963,510...51,993,232
|
|
G
|
Myh9
|
myosin, heavy chain 9
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of MYH9 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:109,343,706...109,424,457
|
|
G
|
Myl1
|
myosin, light chain 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:68,437,514...68,458,256
Ensembl chr 9:68,437,517...68,458,261
|
|
G
|
Myl3
|
myosin light chain 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:110,738,669...110,744,814
Ensembl chr 8:110,738,661...110,744,816
|
|
G
|
Myl4
|
myosin, light chain 4
|
multiple interactions increases expression decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of MYL4 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MYL4 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr10:89,949,733...89,985,308
Ensembl chr10:89,449,443...89,485,363
|
|
G
|
Myl6
|
myosin light chain 6
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of MYL6 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of MYL6 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:910,764...914,062
Ensembl chr 7:910,774...933,791
|
|
G
|
Myl7
|
myosin light chain 7
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of MYL7 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr14:80,780,684...80,783,259
Ensembl chr14:80,779,776...80,783,244
|
|
G
|
Myl9
|
myosin light chain 9
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of MYL9 protein Dextran Sulfate results in decreased expression of MYL9 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G
|
Mylk2
|
myosin light chain kinase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYLK2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:141,376,450...141,388,357
Ensembl chr 3:141,376,691...141,387,728
|
|
G
|
Myo1b
|
myosin Ib
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of MYO1B protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MYO1B protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798
|
|
G
|
Myo5b
|
myosin Vb
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of MYO5B mRNA
|
CTD |
PMID:37385329 |
|
NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745
|
|
G
|
Myo7a
|
myosin VIIA
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYO7A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:152,342,611...152,414,171
Ensembl chr 1:152,344,448...152,414,157
|
|
G
|
Mzb1
|
marginal zone B and B1 cell-specific protein
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of MZB1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:27,238,999...27,241,060
Ensembl chr18:27,239,001...27,241,094
|
|
G
|
N4bp3
|
Nedd4 binding protein 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of N4BP3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:35,898,031...35,906,704
Ensembl chr10:35,899,096...35,907,001
|
|
G
|
Nagk
|
N-acetylglucosamine kinase
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of NAGK protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:116,281,179...116,293,870
Ensembl chr 4:116,281,328...116,313,137
|
|
G
|
Nalcn
|
sodium leak channel, non-selective
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of NALCN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:100,398,583...100,741,243
Ensembl chr15:100,398,615...100,741,001
|
|
G
|
Nans
|
N-acetylneuraminate synthase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NANS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:60,780,441...60,797,583
Ensembl chr 5:60,780,392...60,814,950
|
|
G
|
Napepld
|
N-acyl phosphatidylethanolamine phospholipase D
|
multiple interactions decreases expression
|
ISO
|
GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]
|
CTD |
PMID:30611738 |
|
NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748
|
|
G
|
Napg
|
NSF attachment protein gamma
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of NAPG protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of NAPG protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:56,439,620...56,459,159
Ensembl chr18:56,440,505...56,459,153
|
|
G
|
Nat2
|
N-acetyltransferase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NAT2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:26,974,874...27,005,191
Ensembl chr16:22,208,194...22,238,520
|
|
G
|
Ncan
|
neurocan
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCAN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
|
|
G
|
Nceh1
|
neutral cholesterol ester hydrolase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCEH1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G
|
Nckipsd
|
NCK interacting protein with SH3 domain
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCKIPSD mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:109,511,484...109,522,622
Ensembl chr 8:109,511,658...109,522,246
|
|
G
|
Ncor2
|
nuclear receptor co-repressor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCOR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G
|
Ndrg2
|
NDRG family member 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of NDRG2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NDRG2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626
|
|
G
|
Ndufaf3
|
NADH:ubiquinone oxidoreductase complex assembly factor 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of NDUFAF3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:109,261,362...109,263,194
Ensembl chr 8:109,261,363...109,263,194
|
|
G
|
Neb
|
nebulin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NEB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574
|
|
G
|
Nedd4
|
NEDD4 E3 ubiquitin protein ligase
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of NEDD4 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G
|
Neurod1
|
neuronal differentiation 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NEUROD1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:64,359,554...64,363,526
Ensembl chr 3:64,359,395...64,363,649
|
|
G
|
Nfat5
|
nuclear factor of activated T-cells 5
|
increases activity decreases expression
|
ISO
|
Dextran Sulfate results in increased activity of NFAT5 protein Dextran Sulfate results in decreased expression of NFAT5 mRNA
|
CTD |
PMID:27920257 PMID:35093514 |
|
NCBI chr19:52,108,982...52,196,418
Ensembl chr19:35,199,016...35,286,675
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
affects response to substance decreases expression multiple interactions
|
ISO
|
NFE2L2 affects the susceptibility to Dextran Sulfate Dextran Sulfate results in decreased expression of NFE2L2 mRNA; Dextran Sulfate results in decreased expression of NFE2L2 protein [asperuloside co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; [Cholecalciferol co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; NFE2L2 results in decreased susceptibility to [Dextran Sulfate co-treated with Azoxymethane]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 protein]
|
CTD |
PMID:20404090 PMID:23056183 PMID:23261717 PMID:30142311 PMID:30844440 PMID:31737179 PMID:33974900 PMID:36135333 More...
|
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions affects localization
|
EXP ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein] monotropein inhibits the reaction [Dextran Sulfate affects the localization of NFKB1 protein]
|
CTD |
PMID:19028472 PMID:23261679 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions increases expression increases phosphorylation decreases expression
|
ISO EXP
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; Dextran Sulfate results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; nuciferine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein] banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:19940103 PMID:21724996 PMID:23261679 PMID:25472953 PMID:26190278 PMID:32272095 PMID:35362542 PMID:36577154 PMID:36806191 PMID:38583725 More...
|
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G
|
Nfkbil1
|
NFKB inhibitor like 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of NFKBIL1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr20:3,595,319...3,610,295
Ensembl chr20:3,590,642...3,605,616
|
|
G
|
Niban1
|
niban apoptosis regulator 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of NIBAN1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G
|
Nid2
|
nidogen 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NID2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:4,458,082...4,513,808
Ensembl chr15:4,458,084...4,513,843
|
|
G
|
Nipsnap1
|
nipsnap homolog 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of NIPSNAP1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of NIPSNAP1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098
|
|
G
|
Nkd1
|
NKD inhibitor of WNT signaling pathway 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr19:34,649,803...34,722,846
Ensembl chr19:18,476,344...18,549,380
|
|
G
|
Nkx2-2
|
NK2 homeobox 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NKX2-2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:155,072,621...155,083,699
Ensembl chr 3:134,620,039...134,622,411
|
|
G
|
Nlgn1
|
neuroligin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:110,184,987...111,110,316
Ensembl chr 2:108,257,824...109,002,464
|
|
G
|
Nlgn3
|
neuroligin 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:70,469,251...70,497,380
Ensembl chr X:66,429,458...66,451,876
|
|
G
|
Nln
|
neurolysin
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of NLN protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NLN protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:35,133,634...35,232,927
Ensembl chr 2:35,134,145...35,232,914
|
|
G
|
Nlrc5
|
NLR family, CARD domain containing 5
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of NLRC5 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr19:10,477,638...10,581,023
Ensembl chr19:10,477,628...10,562,121
|
|
G
|
Nlrp1a
|
NLR family, pyrin domain containing 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLRP1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions increases expression
|
ISO EXP
|
[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of NLRP3 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of NLRP3 mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; nuciferine inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein] Dextran Sulfate results in increased expression of NLRP3 mRNA; Dextran Sulfate results in increased expression of NLRP3 protein celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]]
|
CTD |
PMID:27611972 PMID:30270565 PMID:32470352 PMID:36577154 PMID:37001609 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811
|
|
G
|
Nmb
|
neuromedin B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NMB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:134,869,446...134,875,507
Ensembl chr 1:134,869,446...134,872,190
|
|
G
|
Nme1
|
NME/NM23 nucleoside diphosphate kinase 1
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of NME1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of NME1 protein]
|
CTD |
PMID:35362542 PMID:35999755 |
|
NCBI chr10:79,403,939...79,426,620
Ensembl chr10:78,906,083...78,916,408
|
|
G
|
Nme2
|
NME/NM23 nucleoside diphosphate kinase 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of NME2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:79,394,999...79,400,418
Ensembl chr10:78,897,770...78,903,538 Ensembl chr20:78,897,770...78,903,538
|
|
G
|
Nmur2
|
neuromedin U receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NMUR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:40,666,824...40,682,679
Ensembl chr10:40,166,226...40,182,078
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression affects response to substance increases activity
|
ISO
|
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of NOS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased activity of NOS2 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of NOS2 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; RELA protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA] Dextran Sulfate results in increased expression of NOS2 mRNA; Dextran Sulfate results in increased expression of NOS2 protein NOS2 protein affects the susceptibility to Dextran Sulfate
|
CTD |
PMID:15459021 PMID:15652231 PMID:16049979 PMID:17438113 PMID:17449036 PMID:19285099 PMID:20132809 PMID:20155626 PMID:23261679 PMID:23894361 PMID:25026504 PMID:25448682 PMID:25472953 PMID:26190278 PMID:26631293 PMID:27920257 PMID:29496522 PMID:30142311 PMID:30972795 PMID:32033881 PMID:33130971 PMID:36281492 PMID:36543318 PMID:38164749 PMID:38437956 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166
|
|
G
|
Notum
|
NOTUM, palmitoleoyl-protein carboxylesterase
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:106,431,572...106,438,654
Ensembl chr10:105,933,249...105,940,315
|
|
G
|
Nox4
|
NADPH oxidase 4
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of NOX4 mRNA; Dextran Sulfate results in increased expression of NOX4 protein
|
CTD |
PMID:36281492 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:140,901,097...141,077,406
|
|
G
|
Npl
|
N-acetylneuraminate pyruvate lyase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of NPL protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of NPL protein]
|
CTD |
PMID:32272095 |
|
NCBI chr13:65,655,099...65,697,464
Ensembl chr13:65,655,118...65,697,372
|
|
G
|
Nptx1
|
neuronal pentraxin 1
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of NPTX1 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr10:104,811,107...104,820,358
Ensembl chr10:104,811,403...104,820,367
|
|
G
|
Npy
|
neuropeptide Y
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:78,881,264...78,888,495
|
|
G
|
Npy1r
|
neuropeptide Y receptor Y1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY1R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759
|
|
G
|
Npy2r
|
neuropeptide Y receptor Y2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NPY2R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:167,901,999...167,912,165
Ensembl chr 2:167,903,879...167,905,024
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of NQO1 mRNA; Dextran Sulfate results in decreased expression of NQO1 protein gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of NQO1 protein]
|
CTD |
PMID:36135333 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1H4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1I2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G
|
Nr5a2
|
nuclear receptor subfamily 5, group A, member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR5A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:50,865,253...50,985,107
Ensembl chr13:48,316,301...48,433,326
|
|
G
|
Nrk
|
Nik related kinase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of NRK mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr X:102,365,765...102,462,957
Ensembl chr X:102,365,765...102,459,657
|
|
G
|
Nrp1
|
neuropilin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NRP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G
|
Ntng1
|
netrin G1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NTNG1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:197,462,785...197,827,681
Ensembl chr 2:197,463,945...197,826,997
|
|
G
|
Nts
|
neurotensin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NTS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G
|
Nucb1
|
nucleobindin 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of NUCB1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220
|
|
G
|
Nudc
|
nuclear distribution C, dynein complex regulator
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of NUDC mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:145,758,006...145,771,390
Ensembl chr 5:145,758,002...145,771,425
|
|
G
|
Nudt16
|
nudix hydrolase 16
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NUDT16 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 8:114,618,706...114,620,761
Ensembl chr 8:105,739,623...105,741,998
|
|
G
|
Nup133
|
nucleoporin 133
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of NUP133 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:51,891,606...51,941,243
Ensembl chr19:51,891,629...51,941,239
|
|
G
|
Nup205
|
nucleoporin 205
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of NUP205 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of NUP205 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 4:63,854,934...63,920,852
Ensembl chr 4:63,854,783...63,920,844
|
|
G
|
Nup93
|
nucleoporin 93
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of NUP93 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:10,684,214...10,788,009
Ensembl chr19:10,682,075...10,788,026
|
|
G
|
Nupr2
|
nuclear protein 2, transcriptional regulator
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of NUPR2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr12:32,436,233...32,439,391
Ensembl chr12:26,799,800...26,803,304
|
|
G
|
Nxn
|
nucleoredoxin
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of NXN protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of NXN protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:61,109,322...61,247,578
Ensembl chr10:61,110,020...61,248,251
|
|
G
|
Ocln
|
occludin
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of OCLN mRNA; Dextran Sulfate results in decreased expression of OCLN protein 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of OCLN protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; HU 211 inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; isomaltulose inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN mRNA]; isomaltulose inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of OCLN protein]
|
CTD |
PMID:23261717 PMID:27995407 PMID:35439472 PMID:35670535 PMID:35894244 PMID:36281492 PMID:36543318 PMID:37001609 PMID:37209277 PMID:37385329 PMID:38648921 PMID:38663798 More...
|
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:31,657,220...31,764,150
|
|
G
|
Oga
|
O-GlcNAcase
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of OGA protein Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of OGA protein]; thiamet G inhibits the reaction [Dextran Sulfate results in decreased expression of OGA protein]
|
CTD |
PMID:38437956 |
|
NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359
|
|
G
|
Ogt
|
O-linked N-acetylglucosamine (GlcNAc) transferase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of OGT protein Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of OGT protein]; thiamet G inhibits the reaction [Dextran Sulfate results in increased expression of OGT protein]
|
CTD |
PMID:38437956 |
|
NCBI chr X:70,811,317...70,856,123
Ensembl chr X:66,771,349...66,816,146
|
|
G
|
Olr1088
|
olfactory receptor 1088
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:11,111,768...11,115,501
Ensembl chr 7:11,111,581...11,114,960
|
|
G
|
Olr1096
|
olfactory receptor 1096
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2Z9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:14,774,197...14,775,147
|
|
G
|
Olr1877
|
olfactory receptor 1877
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10AD1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:129,370,144...129,381,836
Ensembl chr 7:129,370,929...129,382,142 Ensembl chr 7:129,370,929...129,382,142
|
|
G
|
Olr59
|
olfactory receptor 59
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51E2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179
|
|
G
|
Opn1mw
|
opsin 1, medium wave sensitive
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPN1MW mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:157,056,355...157,076,716
Ensembl chr X:151,905,096...151,925,388
|
|
G
|
Oprd1
|
opioid receptor, delta 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPRD1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G
|
Oprk1
|
opioid receptor, kappa 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OPRK1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G
|
Or10al6
|
olfactory receptor family 10 subfamily AL member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10AL6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:738,257...739,607
Ensembl chr20:734,965...811,125
|
|
G
|
Or10h28
|
olfactory receptor family 10 subfamily H member 28
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10H28 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:12,591,719...12,592,669
Ensembl chr 7:12,782,691...12,788,381
|
|
G
|
Or10j3
|
olfactory receptor family 10 subfamily J member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10J3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:85,667,254...85,668,195
Ensembl chr13:85,662,666...85,669,540
|
|
G
|
Or11a4
|
olfactory receptor family 11 subfamily A member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR11A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:1,354,527...1,355,468
Ensembl chr20:1,353,852...1,360,783
|
|
G
|
Or13c25
|
olfactory receptor family 13 subfamily C member 25
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR13C25 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:67,518,691...67,519,650
Ensembl chr 5:67,518,123...67,527,767
|
|
G
|
Or1b1
|
olfactory receptor family 1 subfamily B member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:20,639,976...20,640,929
Ensembl chr 3:20,637,490...20,646,767
|
|
G
|
Or1f34
|
olfactory receptor family 1 subfamily F member 34
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1F19 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:12,333,860...12,334,801
Ensembl chr10:12,333,860...12,334,801
|
|
G
|
Or1m1
|
olfactory receptor family 1 subfamily M member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1M1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:16,447,986...16,448,927
Ensembl chr 8:16,444,273...16,458,148
|
|
G
|
Or1q1
|
olfactory receptor family 1 subfamily Q member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1Q1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:20,506,995...20,507,921
Ensembl chr 3:20,503,077...20,509,271
|
|
G
|
Or1r1
|
olfactory receptor family 1 subfamily R member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR1R1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:58,890,357...58,891,301
Ensembl chr10:58,890,357...58,891,301
|
|
G
|
Or2ag2
|
olfactory receptor family 2 subfamily AG member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2AG2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:160,695,621...160,696,571
Ensembl chr 1:160,695,621...160,696,571
|
|
G
|
Or2f2
|
olfactory receptor family 2 subfamily F member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2F2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:71,740,193...71,741,149
Ensembl chr 4:71,735,342...71,741,785
|
|
G
|
Or2l13
|
olfactory receptor family 2 subfamily L member 13
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2L13 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:81,400,197...81,401,135
Ensembl chr11:81,399,173...81,404,284
|
|
G
|
Or2t26
|
olfactory receptor family 2 subfamily T member 26
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2T26 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:33,446,540...33,447,493
Ensembl chr10:33,439,638...33,448,773
|
|
G
|
Or2v1
|
olfactory receptor family 2 subfamily V member 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of OR2V1 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr10:33,399,891...33,404,298
Ensembl chr10:33,398,913...33,404,401
|
|
G
|
Or2v2
|
olfactory receptor family 2 subfamily V member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2V2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:33,379,863...33,380,810
Ensembl chr10:33,376,687...33,381,900
|
|
G
|
Or3a4
|
olfactory receptor family 3 subfamily A member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR3A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:58,967,244...58,968,179
Ensembl chr10:58,964,878...58,969,914
|
|
G
|
Or4c105
|
olfactory receptor family 4 subfamily C member 105
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4C10B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:74,582,417...74,583,346
Ensembl chr 3:74,579,912...74,593,375
|
|
G
|
Or4c123
|
olfactory receptor family 4 subfamily C member 123
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C123 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:75,272,475...75,273,392
Ensembl chr 3:75,272,475...75,273,392
|
|
G
|
Or4c15
|
olfactory receptor family 4 subfamily C member 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:74,692,006...74,694,901
Ensembl chr 3:74,689,082...74,707,227
|
|
G
|
Or4e2
|
olfactory receptor family 4 subfamily E member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4E2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:25,187,633...25,188,559
Ensembl chr15:25,179,800...25,191,297
|
|
G
|
Or4f15
|
olfactory receptor family 4 subfamily F member 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4F15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:98,556,667...98,566,115
Ensembl chr 3:98,563,361...98,573,326
|
|
G
|
Or4n5
|
olfactory receptor family 4 subfamily N member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4N5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:23,167,750...23,168,676
Ensembl chr15:23,166,235...23,174,805
|
|
G
|
Or4q3
|
olfactory receptor family 4 subfamily Q member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4Q3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:23,531,029...23,535,992
|
|
G
|
Or51a39
|
olfactory receptor family 51 subfamily A member 39
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR51A39 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:157,152,386...157,153,348
Ensembl chr 1:157,152,445...157,157,349
|
|
G
|
Or51a7
|
olfactory receptor family 51 subfamily A member 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51A7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:157,395,779...157,396,717
Ensembl chr 1:157,395,779...157,396,717
|
|
G
|
Or51b6
|
olfactory receptor family 51 subfamily B member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51B6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:158,347,649...158,348,596
Ensembl chr 1:158,344,509...158,349,843
|
|
G
|
Or51d1
|
olfactory receptor family 51 subfamily D member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51D1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:157,134,584...157,135,641
Ensembl chr 1:157,134,673...157,135,641
|
|
G
|
Or51g1
|
olfactory receptor family 51 subfamily G member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51G1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:157,438,123...157,439,064
Ensembl chr 1:157,437,827...157,443,743
|
|
G
|
Or51g2
|
olfactory receptor family 51 subfamily G member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51G2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:157,421,637...157,422,575
Ensembl chr 1:157,421,637...157,422,575
|
|
G
|
Or52b1
|
olfactory receptor family 52 subfamily B member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR52B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:159,684,419...159,685,363
Ensembl chr 1:159,684,419...159,685,363
|
|
G
|
Or52e8
|
olfactory receptor family 52 subfamily E member 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR52E8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:159,360,430...159,361,380
Ensembl chr 1:159,360,430...159,361,380
|
|
G
|
Or5b12b
|
olfactory receptor family 5 subfamily B member 12B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5B12B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:210,042,752...210,043,696
Ensembl chr 1:210,042,752...210,043,696
|
|
G
|
Or5c1
|
olfactory receptor family 5 subfamily C member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5C1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:20,862,297...20,863,280
Ensembl chr 3:20,859,540...20,863,471
|
|
G
|
Or5e1
|
olfactory receptor family 5 subfamily E member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5E1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:162,724,328...162,725,263
Ensembl chr 1:162,718,237...162,727,919
|
|
G
|
Or5h17
|
olfactory receptor family 5 subfamily H member 17
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5H19 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:41,462,116...41,463,045
Ensembl chr11:41,460,540...41,468,102
|
|
G
|
Or5h18
|
olfactory receptor family 5 subfamily H member 18
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5H26 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:41,405,194...41,423,800
Ensembl chr11:41,385,342...41,424,011
|
|
G
|
Or5k3
|
olfactory receptor family 5 subfamily K member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5K3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:41,259,026...41,259,952
Ensembl chr11:41,257,865...41,262,045
|
|
G
|
Or5p76b
|
olfactory receptor family 5 subfamily P member 76B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5P76 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:162,591,358...162,592,302
Ensembl chr 1:162,588,410...162,593,423
|
|
G
|
Or6b2
|
olfactory receptor family 6 subfamily B member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6B3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:93,048,475...93,049,413
Ensembl chr 9:93,045,014...93,053,641
|
|
G
|
Or6c1h
|
olfactory receptor family 6 subfamily C member 1H
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:2,099,351...2,100,301
Ensembl chr 7:2,092,631...2,101,801
|
|
G
|
Or6c2
|
olfactory receptor family 6 subfamily C member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:2,188,601...2,189,539
Ensembl chr 7:2,182,984...2,189,667
|
|
G
|
Or6c3
|
olfactory receptor family 6 subfamily C member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6C3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:4,540,307...4,541,242
Ensembl chr 7:4,540,253...4,542,686
|
|
G
|
Or6c68
|
olfactory receptor family 6 subfamily C member 68
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR6C68 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:5,197,831...5,198,781
Ensembl chr 7:5,197,831...5,198,781
|
|
G
|
Or6c74
|
olfactory receptor family 6 subfamily C member 74
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C74 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:6,663,296...6,664,234
Ensembl chr 7:6,659,998...6,664,564
|
|
G
|
Or6c8
|
olfactory receptor family 6 subfamily C member 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:1,502,160...1,503,089
Ensembl chr 7:1,501,940...1,507,336
|
|
G
|
Or6k4
|
olfactory receptor family 6 subfamily K member 14B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6K4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:86,164,244...86,165,191
Ensembl chr13:86,160,158...86,166,214
|
|
G
|
Or6k6
|
olfactory receptor family 6 subfamily K member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6K6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:86,148,402...86,149,325
Ensembl chr13:86,147,303...86,152,153
|
|
G
|
Or6n2
|
olfactory receptor family 6 subfamily N member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6N2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:86,076,857...86,087,100
|
|
G
|
Or7e178
|
olfactory receptor, family 7, subfamily E, member 178
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR7E178 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:18,723,515...18,735,910
Ensembl chr 8:18,725,214...18,735,776
|
|
G
|
Or8b12
|
olfactory receptor family 8 subfamily B member 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR8B12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:37,479,706...37,480,638
Ensembl chr 8:37,478,794...37,481,315
|
|
G
|
Or8g2
|
olfactory receptor family 8 subfamily G member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:40,266,465...40,268,873
Ensembl chr 8:40,267,950...40,268,873
|
|
G
|
Or9a4
|
olfactory receptor family 9 subfamily A member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR9A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:69,401,606...69,402,550
Ensembl chr 4:69,399,601...69,404,723
|
|
G
|
Or9g4
|
olfactory receptor family 9 subfamily G member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR9G4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:70,727,963...70,728,901
Ensembl chr 3:70,726,935...70,732,439
|
|
G
|
Osm
|
oncostatin M
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSM mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:83,327,202...83,332,073
Ensembl chr14:79,104,344...79,108,313
|
|
G
|
Osmr
|
oncostatin M receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSMR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:57,634,517...57,688,802
Ensembl chr 2:55,907,132...55,961,262
|
|
G
|
Otc
|
ornithine transcarbamylase
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of OTC protein]
|
CTD |
PMID:35362542 |
|
NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918
|
|
G
|
Oxtr
|
oxytocin receptor
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of OXTR mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:147,154,374...147,171,723
Ensembl chr 4:145,599,561...145,614,674
|
|
G
|
P2rx5
|
purinergic receptor P2X 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
|
|
G
|
P2rx7
|
purinergic receptor P2X 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G
|
P2ry4
|
pyrimidinergic receptor P2Y4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of P2RY4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:65,681,680...65,717,404
Ensembl chr X:65,683,232...65,721,748
|
|
G
|
P2ry6
|
pyrimidinergic receptor P2Y6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RY6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:155,295,111...155,330,808
|
|
G
|
P3h3
|
prolyl 3-hydroxylase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P3H3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:157,646,242...157,662,035
Ensembl chr 4:157,646,243...157,662,035
|
|
G
|
P4hb
|
prolyl 4-hydroxylase subunit beta
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P4HB mRNA Dextran Sulfate results in decreased expression of P4HB protein
|
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G
|
Pabpn1
|
poly(A) binding protein, nuclear 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PABPN1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr15:28,368,100...28,372,712
Ensembl chr15:28,368,100...28,372,703
|
|
G
|
Pag1
|
phosphoprotein membrane anchor with glycosphingolipid microdomains 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAG1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:91,935,378...92,076,937
Ensembl chr 2:92,057,216...92,069,849
|
|
G
|
Pak4
|
p21 (RAC1) activated kinase 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAK4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:92,977,437...93,016,721
Ensembl chr 1:83,849,904...83,859,413
|
|
G
|
Palm
|
paralemmin
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PALM protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:10,537,252...10,563,346
Ensembl chr 7:9,886,643...9,912,555
|
|
G
|
Pank1
|
pantothenate kinase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PANK1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:232,328,430...232,396,829
|
|
G
|
Paox
|
polyamine oxidase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAOX mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:194,919,655...194,928,498
Ensembl chr 1:194,903,273...194,928,504
|
|
G
|
Pappa
|
pappalysin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAPPA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
|
|
G
|
Papss2
|
3'-phosphoadenosine 5'-phosphosulfate synthase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAPSS2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:239,867,597...239,952,614
Ensembl chr 1:230,454,426...230,539,331
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage multiple interactions
|
ISO
|
Dextran Sulfate results in increased cleavage of PARP1 protein [Camptothecin co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; [Plant Extracts co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of PARP1 protein]
|
CTD |
PMID:21989142 PMID:25449198 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G
|
Parp9
|
poly (ADP-ribose) polymerase family, member 9
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of PARP9 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PARP9 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr11:64,780,977...64,814,995
Ensembl chr11:64,780,981...64,815,455
|
|
G
|
Parvb
|
parvin, beta
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of PARVB protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PARVB protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:115,360,254...115,445,767
Ensembl chr 7:115,360,261...115,445,766
|
|
G
|
Pawr
|
pro-apoptotic WT1 regulator
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PAWR protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
|
|
G
|
Pax4
|
paired box 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:57,058,453...57,065,995
Ensembl chr 4:57,058,462...57,063,408
|
|
G
|
Pax6
|
paired box 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:92,135,637...92,157,014
|
|
G
|
Pccb
|
propionyl-CoA carboxylase subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCCB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:101,590,737...101,641,234
|
|
G
|
Pcdhgb1
|
protocadherin gamma subfamily B, 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PCDHGB1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr18:29,501,739...29,508,024
|
|
G
|
Pck1
|
phosphoenolpyruvate carboxykinase 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PCK1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:161,930,256...161,936,191
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions decreases expression
|
ISO EXP
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of PCNA protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of PCNA protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein] [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]
|
CTD |
PMID:17438113 PMID:19028472 PMID:34964214 PMID:38648921 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G
|
Pcnp
|
PEST proteolytic signal containing nuclear protein
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PCNP protein]
|
CTD |
PMID:32272095 |
|
NCBI chr11:44,592,766...44,607,372
Ensembl chr11:44,592,742...44,607,348
|
|
G
|
Pcolce
|
procollagen C-endopeptidase enhancer
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PCOLCE mRNA Dextran Sulfate results in decreased expression of PCOLCE mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr12:19,084,191...19,090,508
Ensembl chr12:19,084,210...19,090,508
|
|
G
|
Pcp4l1
|
Purkinje cell protein 4-like 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PCP4L1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr13:83,588,992...83,612,631
Ensembl chr13:83,588,992...83,609,966
|
|
G
|
Pdap1
|
PDGFA associated protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PDAP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr12:9,470,652...9,480,880
Ensembl chr12:9,470,574...9,535,374
|
|
G
|
Pdcd4
|
programmed cell death 4
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PDCD4 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PDCD4 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:252,921,392...252,944,275
|
|
G
|
Pde10a
|
phosphodiesterase 10A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE10A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G
|
Pde1a
|
phosphodiesterase 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:64,747,269...65,024,874
|
|
G
|
Pde1c
|
phosphodiesterase 1C
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE1C mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:85,300,858...85,863,219
|
|
G
|
Pde2a
|
phosphodiesterase 2A
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE2A mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PDE2A protein]
|
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 1:165,235,623...165,327,466
Ensembl chr 1:155,813,180...155,915,434
|
|
G
|
Pde3a
|
phosphodiesterase 3A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE3A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:174,172,868...174,438,274
|
|
G
|
Pde4a
|
phosphodiesterase 4A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961
|
|
G
|
Pde4b
|
phosphodiesterase 4B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4B mRNA; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]
|
CTD |
PMID:29950665 PMID:30188895 |
|
NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:116,799,971...117,367,696
|
|
G
|
Pde7a
|
phosphodiesterase 7A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE7A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681
|
|
G
|
Pde7b
|
phosphodiesterase 7B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE7B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900
|
|
G
|
Pdgfb
|
platelet derived growth factor subunit B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:111,540,345...111,557,984
|
|
G
|
Pdgfra
|
platelet derived growth factor receptor alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,005,839...33,054,335
|
|
G
|
Pdgfrb
|
platelet derived growth factor receptor beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:56,770,348...56,809,228
Ensembl chr18:54,499,964...54,538,843
|
|
G
|
Pdia3
|
protein disulfide isomerase family A, member 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PDIA3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:108,388,245...108,413,236
|
|
G
|
Pdlim4
|
PDZ and LIM domain 4
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PDLIM4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:38,699,444...38,713,696
Ensembl chr10:38,198,689...38,212,938
|
|
G
|
Pds5a
|
PDS5 cohesin associated factor A
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PDS5A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr14:42,551,653...42,651,074
Ensembl chr14:42,552,647...42,648,669
|
|
G
|
Pdyn
|
prodynorphin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDYN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:137,354,161...137,366,503
Ensembl chr 3:116,900,992...116,913,334
|
|
G
|
Pdzk1ip1
|
PDZK1 interacting protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PDZK1IP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:128,618,050...128,623,131
Ensembl chr 5:128,618,237...128,623,131
|
|
G
|
Pea15
|
proliferation and apoptosis adaptor protein 15
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PEA15A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr13:84,657,815...84,667,437
Ensembl chr13:84,654,870...84,667,499
|
|
G
|
Pecam1
|
platelet and endothelial cell adhesion molecule 1
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PECAM1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:92,090,263...92,152,002
Ensembl chr10:91,590,521...91,652,116
|
|
G
|
Pf4
|
platelet factor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PF4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,298,308...17,299,365
|
|
G
|
Pfdn2
|
prefoldin subunit 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of PFDN2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PFDN2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr13:83,772,301...83,791,367
Ensembl chr13:83,753,877...83,790,504
|
|
G
|
Pfdn6
|
prefoldin subunit 6
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PFDN6 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr20:4,945,959...4,947,433
Ensembl chr20:4,945,959...4,947,433
|
|
G
|
Pfn1
|
profilin 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of PFN1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PFN1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G
|
Pfn3
|
profilin 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PFN3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr17:9,217,595...9,218,122
|
|
G
|
Pgam1
|
phosphoglycerate mutase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PGAM1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G
|
Pgam2
|
phosphoglycerate mutase 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PGAM2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:80,681,796...80,683,907
Ensembl chr14:80,681,776...80,683,940
|
|
G
|
Pgf
|
placental growth factor
|
decreases expression multiple interactions
|
EXP
|
Dextran Sulfate results in decreased expression of PGF mRNA Oligosaccharides inhibits the reaction [Dextran Sulfate results in decreased expression of PGF mRNA]
|
CTD |
PMID:16375993 |
|
NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:104,816,104...104,826,685
|
|
G
|
Pgk1
|
phosphoglycerate kinase 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PGK1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr X:75,336,988...75,352,962
Ensembl chr X:71,271,440...71,287,418
|
|
G
|
Pgls
|
6-phosphogluconolactonase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PGLS protein
|
CTD |
PMID:35999755 |
|
NCBI chr16:18,300,317...18,305,803
Ensembl chr16:18,300,317...18,305,803
|
|
G
|
Pgm1
|
phosphoglucomutase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728
|
|
G
|
Pgm2
|
phosphoglucomutase 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PGM2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:44,166,314...44,199,828
Ensembl chr14:44,164,425...44,199,967
|
|
G
|
Pgm3
|
phosphoglucomutase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:87,518,317...87,536,021
Ensembl chr 8:87,517,701...87,536,022
|
|
G
|
Pgp
|
phosphoglycolate phosphatase
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PGP mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G
|
Pgrmc1
|
progesterone receptor membrane component 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PGRMC1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr X:115,832,865...115,841,060
Ensembl chr X:115,832,884...115,888,682
|
|
G
|
Phex
|
phosphate regulating endopeptidase X-linked
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PHEX protein
|
CTD |
PMID:20025956 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G
|
Phka1
|
phosphorylase kinase regulatory subunit alpha 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:71,639,701...71,778,465
Ensembl chr X:67,601,302...67,738,455
|
|
G
|
Phkb
|
phosphorylase kinase regulatory subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:37,179,937...37,383,979
Ensembl chr19:21,025,733...21,210,633
|
|
G
|
Pik3ap1
|
phosphoinositide-3-kinase adaptor protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PIK3AP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:250,040,250...250,194,364
Ensembl chr 1:240,093,065...240,204,828
|
|
G
|
Pik3ca
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PIK3CA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:115,174,984...115,249,032
|
|
G
|
Pik3r5
|
phosphoinositide-3-kinase, regulatory subunit 5
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PIK3R5 protein
|
CTD |
PMID:20025956 |
|
NCBI chr10:53,631,469...53,699,550
Ensembl chr10:53,132,603...53,199,374
|
|
G
|
Pkdcc
|
protein kinase domain containing, cytoplasmic
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PKDCC mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 6:11,455,686...11,465,002
Ensembl chr 6:11,455,686...11,465,556
|
|
G
|
Pklr
|
pyruvate kinase L/R
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PKLR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:174,543,039...174,551,870
|
|
G
|
Pkp2
|
plakophilin 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of PKP2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PKP2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr11:98,165,974...98,231,916
Ensembl chr11:84,661,783...84,727,730
|
|
G
|
Pla2g10
|
phospholipase A2, group X
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:2,104,927...2,117,998
Ensembl chr10:1,597,761...1,609,000
|
|
G
|
Pla2g12a
|
phospholipase A2, group XIIA
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G12A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:221,110,722...221,126,966
Ensembl chr 2:218,436,513...218,452,740
|
|
G
|
Pla2g12b
|
phospholipase A2, group XIIB
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G12B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:27,910,620...27,931,734
Ensembl chr20:27,370,266...27,388,743
|
|
G
|
Pla2g2a
|
phospholipase A2 group IIA
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PLA2G2A mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:151,076,442...151,079,014
|
|
G
|
Pla2g2c
|
phospholipase A2, group IIC
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G2C mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:156,241,142...156,262,368
Ensembl chr 5:150,959,182...150,981,377
|
|
G
|
Pla2g2e
|
phospholipase A2, group IIE
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2E mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:151,121,363...151,127,147
Ensembl chr 5:151,121,439...151,126,821
|
|
G
|
Pla2g2f
|
phospholipase A2, group IIF
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2F mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:156,270,077...156,276,464
Ensembl chr 5:150,986,788...150,993,175
|
|
G
|
Pla2g4a
|
phospholipase A2 group 4A
|
increases phosphorylation multiple interactions
|
ISO
|
Dextran Sulfate results in increased phosphorylation of PLA2G4A protein tussilagone inhibits the reaction [Dextran Sulfate results in increased phosphorylation of PLA2G4A protein]
|
CTD |
PMID:30142311 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:61,877,813...62,022,266
|
|
G
|
Pla2g4c
|
phospholipase A2 group IVC
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PLA2G4C protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PLA2G4C protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PLA2G4C protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 1:83,315,017...83,411,342
Ensembl chr 1:74,236,211...74,274,656
|
|
G
|
Pla2g4f
|
phospholipase A2, group IVF
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G4F mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:127,702,603...127,720,429
Ensembl chr 3:107,250,075...107,264,689
|
|
G
|
Plat
|
plasminogen activator, tissue type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAU mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775
|
|
G
|
Plaur
|
plasminogen activator, urokinase receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAUR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:80,050,324...80,068,595
|
|
G
|
Plcb2
|
phospholipase C, beta 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLCB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:126,134,925...126,158,303
Ensembl chr 3:105,684,815...105,704,302
|
|
G
|
Plcb4
|
phospholipase C, beta 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCB4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:122,952,965...123,322,522
Ensembl chr 3:122,953,196...123,322,392
|
|
G
|
Plce1
|
phospholipase C, epsilon 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCE1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438
|
|
G
|
Plcg2
|
phospholipase C, gamma 2
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PLCG2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:62,456,196...62,592,684
Ensembl chr19:45,547,416...45,683,930
|
|
G
|
Pld3
|
phospholipase D family, member 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PLD3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:82,821,863...82,844,280
Ensembl chr 1:82,821,875...82,844,072
|
|
G
|
Plek
|
pleckstrin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLEK mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:91,397,015...91,429,693
Ensembl chr14:91,397,019...91,454,131
|
|
G
|
Plekho2
|
pleckstrin homology domain containing O2
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PLEKHO2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 8:66,079,106...66,105,283
Ensembl chr 8:66,078,448...66,105,266
|
|
G
|
Plg
|
plasminogen
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLG mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:48,325,185...48,367,786
|
|
G
|
Plod2
|
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLOD2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
|
|
G
|
Pls1
|
plastin 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of PLS1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PLS1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:96,316,703...96,426,592
Ensembl chr 8:96,317,849...96,385,195
|
|
G
|
Pltp
|
phospholipid transfer protein
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PLTP mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:153,574,825...153,592,647
Ensembl chr 3:153,574,825...153,592,647
|
|
G
|
Plxna1
|
plexin A1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PLXNA1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:121,737,934...121,782,901
Ensembl chr 4:121,737,945...122,024,196
|
|
G
|
Plxnc1
|
plexin C1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PLXNC1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779
|
|
G
|
Plxnd1
|
plexin D1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PLXND1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:149,002,786...149,043,097
Ensembl chr 4:149,002,784...149,043,244
|
|
G
|
Pmel
|
premelanosome protein
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PMEL protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746
|
|
G
|
Pmm2
|
phosphomannomutase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PMM2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:6,961,521...6,982,913
Ensembl chr10:6,961,709...6,983,098
|
|
G
|
Pnliprp1
|
pancreatic lipase-related protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PNLIPRP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:257,867,885...257,883,514
Ensembl chr 1:257,867,885...257,883,514
|
|
G
|
Pnp
|
purine nucleoside phosphorylase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PNP2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr15:26,644,147...26,651,808
Ensembl chr15:24,170,602...24,203,986
|
|
G
|
Pnpt1
|
polyribonucleotide nucleotidyltransferase 1
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PNPT1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PNPT1 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr14:102,877,553...102,908,696
Ensembl chr14:102,877,553...102,908,696
|
|
G
|
Podxl
|
podocalyxin-like
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PODXL mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G
|
Polr2h
|
RNA polymerase II, I and III subunit H
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of POLR2H protein]
|
CTD |
PMID:35362542 |
|
NCBI chr11:80,192,017...80,197,468
Ensembl chr11:80,192,032...80,197,515 Ensembl chr10:80,192,032...80,197,515
|
|
G
|
Pon3
|
paraoxonase 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PON3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855
|
|
G
|
Postn
|
periostin
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of POSTN protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of POSTN protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G
|
Ppard
|
peroxisome proliferator-activated receptor delta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARD mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,298,785...6,363,968
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
increases expression multiple interactions affects localization
|
ISO
|
Dextran Sulfate results in increased expression of PPARG protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARG mRNA; ligustilide inhibits the reaction [Dextran Sulfate affects the localization of PPARG protein]; Mesalamine inhibits the reaction [Dextran Sulfate affects the localization of PPARG protein]
|
CTD |
PMID:23261717 PMID:29950665 PMID:33130971 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions decreases expression
|
EXP
|
Hesperidin inhibits the reaction [Dextran Sulfate results in decreased expression of PPARGC1A protein]
|
CTD |
PMID:30811821 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G
|
Ppia
|
peptidylprolyl isomerase A
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PPIA protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
|
|
G
|
Ppic
|
peptidylprolyl isomerase C
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PPIC protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:46,842,410...46,855,016
Ensembl chr18:46,842,409...46,855,017
|
|
G
|
Ppih
|
peptidylprolyl isomerase H
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PPIH protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PPIH protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PPIH protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 5:138,191,624...138,209,625
Ensembl chr 5:132,906,328...132,924,267
|
|
G
|
Ppp1cc
|
protein phosphatase 1 catalytic subunit gamma
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PPP1CC mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr12:40,043,822...40,061,301
Ensembl chr12:34,383,072...34,400,553
|
|
G
|
Ppp1r14a
|
protein phosphatase 1, regulatory (inhibitor) subunit 14A
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of PPP1R14A protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of PPP1R14A protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:84,583,127...84,590,743
Ensembl chr 1:84,586,627...84,590,671
|
|
G
|
Ppp1r1b
|
protein phosphatase 1, regulatory (inhibitor) subunit 1B
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PPP1R1B protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PPP1R1B protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr10:83,843,948...83,853,063
Ensembl chr10:83,347,731...83,356,775
|
|
G
|
Ppp2r5d
|
protein phosphatase 2, regulatory subunit B', delta
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of PPP2R5D protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PPP2R5D protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 9:14,270,364...14,300,396
Ensembl chr 9:14,268,745...14,300,400
|
|
G
|
Ppp3cc
|
protein phosphatase 3 catalytic subunit gamma
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPP3CC mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:51,699,586...51,771,763
Ensembl chr15:45,290,373...45,361,832
|
|
G
|
Ppy
|
pancreatic polypeptide
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPY mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:87,054,747...87,056,044
Ensembl chr10:87,054,756...87,055,455
|
|
G
|
Prdx1
|
peroxiredoxin 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PRDX1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:130,147,204...130,162,856
|
|
G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
decreases phosphorylation multiple interactions
|
ISO
|
Dextran Sulfate results in decreased phosphorylation of PRKAA1 protein biochanin A inhibits the reaction [Dextran Sulfate results in decreased phosphorylation of PRKAA1 protein]
|
CTD |
PMID:38648921 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G
|
Prkaa2
|
protein kinase AMP-activated catalytic subunit alpha 2
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PRKAA2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:119,813,226...119,879,543
|
|
G
|
Prkacb
|
protein kinase cAMP-activated catalytic subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKACB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:238,297,140...238,389,317
Ensembl chr 2:235,636,885...235,726,198
|
|
G
|
Prkag2
|
protein kinase AMP-activated non-catalytic subunit gamma 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKAG2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:10,744,695...10,985,939
Ensembl chr 4:10,010,890...10,252,142
|
|
G
|
Prkca
|
protein kinase C, alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKCA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:92,894,012...93,288,012
|
|
G
|
Prkcb
|
protein kinase C, beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCB mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:176,832,226...177,163,536
|
|
G
|
Prkcq
|
protein kinase C, theta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCQ mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:72,156,215...72,288,508
Ensembl chr17:67,246,394...67,378,704
|
|
G
|
Prkg1
|
protein kinase cGMP-dependent 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of PRKG1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PRKG1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G
|
Prkg2
|
protein kinase cGMP-dependent 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKG2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:10,559,882...10,668,479
Ensembl chr14:10,559,882...10,666,888
|
|
G
|
Prl3d1
|
prolactin family 3, subfamily D member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRL3D1 mRNA
|
CTD |
PMID:29950665 |
|
|
|
G
|
Prlr
|
prolactin receptor
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRLR mRNA Dextran Sulfate results in decreased expression of PRLR mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:59,134,588...59,324,718
|
|
G
|
Prm3
|
protamine 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PRM3 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:4,877,471...4,877,985
Ensembl chr10:4,877,471...4,877,985
|
|
G
|
Proc
|
protein C, inactivator of coagulation factors Va and VIIIa
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PROC mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:24,038,596...24,049,061
Ensembl chr18:23,764,368...23,775,133
|
|
G
|
Prorsd1
|
prolyl-tRNA synthetase associated domain containing 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of PRORSD1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr14:103,257,979...103,260,248
Ensembl chr14:103,257,979...103,260,248
|
|
G
|
Pros1
|
protein S
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PROS1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:13,676,310...13,757,858
Ensembl chr11:230,696...311,286
|
|
G
|
Prox1
|
prospero homeobox 1
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of PROX1 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr13:101,669,184...101,719,804
Ensembl chr13:101,669,184...101,711,183
|
|
G
|
Prpf38b
|
pre-mRNA processing factor 38B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PRPF38B mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 2:196,553,224...196,562,271
Ensembl chr 2:196,553,225...196,562,250
|
|
G
|
Prpf4
|
pre-mRNA splicing tri-snRNP complex factor PRPF4
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of PRPF4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:75,859,934...75,873,924
Ensembl chr 5:75,859,924...75,873,919
|
|
G
|
Prrc1
|
proline-rich coiled-coil 1
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PRRC1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr18:50,812,548...50,846,273
Ensembl chr18:50,812,552...50,849,476
|
|
G
|
Prrc2c
|
proline-rich coiled-coil 2C
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of PRRC2C mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr13:75,003,995...75,073,701
Ensembl chr13:75,004,010...75,073,643
|
|
G
|
Prss3
|
serine protease 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRSS3 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRY4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:71,169,749...71,173,223
Ensembl chr 4:70,203,088...70,206,562
|
|
G
|
Prxl2b
|
peroxiredoxin like 2B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRXL2B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:170,744,953...170,747,556
|
|
G
|
Psen1
|
presenilin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PSEN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
G
|
Psmb8
|
proteasome 20S subunit beta 8
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PSMB8 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr20:4,652,159...4,655,122
Ensembl chr20:4,652,159...4,655,283
|
|
G
|
Pstpip1
|
proline-serine-threonine phosphatase-interacting protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PSTPIP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:56,499,287...56,538,593
Ensembl chr 8:56,499,590...56,538,580
|
|
G
|
Ptafr
|
platelet-activating factor receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTAFR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:150,049,322...150,079,060
Ensembl chr 5:144,765,976...144,795,251
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
multiple interactions
|
ISO
|
[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]
|
CTD |
PMID:26262998 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838
|
|
G
|
Ptgdr2
|
prostaglandin D2 receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
G
|
Ptgds
|
prostaglandin D2 synthase
|
multiple interactions decreases expression increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDS mRNA; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGDS protein] Dextran Sulfate results in decreased expression of PTGDS protein
|
CTD |
PMID:29950665 PMID:30489199 PMID:35999755 |
|
NCBI chr 3:28,680,044...28,682,978
Ensembl chr 3:8,281,899...8,284,833
|
|
G
|
Ptger2
|
prostaglandin E receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:20,694,765...20,708,475
Ensembl chr15:18,217,285...18,228,714
|
|
G
|
Ptger3
|
prostaglandin E receptor 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGER3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
|
|
G
|
Ptger4
|
prostaglandin E receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:54,335,424...54,346,670
|
|
G
|
Ptges
|
prostaglandin E synthase
|
multiple interactions increases expression
|
EXP ISO
|
resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein] 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGES mRNA; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]
|
CTD |
PMID:19228061 PMID:20132809 PMID:29950665 PMID:30489199 PMID:36543318 |
|
NCBI chr 3:34,575,643...34,586,987
|
|
G
|
Ptges3
|
prostaglandin E synthase 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PTGES3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:1,075,230...1,092,363
Ensembl chr 7:490,656...508,084
|
|
G
|
Ptgfr
|
prostaglandin F receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGFR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650
|
|
G
|
Ptgir
|
prostaglandin I2 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979
|
|
G
|
Ptgis
|
prostaglandin I2 synthase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIS mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:176,347,589...176,383,251
Ensembl chr 3:155,916,412...155,965,451
|
|
G
|
Ptgr1
|
prostaglandin reductase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions increases expression
|
ISO EXP
|
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGS2 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein] resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein] Dextran Sulfate results in increased expression of PTGS2 mRNA; Dextran Sulfate results in increased expression of PTGS2 protein
|
CTD |
PMID:15459021 PMID:15652231 PMID:16049979 PMID:17438113 PMID:19228061 PMID:19940103 PMID:20079348 PMID:20132809 PMID:23261679 PMID:23261717 PMID:25026504 PMID:25448682 PMID:25472953 PMID:26190278 PMID:26631293 PMID:26973525 PMID:27920257 PMID:29496522 PMID:29950665 PMID:30142311 PMID:30489199 PMID:30844440 PMID:30972795 PMID:32033881 PMID:36519841 PMID:38437956 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G
|
Pth1r
|
parathyroid hormone 1 receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTH1R mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G
|
Pthlh
|
parathyroid hormone-like hormone
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTHLH mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:180,188,792...180,199,847
|
|
G
|
Ptn
|
pleiotrophin
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PTN mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:66,260,764...66,342,614
Ensembl chr 4:65,293,734...65,375,456
|
|
G
|
Ptprc
|
protein tyrosine phosphatase, receptor type, C
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of PTPRC mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr13:52,147,717...52,259,810
Ensembl chr13:49,596,193...49,708,692
|
|
G
|
Ptprh
|
protein tyrosine phosphatase, receptor type, H
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PTPRH mRNA
|
CTD |
PMID:37385329 |
|
NCBI chr 1:78,272,414...78,318,977
Ensembl chr 1:69,242,321...69,285,077
|
|
G
|
Ptprm
|
protein tyrosine phosphatase, receptor type, M
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PTPRM protein
|
CTD |
PMID:35999755 |
|
NCBI chr 9:106,639,573...107,343,698
Ensembl chr 9:106,639,573...107,343,698
|
|
G
|
Ptpru
|
protein tyrosine phosphatase, receptor type, U
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTPRU mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:149,234,624...149,308,857
Ensembl chr 5:143,950,965...144,024,768
|
|
G
|
Pycard
|
PYD and CARD domain containing
|
multiple interactions increases expression
|
ISO
|
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of PYCARD protein; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of PYCARD mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of PYCARD protein] Dextran Sulfate results in increased expression of PYCARD mRNA; Dextran Sulfate results in increased expression of PYCARD protein
|
CTD |
PMID:30270565 PMID:34964214 |
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:182,601,174...182,602,955
|
|
G
|
Pygb
|
glycogen phosphorylase B
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PYGB protein Dextran Sulfate results in decreased expression of PYGB protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:160,072,141...160,118,930
Ensembl chr 3:139,611,749...139,663,553
|
|
G
|
Pygl
|
glycogen phosphorylase L
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of PYGL protein
|
CTD |
PMID:35999755 |
|
NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:88,697,593...88,740,310
|
|
G
|
Pyy
|
peptide YY
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PYY mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:87,561,347...87,562,470
Ensembl chr10:87,061,161...87,061,815
|
|
G
|
R3hcc1
|
R3H domain and coiled-coil containing 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of R3HCC1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr15:44,774,552...44,781,864
Ensembl chr15:44,774,554...44,791,800
|
|
G
|
Rab11b
|
RAB11B, member RAS oncogene family
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of RAB11B protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:14,521,448...14,534,589
Ensembl chr 7:14,521,368...14,534,593
|
|
G
|
Rab1b
|
RAB1B, member RAS oncogene family
|
multiple interactions decreases expression increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RAB1B protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of RAB1B protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868 Ensembl chr X:202,405,759...202,413,868
|
|
G
|
Rab21
|
RAB21, member RAS oncogene family
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB21 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:52,790,158...52,814,943
Ensembl chr 7:50,904,057...50,928,839
|
|
G
|
Rab27a
|
RAB27A, member RAS oncogene family
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of RAB27A protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RAB27A protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 8:73,782,730...73,836,630
Ensembl chr 8:73,782,694...73,847,829
|
|
G
|
Rab27b
|
RAB27B, member RAS oncogene family
|
multiple interactions decreases expression
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB27B protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RAB27B mRNA Dextran Sulfate results in decreased expression of RAB27B protein
|
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr18:63,597,554...63,794,124
Ensembl chr18:63,600,937...63,757,180
|
|
G
|
Rab32
|
RAB32, member RAS oncogene family
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of RAB32 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934
|
|
G
|
Rab4b
|
RAB4B, member RAS oncogene family
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of RAB4B protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:82,461,396...82,472,784
Ensembl chr 1:82,461,396...82,472,763
|
|
G
|
Rac3
|
Rac family small GTPase 3
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:106,002,808...106,005,243
Ensembl chr10:105,993,087...106,005,260
|
|
G
|
Ramp1
|
receptor activity modifying protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G
|
Ramp2
|
receptor activity modifying protein 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:86,689,148...86,690,956
Ensembl chr10:86,188,812...86,231,829
|
|
G
|
Ramp3
|
receptor activity modifying protein 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:85,741,314...85,758,813
Ensembl chr14:81,527,385...81,544,902
|
|
G
|
Ranbp3
|
RAN binding protein 3
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of RANBP3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 9:1,507,233...1,544,460
Ensembl chr 9:1,507,361...1,544,460
|
|
G
|
Rap1b
|
RAP1B, member of RAS oncogene family
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of RAP1B protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:53,423,130...53,456,370
|
|
G
|
Rapgef4
|
Rap guanine nucleotide exchange factor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAPGEF4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316
|
|
G
|
Rarg
|
retinoic acid receptor, gamma
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RARG mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177
|
|
G
|
Rarres1
|
retinoic acid receptor responder 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of RARRES1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 2:151,749,715...151,783,975
Ensembl chr 2:151,749,715...151,783,978
|
|
G
|
Rasgrp3
|
RAS guanyl releasing protein 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RASGRP3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:25,647,386...25,745,952
Ensembl chr 6:19,895,390...19,958,578
|
|
G
|
Rassf1
|
Ras association domain family member 1
|
increases response to substance multiple interactions
|
ISO
|
RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in decreased activity of STK4 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased activity of MPO protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased phosphorylation of and affects the localization of YAP1 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of IL6 protein
|
CTD |
PMID:24146755 |
|
NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164
|
|
G
|
Rbm47
|
RNA binding motif protein 47
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of RBM47 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr14:42,053,290...42,191,572
Ensembl chr14:42,154,142...42,189,431
|
|
G
|
Rbp4
|
retinol binding protein 4
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RBP4 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:245,306,349...245,313,551
Ensembl chr 1:235,893,917...235,901,399
|
|
G
|
Rbpms
|
RNA binding protein, mRNA processing factor
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of RBPMS protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of RBPMS protein]
|
CTD |
PMID:35362542 |
|
NCBI chr16:58,239,370...58,395,424
Ensembl chr16:58,239,474...58,395,426
|
|
G
|
Rcbtb2
|
RCC1 and BTB domain containing protein 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RCBTB2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr15:48,319,809...48,364,441
Ensembl chr15:48,323,866...48,383,750
|
|
G
|
Rcn3
|
reticulocalbin 3
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of RCN3 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of RCN3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:104,700,969...104,710,228
Ensembl chr 1:95,564,380...95,573,725
|
|
G
|
Rdx
|
radixin
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RDX protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 8:61,275,792...61,348,260
Ensembl chr 8:52,379,494...52,437,678
|
|
G
|
Reg1a
|
regenerating family member 1 alpha
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of REG1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 4:112,450,466...112,453,130
Ensembl chr 4:110,892,453...110,895,570
|
|
G
|
Reg3b
|
regenerating family member 3 beta
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of REG3B mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 4:112,419,776...112,423,014
Ensembl chr 4:110,861,775...110,865,015
|
|
G
|
Reg3g
|
regenerating family member 3 gamma
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of REG3G mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 4:112,482,183...112,484,738
Ensembl chr 4:110,924,168...110,926,723
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions increases activity affects localization increases phosphorylation increases expression
|
ISO EXP
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; [Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RELA protein; [Streptozocin co-treated with Dextran Sulfate] results in increased phosphorylation of RELA protein; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Dextran Sulfate results in decreased expression of and results in increased phosphorylation of RELA protein; Dextran Sulfate results in increased activity of and results in increased phosphorylation of RELA protein; Dextran Sulfate results in increased expression of and affects the localization of and results in increased activity of RELA protein; Dextran Sulfate results in increased expression of and affects the localization of RELA protein; Dextran Sulfate results in increased phosphorylation of and affects the localization of RELA protein; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of and results in increased phosphorylation of RELA protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of and results in increased activity of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of RELA protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; monotropein inhibits the reaction [Dextran Sulfate affects the localization of RELA protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; nuciferine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased phosphorylation of RELA protein]; RELA protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein] Dextran Sulfate results in increased expression of RELA protein; Dextran Sulfate results in increased expression of RELA protein modified form banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of RELA protein]
|
CTD |
PMID:21724996 PMID:23261679 PMID:24038091 PMID:25449198 PMID:25472953 PMID:26190278 PMID:26631293 PMID:27920257 PMID:30142311 PMID:30972795 PMID:32272095 PMID:33130971 PMID:33974900 PMID:34273909 PMID:34964214 PMID:35362542 PMID:36543318 PMID:36577154 PMID:36806191 PMID:37385329 PMID:38583725 More...
|
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G
|
Renbp
|
renin binding protein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RENBP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:151,661,463...151,670,538
Ensembl chr X:151,661,458...151,670,516
|
|
G
|
Rer1
|
retention in endoplasmic reticulum sorting receptor 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of RER1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of RER1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:165,634,567...165,646,643
Ensembl chr 5:165,634,300...165,646,750
|
|
G
|
Retnlb
|
resistin like beta
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RETNLB mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368
|
|
G
|
Retsat
|
retinol saturase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RETSAT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G
|
Rexo2
|
RNA exonuclease 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of REXO2 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of REXO2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 8:48,811,900...48,823,622
Ensembl chr 8:48,811,900...48,823,622
|
|
G
|
Rgr
|
retinal G protein coupled receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:12,801,594...12,816,402
Ensembl chr16:12,801,594...12,816,223
|
|
G
|
Rgs10
|
regulator of G-protein signaling 10
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of RGS10 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of RGS10 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:192,376,772...192,422,640
Ensembl chr 1:182,946,336...182,987,697
|
|
G
|
Rgs19
|
regulator of G-protein signaling 19
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS19 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:168,804,532...168,813,035
Ensembl chr 3:168,804,874...168,810,097
|
|
G
|
Rgs7
|
regulator of G-protein signaling 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:86,979,269...87,408,834
Ensembl chr13:86,979,279...87,408,888
|
|
G
|
Rhbg
|
Rh family B glycoprotein
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RHBG mRNA Dextran Sulfate results in decreased expression of RHBG mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 2:173,704,852...173,717,380
Ensembl chr 2:173,704,562...173,717,321
|
|
G
|
Rhoj
|
ras homolog family member J
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RHOJ mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:94,035,307...94,117,642
Ensembl chr 6:94,035,483...94,118,275
|
|
G
|
Rida
|
reactive intermediate imine deaminase A homolog
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of RIDA protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716
|
|
G
|
Ripk1
|
receptor interacting serine/threonine kinase 1
|
multiple interactions increases expression
|
ISO
|
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of RIPK1 protein]
|
CTD |
PMID:29496522 |
|
NCBI chr17:31,044,983...31,077,167
Ensembl chr17:30,839,650...30,871,824
|
|
G
|
Ripk3
|
receptor-interacting serine-threonine kinase 3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of RIPK3 protein dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of RIPK3 protein]
|
CTD |
PMID:29496522 |
|
NCBI chr15:33,253,071...33,262,025
Ensembl chr15:29,283,145...29,292,121
|
|
G
|
Rnasel
|
ribonuclease L
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of RNASEL protein]
|
CTD |
PMID:35362542 |
|
NCBI chr13:68,446,641...68,460,804
Ensembl chr13:65,901,459...65,908,704
|
|
G
|
Rnf213
|
ring finger protein 213
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of RNF213 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:104,656,329...104,755,669
Ensembl chr10:104,656,883...104,757,918
|
|
G
|
Rorc
|
RAR-related orphan receptor C
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of RORC mRNA; Dextran Sulfate results in increased expression of RORC mRNA alternative form Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of RORC mRNA alternative form]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of RORC mRNA]
|
CTD |
PMID:31737179 PMID:31807802 |
|
NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:182,009,286...182,034,907
|
|
G
|
Rpl39l1
|
ribosomal protein L39 like 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RPL39L mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:5,455,712...5,459,828
Ensembl chr10:5,454,559...5,462,029
|
|
G
|
Rpl41
|
ribosomal protein L41
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RPL41 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:977,885...978,965
|
|
G
|
Rps14
|
ribosomal protein S14
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RPS14 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr18:54,227,854...54,232,638
Ensembl chr18:54,227,854...54,233,166
|
|
G
|
Rps15
|
ribosomal protein S15
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of RPS15 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RPS15 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of RPS15 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 7:9,416,003...9,417,442
Ensembl chr 7:9,416,004...9,417,450 Ensembl chr 7:9,416,004...9,417,450
|
|
G
|
Rps15a
|
ribosomal protein S15a
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of RPS15A protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RPS15A protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:172,420,151...172,427,021
Ensembl chr 1:172,419,761...172,426,995
|
|
G
|
Rps21-ps1
|
ribosomal protein S21, pseudogene 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of RPS21 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:153,387,133...153,387,476
Ensembl chr 5:153,387,176...153,387,427
|
|
G
|
Rps29
|
ribosomal protein S29
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RPS29 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 6:87,635,229...87,636,627
Ensembl chr 6:87,635,230...87,636,636 Ensembl chr13:87,635,230...87,636,636
|
|
G
|
Rps6
|
ribosomal protein S6
|
multiple interactions increases phosphorylation
|
ISO
|
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6 protein]]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of RPS6 protein; alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6 protein]
|
CTD |
PMID:19931517 PMID:31676321 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
increases phosphorylation multiple interactions decreases phosphorylation
|
ISO
|
Dextran Sulfate results in increased phosphorylation of RPS6KB1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6KB1 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]
|
CTD |
PMID:27611972 PMID:31676321 PMID:31926917 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G
|
Rras2
|
RAS related 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of RRAS2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RRAS2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:177,668,143...177,737,551
Ensembl chr 1:168,233,693...168,303,111
|
|
G
|
Rrbp1
|
ribosome binding protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RRBP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:131,314,996...131,376,930
Ensembl chr 3:131,314,998...131,376,981
|
|
G
|
Rrp1
|
ribosomal RNA processing 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RRP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr20:10,260,892...10,272,141
Ensembl chr20:10,260,870...10,272,144
|
|
G
|
Rsph1
|
radial spoke head component 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of RSPH1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr20:9,341,910...9,360,640
Ensembl chr20:9,341,913...9,360,640
|
|
G
|
Rsu1
|
Ras suppressor protein 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of RSU1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr17:76,128,774...76,377,515
Ensembl chr17:76,188,812...76,377,454
|
|
G
|
RT1-Ba
|
RT1 class II, locus Ba
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of H2-AA mRNA evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of H2-AA protein]
|
CTD |
PMID:23894361 PMID:35362542 |
|
NCBI chr20:4,577,057...4,581,650
Ensembl chr20:4,575,134...4,579,744
|
|
G
|
RT1-Bb
|
RT1 class II, locus Bb
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of H2-AB1 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,596,559...4,607,597
|
|
G
|
RT1-Db1
|
RT1 class II, locus Db1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of H2-EB1 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,548,666...4,558,258
|
|
G
|
RT1-DMa
|
RT1 class II, locus DMa
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of H2-DMA mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,707,028...4,710,432
|
|
G
|
RT1-DOb
|
RT1 class II, locus DOb
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of H2-OB mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr20:4,621,336...4,627,537
Ensembl chr20:4,619,816...4,625,667
|
|
G
|
RT1-M3-1
|
RT1 class Ib, locus M3, gene 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of H2-M3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,287,521...1,328,117
|
|
G
|
Rxfp1
|
relaxin family peptide receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:164,772,270...164,893,484
Ensembl chr 2:164,774,799...164,893,412
|
|
G
|
Rxfp4
|
relaxin family peptide/INSL5 receptor 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:174,123,510...174,124,664
|
|
G
|
Rxra
|
retinoid X receptor alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RXRA mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:10,989,832...11,073,712
|
|
G
|
Ryr1
|
ryanodine receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RYR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812
|
|
G
|
S100a11
|
S100 calcium binding protein A11
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of S100A11 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of S100A11 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G
|
S100a4
|
S100 calcium-binding protein A4
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of S100A4 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of S100A4 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of S100A4 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:176,091,804...176,093,254
|
|
G
|
S100a8
|
S100 calcium binding protein A8
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of S100A8 mRNA
|
CTD |
PMID:20824662 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G
|
S100a9
|
S100 calcium binding protein A9
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of S100A9 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of S100A9 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of S100A9 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of S100A9 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of S100A9 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G
|
S100g
|
S100 calcium binding protein G
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of S100G mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433
|
|
G
|
S1pr2
|
sphingosine-1-phosphate receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of S1PR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574
|
|
G
|
Safb
|
scaffold attachment factor B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SAFB mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:1,417,449...1,438,408
Ensembl chr 9:1,417,525...1,438,644
|
|
G
|
Safb2
|
scaffold attachment factor B2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SAFB2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:1,395,852...1,417,010
Ensembl chr 9:1,387,107...1,417,038
|
|
G
|
Sap30
|
Sin3A associated protein 30
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SAP30 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr16:37,758,494...37,763,825
Ensembl chr16:32,747,734...32,753,112
|
|
G
|
Sardh
|
sarcosine dehydrogenase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SARDH mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 3:10,510,553...10,575,342
Ensembl chr 3:10,510,553...10,573,874
|
|
G
|
Sarnp
|
SAP domain containing ribonucleoprotein
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SARNP protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SARNP protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 7:1,251,096...1,305,335
Ensembl chr 7:1,251,098...1,305,332
|
|
G
|
Sart1
|
spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SART1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:212,119,824...212,128,517
Ensembl chr 1:202,690,459...202,699,136
|
|
G
|
Sc5d
|
sterol-C5-desaturase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SC5D mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G
|
Scamp1
|
secretory carrier membrane protein 1
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SCAMP1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SCAMP1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:25,433,958...25,516,734
Ensembl chr 2:25,433,959...25,516,673
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SCD1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G
|
Scd2
|
stearoyl-Coenzyme A desaturase 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SCD2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:253,118,377...253,131,436
Ensembl chr 1:243,169,236...243,182,232
|
|
G
|
Scgb1a1
|
secretoglobin family 1A member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SCGB1A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:205,977,060...205,980,610
Ensembl chr 1:205,977,060...205,980,610
|
|
G
|
Scgb3a1
|
secretoglobin, family 3A, member 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SCGB3A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:33,968,059...33,969,366
Ensembl chr10:33,968,059...33,969,476
|
|
G
|
Scin
|
scinderin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCIN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:62,836,641...62,915,287
Ensembl chr 6:57,109,403...57,188,242
|
|
G
|
Scnn1a
|
sodium channel epithelial 1 subunit alpha
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:158,122,962...158,146,181
|
|
G
|
Scnn1b
|
sodium channel epithelial 1 subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:176,430,103...176,484,451
|
|
G
|
Sct
|
secretin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658
|
|
G
|
Sdc3
|
syndecan 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SDC3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:142,965,659...142,998,390
Ensembl chr 5:142,965,591...142,996,480
|
|
G
|
Sec62
|
SEC62 homolog, preprotein translocation factor
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SEC62 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SEC62 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:112,570,810...112,598,198
Ensembl chr 2:112,570,819...112,601,814
|
|
G
|
Selp
|
selectin P
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SELP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:79,009,379...79,044,994
Ensembl chr13:76,476,295...76,511,845
|
|
G
|
Serpina3n
|
serpin family A member 3N
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SERPINA3N mRNA
|
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G
|
Serpina5
|
serpin family A member 5
|
multiple interactions
|
ISO
|
Dextran Sulfate affects the reaction [SEMG2 protein binds to SERPINA5 protein]
|
CTD |
PMID:17253189 |
|
NCBI chr 6:128,774,006...128,793,187
Ensembl chr 6:123,023,306...123,028,407
|
|
G
|
Serpinb1a
|
serpin family B member 1A
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SERPINB1A protein
|
CTD |
PMID:35999755 |
|
NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102
|
|
G
|
Serpine1
|
serpin family E member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPINE1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657
|
|
G
|
Serping1
|
serpin family G member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPING1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:69,842,739...69,852,034
|
|
G
|
Sf1
|
splicing factor 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SF1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
|
|
G
|
Sf3a2
|
splicing factor 3A subunit 2
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SF3A2 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 7:8,909,507...8,916,104
Ensembl chr 7:8,909,507...8,915,530
|
|
G
|
Sgcd
|
sarcoglycan, delta
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SGCD protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:31,346,480...32,328,364
Ensembl chr10:31,280,511...31,724,840
|
|
G
|
Sgk2
|
serum/glucocorticoid regulated kinase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SGK2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G
|
Sgms2
|
sphingomyelin synthase 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SGMS2 mRNA
|
CTD |
PMID:25035112 |
|
NCBI chr 2:219,889,809...219,967,704
Ensembl chr 2:219,893,572...219,967,546
|
|
G
|
Sgpp2
|
sphingosine-1-phosphate phosphatase 2
|
increases expression multiple interactions
|
EXP
|
Dextran Sulfate results in increased expression of SGPP2 mRNA Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SGPP2 mRNA]
|
CTD |
PMID:30811821 |
|
NCBI chr 9:87,211,155...87,331,787
Ensembl chr 9:79,763,284...79,880,457
|
|
G
|
Sh3bgrl1
|
SH3 domain binding glutamate rich protein like 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SH3BGRL protein
|
CTD |
PMID:35999755 |
|
NCBI chr X:78,242,704...78,343,633
Ensembl chr X:74,166,871...74,263,783
|
|
G
|
Sh3bgrl3
|
SH3 domain binding glutamate-rich protein like 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SH3BGRL3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 5:146,354,152...146,355,525
Ensembl chr 5:146,354,152...146,355,331
|
|
G
|
Sh3gl2
|
SH3 domain containing GRB2 like 2, endophilin A1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SH3GL2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:99,653,189...99,827,500
Ensembl chr 5:99,653,152...100,113,843
|
|
G
|
Sh3kbp1
|
SH3 domain-containing kinase-binding protein 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SH3KBP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:34,877,862...35,223,013
Ensembl chr X:34,877,866...35,222,747
|
|
G
|
Shmt1
|
serine hydroxymethyltransferase 1
|
decreases expression multiple interactions increases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SHMT1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SHMT1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SHMT1 protein]
|
CTD |
PMID:32272095 PMID:35362542 |
|
NCBI chr10:45,968,959...45,990,341
Ensembl chr10:45,468,700...45,497,820
|
|
G
|
Siae
|
sialic acid acetylesterase
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SIAE protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 8:37,318,724...37,354,004
Ensembl chr 8:37,318,747...37,353,996
|
|
G
|
Sipa1
|
signal-induced proliferation-associated 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SIPA1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:202,938,532...202,950,672
Ensembl chr 1:202,938,580...202,950,591
|
|
G
|
Sirt1
|
sirtuin 1
|
multiple interactions decreases expression
|
ISO
|
ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of SIRT1 protein] Dextran Sulfate results in decreased expression of SIRT1 mRNA; Dextran Sulfate results in decreased expression of SIRT1 protein
|
CTD |
PMID:19940103 PMID:24548422 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G
|
Sirt2
|
sirtuin 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SIRT2 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SIRT2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:93,181,472...93,204,499
Ensembl chr 1:84,052,903...84,076,975
|
|
G
|
Skic3
|
SKI3 subunit of superkiller complex
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of SKIC3 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SKIC3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:5,631,544...5,783,643
Ensembl chr 2:5,631,635...5,751,626
|
|
G
|
Slc10a1
|
solute carrier family 10 member 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SLC10A1 mRNA; Dextran Sulfate results in decreased expression of SLC10A1 protein
|
CTD |
PMID:27580383 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G
|
Slc10a2
|
solute carrier family 10 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC10A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G
|
Slc10a6
|
solute carrier family 10 member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC10A6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:6,080,716...6,102,902
Ensembl chr14:6,080,717...6,103,037
|
|
G
|
Slc11a1
|
solute carrier family 11 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC11A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:83,406,327...83,417,252
Ensembl chr 9:75,957,316...75,968,101
|
|
G
|
Slc12a2
|
solute carrier family 12 member 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SLC12A2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G
|
Slc12a4
|
solute carrier family 12 member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC12A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:33,838,418...33,860,369
Ensembl chr19:33,838,419...33,860,331
|
|
G
|
Slc12a7
|
solute carrier family 12 member 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC12A7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:29,472,692...29,554,246
Ensembl chr 1:29,472,692...29,554,302
|
|
G
|
Slc13a1
|
solute carrier family 13 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:52,569,179...52,647,126
Ensembl chr 4:52,569,375...52,647,099
|
|
G
|
Slc13a2
|
solute carrier family 13 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,291,815...63,319,127
|
|
G
|
Slc13a5
|
solute carrier family 13 member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:56,866,249...56,891,189
Ensembl chr10:56,866,249...56,890,945
|
|
G
|
Slc15a1
|
solute carrier family 15 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC15A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G
|
Slc15a4
|
solute carrier family 15 member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC15A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:29,048,634...29,082,480
Ensembl chr12:29,063,015...29,082,480
|
|
G
|
Slc16a1
|
solute carrier family 16 member 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SLC16A1 mRNA; Dextran Sulfate results in decreased expression of SLC16A1 protein
|
CTD |
PMID:38844255 |
|
NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:192,124,289...192,144,611
|
|
G
|
Slc16a3
|
solute carrier family 16 member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:106,712,328...106,756,168
Ensembl chr10:106,212,778...106,222,562
|
|
G
|
Slc16a8
|
solute carrier family 16 member 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:112,698,701...112,702,496
Ensembl chr 7:110,818,274...110,822,069
|
|
G
|
Slc17a5
|
solute carrier family 17 member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:79,394,416...79,429,387
|
|
G
|
Slc17a6
|
solute carrier family 17 member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC17A6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
|
|
G
|
Slc17a8
|
solute carrier family 17 member 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:23,994,217...24,048,079
|
|
G
|
Slc18a1
|
solute carrier family 18 member A1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC18A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:25,408,485...25,453,786
Ensembl chr16:20,653,508...20,687,051
|
|
G
|
Slc1a2
|
solute carrier family 1 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:89,005,129...89,126,498
|
|
G
|
Slc1a5
|
solute carrier family 1 member 5
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SLC1A5 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SLC1A5 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:86,584,949...86,599,052
Ensembl chr 1:77,456,694...77,470,952
|
|
G
|
Slc1a6
|
solute carrier family 1 member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:10,841,836...10,870,424
Ensembl chr 7:10,841,837...10,870,449
|
|
G
|
Slc1a7
|
solute carrier family 1 member 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:122,731,003...122,775,139
Ensembl chr 5:122,731,003...122,775,134
|
|
G
|
Slc22a1
|
solute carrier family 22 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G
|
Slc22a18
|
solute carrier family 22, member 18
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A18 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SLC22A18 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr 1:208,100,032...208,124,382
Ensembl chr 1:198,671,731...198,694,975
|
|
G
|
Slc22a21
|
solute carrier family 22 (organic cation transporter), member 21
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A21 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,104,122...38,130,671
|
|
G
|
Slc22a3
|
solute carrier family 22 member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G
|
Slc22a4
|
solute carrier family 22 member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC22A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G
|
Slc22a5
|
solute carrier family 22 member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G
|
Slc22a8
|
solute carrier family 22 member 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:205,498,084...205,517,450
|
|
G
|
Slc25a10
|
solute carrier family 25 member 10
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC25A10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:105,765,598...105,775,159
Ensembl chr10:105,765,372...105,773,556
|
|
G
|
Slc25a13
|
solute carrier family 25 member 13
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SLC25A13 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SLC25A13 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:34,179,224...34,361,912
Ensembl chr 4:34,179,224...34,361,902
|
|
G
|
Slc25a28
|
solute carrier family 25 member 28
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SLC25A28 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:252,480,106...252,491,365
Ensembl chr 1:242,530,899...242,542,115
|
|
G
|
Slc25a4
|
solute carrier family 25 member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC25A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:52,805,521...52,809,316
Ensembl chr16:46,072,939...46,076,733
|
|
G
|
Slc26a1
|
solute carrier family 26 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:1,040,565...1,045,851
Ensembl chr14:1,040,243...1,045,849
|
|
G
|
Slc26a2
|
solute carrier family 26 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:54,648,276...54,666,627
Ensembl chr18:54,652,951...54,666,626
|
|
G
|
Slc26a3
|
solute carrier family 26 member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
|
|
G
|
Slc26a7
|
solute carrier family 26 member 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:27,884,400...28,021,865
Ensembl chr 5:27,887,042...28,021,658
|
|
G
|
Slc26a9
|
solute carrier family 26 member 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC26A9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:43,177,806...43,205,450
Ensembl chr13:43,177,867...43,204,330
|
|
G
|
Slc27a1
|
solute carrier family 27 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:18,311,859...18,337,024
Ensembl chr16:18,278,984...18,296,063
|
|
G
|
Slc27a4
|
solute carrier family 27 member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:13,075,022...13,087,943
Ensembl chr 3:13,075,022...13,087,943
|
|
G
|
Slc28a3
|
solute carrier family 28 member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC28A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:6,062,563...6,112,965
Ensembl chr17:6,062,549...6,114,038
|
|
G
|
Slc29a2
|
solute carrier family 29 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC29A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:202,327,354...202,335,171
|
|
G
|
Slc2a1
|
solute carrier family 2 member 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SLC2A1 protein
|
CTD |
PMID:20025956 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:132,717,196...132,745,416
|
|
G
|
Slc2a12
|
solute carrier family 2 member 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:24,623,558...24,683,577
Ensembl chr 1:22,804,418...22,860,971
|
|
G
|
Slc2a3
|
solute carrier family 2 member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:155,960,946...156,025,472
|
|
G
|
Slc30a1
|
solute carrier family 30 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC30A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:106,022,019...106,025,892
Ensembl chr13:103,491,037...103,494,910
|
|
G
|
Slc30a2
|
solute carrier family 30 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC30A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:151,843,451...151,855,674
Ensembl chr 5:146,559,733...146,571,956
|
|
G
|
Slc30a7
|
solute carrier family 30 member 7
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SLC30A7 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:206,544,800...206,607,087
Ensembl chr 2:203,859,175...203,922,132
|
|
G
|
Slc34a2
|
solute carrier family 34 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC34A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436
|
|
G
|
Slc35a1
|
solute carrier family 35 member A1
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A1 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SLC35A1 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr 5:49,225,599...49,248,382
Ensembl chr 5:49,225,602...49,248,335
|
|
G
|
Slc35a3
|
solute carrier family 35 member A3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:204,620,103...204,659,319
Ensembl chr 2:204,579,174...204,659,319
|
|
G
|
Slc35d1
|
solute carrier family 35 member D1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:117,928,628...117,981,289
Ensembl chr 5:117,934,352...117,981,311
|
|
G
|
Slc35d2
|
solute carrier family 35 member D2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:987,899...1,019,747
Ensembl chr17:988,157...1,019,743
|
|
G
|
Slc36a1
|
solute carrier family 36 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC36A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:39,819,753...39,858,068
Ensembl chr10:39,324,337...39,354,217
|
|
G
|
Slc38a1
|
solute carrier family 38, member 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SLC38A1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 7:129,612,414...129,681,727
Ensembl chr 7:127,738,226...127,802,218
|
|
G
|
Slc38a2
|
solute carrier family 38, member 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SLC38A2 mRNA
|
CTD |
PMID:27920257 |
|
NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:127,851,267...127,863,436
|
|
G
|
Slc39a10
|
solute carrier family 39 member 10
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A10 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:62,331,281...62,454,754
Ensembl chr 9:54,876,141...54,960,325
|
|
G
|
Slc39a14
|
solute carrier family 39 member 14
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr15:51,786,517...51,833,260
Ensembl chr15:45,376,917...45,423,524
|
|
G
|
Slc39a4
|
solute carrier family 39 member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:108,333,368...108,337,553
Ensembl chr 7:108,333,381...108,337,553
|
|
G
|
Slc39a5
|
solute carrier family 39 member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:822,873...830,865
Ensembl chr 7:824,818...830,242
|
|
G
|
Slc39a6
|
solute carrier family 39 member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:15,864,874...15,885,417
Ensembl chr18:15,864,875...15,885,417
|
|
G
|
Slc39a8
|
solute carrier family 39 member 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:224,256,654...224,319,129
|
|
G
|
Slc3a1
|
solute carrier family 3 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC3A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:15,361,037...15,396,695
Ensembl chr 6:9,608,178...9,641,907
|
|
G
|
Slc40a1
|
solute carrier family 40 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC40A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:48,033,526...48,051,481
|
|
G
|
Slc44a3
|
solute carrier family 44, member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:209,552,138...209,628,182
Ensembl chr 2:209,552,144...209,629,044
|
|
G
|
Slc44a4
|
solute carrier family 44, member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:3,903,099...3,919,215
Ensembl chr20:3,903,099...3,919,215
|
|
G
|
Slc46a1
|
solute carrier family 46 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC46A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848
|
|
G
|
Slc47a1
|
solute carrier family 47 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G
|
Slc47a2
|
solute carrier family 47 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G
|
Slc4a1
|
solute carrier family 4 member 1 (Diego blood group)
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117
|
|
G
|
Slc4a2
|
solute carrier family 4 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:10,736,425...10,752,965
|
|
G
|
Slc4a7
|
solute carrier family 4 member 7
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A7 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SLC4A7 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr15:10,585,307...10,664,780
Ensembl chr15:10,588,979...10,664,781
|
|
G
|
Slc51a
|
solute carrier family 51 member A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G
|
Slc51b
|
SLC51 subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:65,931,890...65,940,145
|
|
G
|
Slc52a2
|
solute carrier family 52 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC52A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:108,246,003...108,267,642
Ensembl chr 7:108,262,612...108,268,034
|
|
G
|
Slc5a1
|
solute carrier family 5 member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G
|
Slc5a11
|
solute carrier family 5 member 11
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A11 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:177,735,511...177,795,193
Ensembl chr 1:177,756,561...177,795,193
|
|
G
|
Slc5a3
|
solute carrier family 5 member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC5A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883
|
|
G
|
Slc5a8
|
solute carrier family 5 member 8
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A8 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 7:23,272,891...23,313,811
Ensembl chr 7:23,272,427...23,314,642
|
|
G
|
Slc5a9
|
solute carrier family 5 member 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:126,709,762...126,733,468
Ensembl chr 5:126,709,769...126,733,468
|
|
G
|
Slc6a11
|
solute carrier family 6 member 11
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A11 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:148,853,557...148,968,895
Ensembl chr 4:147,297,969...147,413,443
|
|
G
|
Slc6a12
|
solute carrier family 6 member 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750
|
|
G
|
Slc6a14
|
solute carrier family 6 member 14
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:112,314,643...112,375,412
Ensembl chr X:112,314,691...112,375,096
|
|
G
|
Slc6a19
|
solute carrier family 6 member 19
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A19 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:31,414,744...31,434,932
Ensembl chr 1:29,586,195...29,604,962
|
|
G
|
Slc6a2
|
solute carrier family 6 member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G
|
Slc6a3
|
solute carrier family 6 member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:29,709,443...29,750,413
|
|
G
|
Slc6a6
|
solute carrier family 6 member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:125,752,340...125,826,033
Ensembl chr 4:124,195,218...124,268,875
|
|
G
|
Slc7a5
|
solute carrier family 7 member 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:66,843,808...66,872,412
Ensembl chr19:49,935,220...49,963,823
|
|
G
|
Slc7a6
|
solute carrier family 7 member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC7A6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr19:50,982,459...51,010,140
Ensembl chr19:34,074,286...34,100,268
|
|
G
|
Slc7a9
|
solute carrier family 7 member 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:97,246,253...97,269,546
Ensembl chr 1:88,110,644...88,132,641
|
|
G
|
Slc8a1
|
solute carrier family 8 member A1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628
|
|
G
|
Slc8a3
|
solute carrier family 8 member A3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508
|
|
G
|
Slc9a2
|
solute carrier family 9 member A2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:42,932,001...43,014,447
Ensembl chr 9:42,931,346...43,014,444
|
|
G
|
Slc9a3
|
solute carrier family 9 member A3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
|
|
G
|
Slc9a7
|
solute carrier family 9 member A7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC9A7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:2,214,064...2,395,052
Ensembl chr X:2,214,441...2,388,012
|
|
G
|
Slco1a4
|
solute carrier organic anion transporter family, member 1a4
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO1A4 mRNA Dextran Sulfate results in decreased expression of SLCO1A4 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G
|
Slco2b1
|
solute carrier organic anion transporter family, member 2b1
|
multiple interactions increases expression decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO2B1 mRNA Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA] Dextran Sulfate results in increased expression of SLCO2B1 mRNA; Dextran Sulfate results in increased expression of SLCO2B1 protein Dextran Sulfate results in decreased expression of SLCO2B1 mRNA; Dextran Sulfate results in decreased expression of SLCO2B1 protein
|
CTD |
PMID:29950665 PMID:38423481 PMID:38844255 |
|
NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:153,959,293...154,007,353
|
|
G
|
Slco3a1
|
solute carrier organic anion transporter family, member 3a1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLCO3A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:128,106,232...128,388,043
Ensembl chr 1:128,106,228...128,387,925
|
|
G
|
Smad4
|
SMAD family member 4
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SMAD4 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:69,518,988...69,549,684
Ensembl chr18:67,243,742...67,274,438
|
|
G
|
Smarcb1
|
SWI/SNF related BAF chromatin remodeling complex subunit B1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SMARCB1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr20:12,741,164...12,763,616
Ensembl chr20:12,741,477...12,763,620
|
|
G
|
Smarce1
|
SWI/SNF related BAF chromatin remodeling complex subunit E1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SMARCE1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:84,159,270...84,180,547
Ensembl chr10:84,159,275...84,179,989
|
|
G
|
Smo
|
smoothened, frizzled class receptor
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMO mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:59,311,084...59,341,280
Ensembl chr 4:58,343,529...58,373,829
|
|
G
|
Smox
|
spermine oxidase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMOX mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:139,184,793...139,220,174
Ensembl chr 3:118,731,900...118,765,710 Ensembl chr X:118,731,900...118,765,710
|
|
G
|
Smpd2
|
sphingomyelin phosphodiesterase 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SMPD2 mRNA Fenofibrate promotes the reaction [Dextran Sulfate results in decreased expression of SMPD2 mRNA]
|
CTD |
PMID:25035112 |
|
NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441
|
|
G
|
Smpd3
|
sphingomyelin phosphodiesterase 3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of SMPD3 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SMPD3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr19:51,072,209...51,155,639
Ensembl chr19:34,162,341...34,245,749
|
|
G
|
Smpd4
|
sphingomyelin phosphodiesterase 4
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SMPD4 mRNA Fenofibrate promotes the reaction [Dextran Sulfate results in decreased expression of SMPD4 mRNA]
|
CTD |
PMID:25035112 |
|
NCBI chr11:83,362,534...83,386,257
Ensembl chr11:83,362,534...83,386,250
|
|
G
|
Smpdl3a
|
sphingomyelin phosphodiesterase, acid-like 3A
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SMPDL3A protein]
|
CTD |
PMID:35362542 |
|
NCBI chr20:37,132,592...37,155,567
Ensembl chr20:37,132,592...37,155,567
|
|
G
|
Snai1
|
snail family transcriptional repressor 1
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SNAI1 protein
|
CTD |
PMID:34273909 |
|
NCBI chr 3:176,667,476...176,671,965
Ensembl chr 3:156,248,485...156,252,969
|
|
G
|
Snord118
|
small nucleolar RNA, C/D box 118
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SNORD118 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr10:53,774,811...53,774,946
Ensembl chr10:53,774,811...53,774,946
|
|
G
|
Snrpf
|
small nuclear ribonucleoprotein polypeptide F
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SNRPF protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SNRPF protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:28,130,427...28,137,129
Ensembl chr 7:28,130,427...28,137,129
|
|
G
|
Snrpg
|
small nuclear ribonucleoprotein polypeptide G
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SNRPG protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of SNRPG protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:120,369,676...120,377,263
Ensembl chr 4:118,812,252...118,819,826 Ensembl chr X:118,812,252...118,819,826
|
|
G
|
Snx9
|
sorting nexin 9
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SNX9 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:46,424,897...46,510,096
Ensembl chr 1:46,423,553...46,509,036
|
|
G
|
Sox4
|
SRY-box transcription factor 4
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of SOX4 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,667,537...35,673,665
|
|
G
|
Sox9
|
SRY-box transcription factor 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SOX9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G
|
Sparc
|
secreted protein acidic and cysteine rich
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPARC mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:40,017,065...40,038,816
Ensembl chr10:39,516,406...39,538,396
|
|
G
|
Sphk1
|
sphingosine kinase 1
|
multiple interactions increases expression
|
ISO EXP
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPHK1 mRNA Dextran Sulfate results in increased expression of SPHK1 protein Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SPHK1 protein]
|
CTD |
PMID:29950665 PMID:30811821 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:101,758,711...101,764,240
|
|
G
|
Spink1
|
serine peptidase inhibitor, Kazal type 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SPINK1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
|
|
G
|
Spn
|
sialophorin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:191,177,449...191,190,115
Ensembl chr 1:181,746,429...181,759,628
|
|
G
|
Spp1
|
secreted phosphoprotein 1
|
multiple interactions increases expression decreases expression
|
ISO
|
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of SPP1 mRNA] Dextran Sulfate results in decreased expression of SPP1 protein
|
CTD |
PMID:32033881 PMID:35999755 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G
|
Sprr1a
|
small proline-rich protein 1A
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SPRR1A mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063
|
|
G
|
Sptbn1
|
spectrin, beta, non-erythrocytic 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SPTBN1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507
|
|
G
|
Sqstm1
|
sequestosome 1
|
multiple interactions decreases expression increases expression
|
ISO
|
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in decreased expression of SQSTM1 protein; [Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of SQSTM1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in increased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]
|
CTD |
PMID:27611972 PMID:31676321 PMID:31926917 PMID:38648921 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673
|
|
G
|
Srd5a2
|
steroid 5 alpha-reductase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SRD5A2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112
|
|
G
|
Srgap3
|
SLIT-ROBO Rho GTPase activating protein 3
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SRGAP3 mRNA Dextran Sulfate results in decreased expression of SRGAP3 mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 4:145,839,369...146,070,556
Ensembl chr 4:145,840,078...146,070,575
|
|
G
|
Srp9
|
signal recognition particle 9
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of SRP9 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
|
|
G
|
Srrm2
|
serine/arginine repetitive matrix 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of SRRM2 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SRRM2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:12,815,471...12,848,750
Ensembl chr10:12,815,471...12,848,751
|
|
G
|
Srsf11
|
serine and arginine rich splicing factor 11
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of SRSF11 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SRSF11 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:247,074,623...247,101,460
Ensembl chr 2:247,074,631...247,101,425
|
|
G
|
Srsf4
|
serine and arginine rich splicing factor 4
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of SRSF4 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 5:144,060,981...144,090,798
Ensembl chr 5:144,061,463...144,089,229
|
|
G
|
Sstr1
|
somatostatin receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SSTR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:81,567,237...81,571,759
Ensembl chr 6:75,832,530...75,836,802
|
|
G
|
St3gal3
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ST3GAL3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:136,755,780...136,958,081
Ensembl chr 5:131,470,348...131,670,810
|
|
G
|
St3gal6
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ST3GAL6 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ST3GAL6 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr11:55,530,120...55,590,950
Ensembl chr11:42,077,621...42,121,776
|
|
G
|
Star
|
steroidogenic acute regulatory protein
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of STAR mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G
|
Stard5
|
StAR-related lipid transfer domain containing 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STARD5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:137,606,151...137,616,017
Ensembl chr 1:137,606,177...137,616,469
|
|
G
|
Stat1
|
signal transducer and activator of transcription 1
|
multiple interactions increases phosphorylation decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of STAT1 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT1 protein]
|
CTD |
PMID:31737179 PMID:35362542 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions increases expression increases phosphorylation
|
EXP ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein] 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of STAT3 protein; Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of STAT3 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; xianglian pill inhibits the reaction [Dextran Sulfate results in increased expression of STAT3 mRNA] Dextran Sulfate results in increased expression of STAT3 mRNA; Dextran Sulfate results in increased expression of STAT3 protein
|
CTD |
PMID:19028472 PMID:20155626 PMID:22334590 PMID:25026504 PMID:26074695 PMID:31737179 PMID:32272095 PMID:33486267 PMID:36543318 PMID:38164749 PMID:38437956 PMID:38663798 More...
|
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G
|
Steap1
|
STEAP family member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:28,276,972...28,287,484
Ensembl chr 4:28,276,909...28,287,479
|
|
G
|
Steap2
|
STEAP2 metalloreductase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791
|
|
G
|
Stim1
|
stromal interaction molecule 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STIM1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
G
|
Stip1
|
stress-induced phosphoprotein 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of STIP1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G
|
Stk4
|
serine/threonine kinase 4
|
multiple interactions
|
ISO
|
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in decreased activity of STK4 protein
|
CTD |
PMID:24146755 |
|
NCBI chr 3:173,165,238...173,247,135
Ensembl chr 3:152,745,681...152,827,744
|
|
G
|
Stra8
|
stimulated by retinoic acid 8
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of STRA8 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:64,568,580...64,591,914
Ensembl chr 4:63,601,604...63,624,771
|
|
G
|
Stx1a
|
syntaxin 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STX1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930
|
|
G
|
Sub1
|
SUB1 regulator of transcription
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SUB1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SUB1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 2:61,005,646...61,020,486
Ensembl chr 2:61,005,666...61,020,436 Ensembl chr 2:61,005,666...61,020,436
|
|
G
|
Suclg2
|
succinate-CoA ligase GDP-forming subunit beta
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SUCLG2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:128,067,031...128,337,146
Ensembl chr 4:128,067,033...128,337,170
|
|
G
|
Sult1b1
|
sulfotransferase family 1B member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1B1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G
|
Sult1c2a
|
sulfotransferase family 1C member 2A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1C2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G
|
Sult1e1
|
sulfotransferase family 1E member 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SULT1E1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,422,324...20,439,275
|
|
G
|
Sun1
|
Sad1 and UNC84 domain containing 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of SUN1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SUN1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr12:15,396,378...15,441,277
Ensembl chr12:15,396,381...15,441,571
|
|
G
|
Suox
|
sulfite oxidase
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of SUOX protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SUOX protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 7:1,687,666...1,691,759
Ensembl chr 7:1,103,151...1,107,038
|
|
G
|
Susd2
|
sushi domain containing 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SUSD2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903
|
|
G
|
Suv39h1
|
SUV39H1 histone lysine methyltransferase
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of SUV39H1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]
|
CTD |
PMID:31676321 |
|
NCBI chr X:17,093,059...17,105,942
Ensembl chr X:14,421,109...14,433,982
|
|
G
|
Suv39h1-ps1
|
SUV39H1 histone lysine methyltransferase, pseudogene 1
|
multiple interactions increases expression
|
ISO
|
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]
|
CTD |
PMID:31676321 |
|
NCBI chr X:146,828,818...146,831,485
|
|
G
|
Svil
|
supervillin
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of SVIL mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr17:52,648,502...52,844,114
Ensembl chr17:52,648,502...52,793,404
|
|
G
|
Syne2
|
spectrin repeat containing nuclear envelope protein 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of SYNE2 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SYNE2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064
|
|
G
|
Syvn1
|
synoviolin 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of SYVN1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:212,766,736...212,775,426
Ensembl chr 1:203,339,619...203,346,152
|
|
G
|
Taar5
|
trace amine-associated receptor 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAAR5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:21,469,923...21,470,936
Ensembl chr 1:21,469,923...21,470,936
|
|
G
|
Tac1
|
tachykinin, precursor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAC1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178
|
|
G
|
Tacr1
|
tachykinin receptor 1
|
affects response to substance multiple interactions
|
ISO
|
TACR1 protein affects the susceptibility to Dextran Sulfate [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TACR1 mRNA
|
CTD |
PMID:20889569 PMID:29950665 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G
|
Tacr2
|
tachykinin receptor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TACR2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:30,208,907...30,223,446
Ensembl chr20:30,208,907...30,223,446
|
|
G
|
Taf15
|
TATA-box binding protein associated factor 15
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TAF15 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:68,272,921...68,304,951
Ensembl chr10:68,272,969...68,304,949
|
|
G
|
Tagap
|
T-cell activation RhoGTPase activating protein
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAGAP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:47,170,725...47,179,705
Ensembl chr 1:47,170,725...47,179,792
|
|
G
|
Tagln
|
transgelin
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN protein
|
CTD |
PMID:35999755 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G
|
Tagln2
|
transgelin 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of TAGLN2 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN2 protein
|
CTD |
PMID:35999755 |
|
NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972
|
|
G
|
Tap1
|
transporter 1, ATP binding cassette subfamily B member
|
increases expression multiple interactions decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of TAP1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAP1 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of TAP1 protein]
|
CTD |
PMID:23894361 PMID:29950665 PMID:35362542 |
|
NCBI chr20:4,658,171...4,668,543
Ensembl chr20:4,656,263...4,666,901
|
|
G
|
Tas1r2
|
taste 1 receptor member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TAS1R2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:157,192,799...157,208,937
Ensembl chr 5:151,830,701...151,925,345
|
|
G
|
Tas1r3
|
taste 1 receptor member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS1R3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:166,468,703...166,472,759
Ensembl chr 5:166,469,589...166,472,742
|
|
G
|
Tas2r118
|
taste receptor, type 2, member 118
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R118 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:52,449,208...52,450,107
Ensembl chr 4:52,449,208...52,450,107
|
|
G
|
Tas2r137
|
taste receptor, type 2, member 137
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R137 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:69,279,276...69,286,935
Ensembl chr 4:69,284,391...69,285,341
|
|
G
|
Tas2r145
|
taste receptor, type 2, member 145
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS2R131 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:166,138,007...166,138,957
Ensembl chr 4:166,138,007...166,138,957
|
|
G
|
Tbc1d15
|
TBC1 domain family, member 15
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TBC1D15 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 7:50,804,553...50,860,272
Ensembl chr 7:50,804,012...50,860,175
|
|
G
|
Tbcc
|
tubulin folding cofactor C
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TBCC mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:14,098,855...14,100,043
Ensembl chr 9:14,098,868...14,100,042
|
|
G
|
Tbl2
|
transducin (beta)-like 2
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of TBL2 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr12:21,517,600...21,531,896
Ensembl chr12:21,520,682...21,531,896
|
|
G
|
Tbx21
|
T-box transcription factor 21
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TBX21 mRNA Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TBX21 mRNA]
|
CTD |
PMID:31737179 |
|
NCBI chr10:82,578,751...82,595,253
Ensembl chr10:82,082,322...82,098,831
|
|
G
|
Tbxas1
|
thromboxane A synthase 1
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TBXAS1 mRNA Dextran Sulfate results in increased expression of TBXAS1 protein
|
CTD |
PMID:29950665 PMID:30489199 |
|
NCBI chr 4:68,631,841...68,803,959
Ensembl chr 4:67,665,007...67,837,096
|
|
G
|
Tcaf1
|
TRPM8 channel-associated factor 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TCAF1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309
|
|
G
|
Tcaf2
|
TRPM8 channel-associated factor 2
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TCAF2 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TCAF2 protein]
|
CTD |
PMID:32272095 |
|
|
|
G
|
Tcap
|
titin-cap
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TCAP mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:83,381,719...83,382,887
Ensembl chr10:83,381,719...83,382,887
|
|
G
|
Tcf7
|
transcription factor 7
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:36,924,363...36,954,279
Ensembl chr10:36,423,445...36,453,535
|
|
G
|
Tchp
|
trichoplein, keratin filament binding
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TCHP mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr12:41,877,888...41,893,264
Ensembl chr12:41,877,889...41,892,427
|
|
G
|
Tf
|
transferrin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRF mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:103,767,995...103,816,511
|
|
G
|
Tff3
|
trefoil factor 3
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TFF3 mRNA
|
CTD |
PMID:31807802 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G
|
Tfrc
|
transferrin receptor
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TFRC protein
|
CTD |
PMID:20025956 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of TGFB1 protein] Dextran Sulfate results in increased expression of TGFB1 mRNA kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of TGFB1 mRNA]
|
CTD |
PMID:20881082 PMID:25026504 PMID:26074695 PMID:35439472 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G
|
Tgfb3
|
transforming growth factor, beta 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TGFB3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:105,704,236...105,726,564
|
|
G
|
Tgm3
|
transglutaminase 3
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TGM3 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of TGM3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:137,681,809...137,717,219
Ensembl chr 3:117,228,661...117,264,075
|
|
G
|
Thbd
|
thrombomodulin
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBD mRNA Dextran Sulfate results in decreased expression of THBD mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:135,862,835...135,867,193
|
|
G
|
Thbs1
|
thrombospondin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G
|
Thbs4
|
thrombospondin 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:25,718,219...25,760,345
Ensembl chr 2:23,983,158...24,026,313
|
|
G
|
Thy1
|
Thy-1 cell surface antigen
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of THY1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions increases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP1 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TIMP1 mRNA]
|
CTD |
PMID:29950665 PMID:32033881 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:103,531,505...103,590,611
|
|
G
|
Timp3
|
TIMP metallopeptidase inhibitor 3
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP3 mRNA; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]
|
CTD |
PMID:24548422 PMID:29950665 |
|
NCBI chr 7:19,408,539...19,459,558
Ensembl chr 7:17,521,919...17,571,839
|
|
G
|
Tjp1
|
tight junction protein 1
|
multiple interactions decreases expression
|
ISO
|
[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TJP1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; HU 211 inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 mRNA]; isomaltulose inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 mRNA]; isomaltulose inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; nuciferine inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TJP1 protein] Dextran Sulfate results in decreased expression of TJP1 mRNA; Dextran Sulfate results in decreased expression of TJP1 protein
|
CTD |
PMID:27995407 PMID:35439472 PMID:35670535 PMID:35894244 PMID:36281492 PMID:36577154 PMID:37209277 PMID:37385329 PMID:38648921 PMID:38663798 More...
|
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:118,849,838...119,094,432
|
|
G
|
Tk1
|
thymidine kinase 1
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA; alfacalcidol inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA]
|
CTD |
PMID:17893519 |
|
NCBI chr10:103,533,449...103,544,818
Ensembl chr10:103,031,521...103,046,920
|
|
G
|
Tkt
|
transketolase
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TKT mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698
|
|
G
|
Tll1
|
tolloid-like 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLL1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:25,509,146...25,710,330
Ensembl chr16:25,509,146...25,709,543
|
|
G
|
Tln1
|
talin 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:62,583,730...62,613,687
Ensembl chr 5:57,787,943...57,817,900
|
|
G
|
Tlr2
|
toll-like receptor 2
|
multiple interactions
|
ISO
|
Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]; flavokawain B inhibits the reaction [Dextran Sulfate promotes the reaction [TLR2 protein binds to MYD88 protein]]
|
CTD |
PMID:38583725 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions increases expression affects response to substance
|
ISO
|
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TLR4 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR4 mRNA; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of IL6 protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of TNF protein]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; Lipopolysaccharides inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TLR4 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]] TLR4 protein affects the susceptibility to Dextran Sulfate
|
CTD |
PMID:21359540 PMID:27995407 PMID:29950665 PMID:31442584 PMID:32272095 PMID:35362542 PMID:35439472 PMID:35670535 PMID:36543318 More...
|
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G
|
Tlr7
|
toll-like receptor 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:27,027,380...27,054,309
Ensembl chr X:27,027,425...27,054,754
|
|
G
|
Tmem109
|
transmembrane protein 109
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of TMEM109 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TMEM109 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 1:207,519,628...207,530,245
Ensembl chr 1:207,519,624...207,530,215
|
|
G
|
Tmem164
|
transmembrane protein 164
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TMEM164 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr X:106,288,019...106,448,642
Ensembl chr X:106,289,371...106,448,640
|
|
G
|
Tmem191c
|
transmembrane protein 191C
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TMEM191C mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr11:83,726,155...83,728,926
Ensembl chr11:83,725,185...83,730,172
|
|
G
|
Tmem252
|
transmembrane protein 252
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TMEM252 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:222,316,982...222,321,946
Ensembl chr 1:222,316,795...222,321,943
|
|
G
|
Tmem30b
|
transmembrane protein 30B
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TMEM30B protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of TMEM30B protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:97,987,471...97,990,546
Ensembl chr 6:92,249,790...92,254,842
|
|
G
|
Tmsb10
|
thymosin, beta 10
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of TMSB10 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of TMSB10 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:105,009,959...105,011,095
Ensembl chr 4:105,009,212...105,011,028
|
|
G
|
Tmsb4x
|
thymosin beta 4, X-linked
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TMSB4X protein
|
CTD |
PMID:35999755 |
|
NCBI chr X:27,144,666...27,146,667
Ensembl chr X:27,128,610...27,146,667 Ensembl chr10:27,128,610...27,146,667
|
|
G
|
Tmt1b
|
thiol methyltransferase 1B
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TMT1B protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TMT1B protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 7:1,388,876...1,391,526
Ensembl chr 7:1,388,879...1,391,526
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases secretion increases expression affects expression
|
ISO EXP
|
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of TNF protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; bisphenol A promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]; Butylated Hydroxytoluene inhibits the reaction [Dextran Sulfate promotes the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]]; Butylated Hydroxytoluene inhibits the reaction [Dextran Sulfate promotes the reaction [Quartz results in increased secretion of TNF protein]]; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; Chlorpyrifos promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of TNF protein]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein]; Dextran Sulfate inhibits the reaction [Polymyxin B results in decreased expression of TNF protein]; Dextran Sulfate promotes the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]; Dextran Sulfate promotes the reaction [Quartz results in increased secretion of TNF protein]; Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Fenofibrate promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein]; isomaltulose inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Lipopolysaccharides promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; nuciferine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; thiamet G promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA] [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; [bisphenol A diglycidyl ether co-treated with Dextran Sulfate co-treated with Rosiglitazone] results in increased expression of TNF protein; [bisphenol A diglycidyl ether co-treated with Dextran Sulfate] results in increased expression of TNF protein; banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Olmesartan Medoxomil inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein] Dextran Sulfate results in increased expression of TNF mRNA; Dextran Sulfate results in increased expression of TNF protein
|
CTD |
PMID:12105854 PMID:16774945 PMID:17438113 PMID:19028472 PMID:19285099 PMID:19298665 PMID:19940103 PMID:20079348 PMID:20132809 PMID:20637373 PMID:21068411 PMID:21724996 PMID:21858153 PMID:21893696 PMID:23261717 PMID:23568217 PMID:23665423 PMID:24038091 PMID:24384223 PMID:24548422 PMID:25026504 PMID:25035112 PMID:25231984 PMID:25448682 PMID:25472953 PMID:25777935 PMID:25837923 PMID:26190278 PMID:26631293 PMID:26973525 PMID:27125760 PMID:27611972 PMID:27920472 PMID:27995407 PMID:28411859 PMID:28421826 PMID:28438436 PMID:29217385 PMID:29496522 PMID:29672155 PMID:30142311 PMID:30489199 PMID:30611738 PMID:30844440 PMID:30972795 PMID:31442584 PMID:31715269 PMID:31737179 PMID:31807802 PMID:31926917 PMID:32272095 PMID:32470352 PMID:33130971 PMID:33974900 PMID:34273909 PMID:34998820 PMID:35093514 PMID:35362542 PMID:35670535 PMID:35894244 PMID:35999755 PMID:36135333 PMID:36265525 PMID:36281492 PMID:36577154 PMID:36806191 PMID:37001609 PMID:37209277 PMID:37263555 PMID:38164749 PMID:38423481 PMID:38437956 PMID:38583725 PMID:38588969 PMID:38648921 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G
|
Tnfrsf11a
|
TNF receptor superfamily member 11A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFRSF11A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695
|
|
G
|
Tnfrsf12a
|
TNF receptor superfamily member 12A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF12A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:13,211,670...13,213,666
Ensembl chr10:12,689,890...12,709,045
|
|
G
|
Tnfrsf18
|
TNF receptor superfamily member 18
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF18 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:166,618,461...166,622,353
Ensembl chr 5:166,618,969...166,622,353
|
|
G
|
Tnfrsf1a
|
TNF receptor superfamily member 1A
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF1A mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:158,150,820...158,163,591
|
|
G
|
Tnfrsf1b
|
TNF receptor superfamily member 1B
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TNFRSF1B mRNA
|
CTD |
PMID:20824662 |
|
NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:157,070,642...157,104,206
|
|
G
|
Tnfrsf8
|
TNF receptor superfamily member 8
|
multiple interactions affects response to substance
|
ISO
|
[TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein
|
CTD |
PMID:21068411 |
|
NCBI chr 5:157,123,183...157,168,421
Ensembl chr 5:157,123,185...157,168,421
|
|
G
|
Tnfsf12
|
TNF superfamily member 12
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF12 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,403,870...54,413,213
|
|
G
|
Tnfsf14
|
TNF superfamily member 14
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF14 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:2,068,295...2,073,128
Ensembl chr 9:2,069,104...2,073,216
|
|
G
|
Tnfsf15
|
TNF superfamily member 15
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFSF15 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:77,134,885...77,156,171
Ensembl chr 5:77,139,878...77,156,228
|
|
G
|
Tnfsf8
|
TNF superfamily member 8
|
increases expression affects response to substance multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TNFSF8 protein TNFSF8 protein affects the susceptibility to Dextran Sulfate [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein
|
CTD |
PMID:21068411 |
|
NCBI chr 5:82,266,436...82,292,858
Ensembl chr 5:77,251,373...77,277,421
|
|
G
|
Tnfsf9
|
TNF superfamily member 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:1,944,017...1,946,345
|
|
G
|
Tnnc1
|
troponin C1, slow skeletal and cardiac type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:6,400,801...6,405,634
Ensembl chr16:6,402,171...6,405,634
|
|
G
|
Tnnc2
|
troponin C2, fast skeletal type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:153,513,272...153,516,033
Ensembl chr 3:153,513,271...153,516,029
|
|
G
|
Tnni1
|
troponin I1, slow skeletal type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNNI1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:47,229,217...47,241,640
Ensembl chr13:47,229,216...47,241,644
|
|
G
|
Tnni2
|
troponin I2, fast skeletal type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNI2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:197,595,012...197,597,554
Ensembl chr 1:197,594,813...197,597,560
|
|
G
|
Tnnt3
|
troponin T3, fast skeletal type
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNT3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:197,652,535...197,669,736
Ensembl chr 1:197,652,431...197,669,535
|
|
G
|
Tollip
|
toll interacting protein
|
multiple interactions decreases expression
|
ISO
|
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of TOLLIP protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in decreased expression of TOLLIP protein]
|
CTD |
PMID:36543318 |
|
NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625
|
|
G
|
Tomm5
|
translocase of outer mitochondrial membrane 5
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of TOMM5 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:64,158,026...64,160,857
Ensembl chr 5:59,362,240...59,365,269
|
|
G
|
Tomm7
|
translocase of outer mitochondrial membrane 7
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TOMM7 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 4:11,305,122...11,311,963
Ensembl chr 4:11,305,110...11,311,962
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TRP53 protein
|
CTD |
PMID:16049979 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G
|
Tpcn1
|
two pore segment channel 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPCN1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:35,972,813...36,029,632
Ensembl chr12:35,972,846...36,029,626
|
|
G
|
Tph1
|
tryptophan hydroxylase 1
|
multiple interactions increases expression
|
ISO
|
Granisetron inhibits the reaction [Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]
|
CTD |
PMID:30611738 |
|
NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344
|
|
G
|
Tpi1
|
triosephosphate isomerase 1
|
increases expression decreases expression
|
ISO
|
Dextran Sulfate results in increased expression of TPI1 mRNA Dextran Sulfate results in decreased expression of TPI1 protein
|
CTD |
PMID:35093514 PMID:35999755 |
|
NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:157,615,386...157,619,541
|
|
G
|
Tpm2
|
tropomyosin 2
|
multiple interactions decreases expression
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of TPM2 mRNA Dextran Sulfate results in decreased expression of TPM2 protein
|
CTD |
PMID:26271895 PMID:35999755 |
|
NCBI chr 5:62,566,712...62,576,066
Ensembl chr 5:57,770,864...57,779,992
|
|
G
|
Tpm3
|
tropomyosin 3
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TPM3 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 2:175,517,198...175,545,014
Ensembl chr 2:175,517,226...175,545,013
|
|
G
|
Tpm4
|
tropomyosin 4
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TPM4 protein
|
CTD |
PMID:35999755 |
|
NCBI chr16:17,718,442...17,732,483
Ensembl chr16:17,683,195...17,705,984
|
|
G
|
Tpmt
|
thiopurine S-methyltransferase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPMT mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:17,644,088...17,662,709
Ensembl chr17:17,644,173...17,662,709
|
|
G
|
Tpsb2
|
tryptase beta 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TPSB2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,382,013...14,383,569
|
|
G
|
Tpt1
|
tumor protein, translationally-controlled 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TPT1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625
|
|
G
|
Traf3ip1
|
TRAF3 interacting protein 1
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TRAF3IP1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:92,073,622...92,110,427
Ensembl chr 9:92,073,640...92,108,977
|
|
G
|
Traf6
|
TNF receptor associated factor 6
|
multiple interactions increases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TRAF6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TRAF6 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:87,963,514...87,983,507
|
|
G
|
Trank1
|
tetratricopeptide repeat and ankyrin repeat containing 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TRANK1 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 8:111,275,973...111,355,491
Ensembl chr 8:111,276,354...111,355,092
|
|
G
|
Trem2
|
triggering receptor expressed on myeloid cells 2
|
multiple interactions increases expression
|
ISO
|
huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TREM2 protein]
|
CTD |
PMID:37263316 |
|
NCBI chr 9:20,145,215...20,151,797
Ensembl chr 9:12,647,259...12,654,170
|
|
G
|
Trh
|
thyrotropin releasing hormone
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRH mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G
|
Trib2
|
tribbles pseudokinase 2
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TRIB2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 6:44,274,762...44,299,139
Ensembl chr 6:38,545,975...38,569,370
|
|
G
|
Trim25
|
tripartite motif-containing 25
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRIM25 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:73,812,818...73,831,271
Ensembl chr10:73,812,818...73,831,257
|
|
G
|
Trim41
|
tripartite motif-containing 41
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TRIM41 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:33,175,213...33,186,472
Ensembl chr10:33,175,213...33,186,694
|
|
G
|
Trir
|
telomerase RNA component interacting RNase
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TRIR mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr19:23,125,083...23,128,502
Ensembl chr19:23,125,083...23,128,510
|
|
G
|
Trpc3
|
transient receptor potential cation channel, subfamily C, member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
|
|
G
|
Trpc6
|
transient receptor potential cation channel, subfamily C, member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:5,758,935...5,828,092
|
|
G
|
Trpc7
|
transient receptor potential cation channel, subfamily C, member 7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPC7 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr17:7,708,911...7,833,435
Ensembl chr17:7,709,583...7,833,435
|
|
G
|
Trpm1
|
transient receptor potential cation channel, subfamily M, member 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRPM1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:117,718,896...117,835,434
Ensembl chr 1:117,718,896...117,834,605
|
|
G
|
Trpm4
|
transient receptor potential cation channel, subfamily M, member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:95,782,000...95,812,532
|
|
G
|
Trpm6
|
transient receptor potential cation channel, subfamily M, member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
G
|
Trpm8
|
transient receptor potential cation channel, subfamily M, member 8
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TRPM8 mRNA
|
CTD |
PMID:23596210 |
|
NCBI chr 9:96,315,567...96,437,959
Ensembl chr 9:88,903,880...88,988,552
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
affects expression multiple interactions
|
ISO
|
Dextran Sulfate affects the expression of TRPV1 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV1 mRNA
|
CTD |
PMID:18687398 PMID:29950665 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:57,851,428...57,876,513
|
|
G
|
Trpv2
|
transient receptor potential cation channel, subfamily V, member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:47,265,524...47,294,263
Ensembl chr10:47,272,931...47,294,260
|
|
G
|
Trpv4
|
transient receptor potential cation channel, subfamily V, member 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr12:47,599,161...47,638,143
Ensembl chr12:41,938,560...41,977,517
|
|
G
|
Trpv6
|
transient receptor potential cation channel, subfamily V, member 6
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV6 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:70,507,348...70,523,017
|
|
G
|
Try5
|
trypsin 5
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRY5 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:70,213,760...70,217,034
Ensembl chr 4:70,213,756...70,217,051
|
|
G
|
Tsc2
|
TSC complex subunit 2
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of TSC2 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in decreased expression of TSC2 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in decreased expression of TSC2 protein]
|
CTD |
PMID:31676321 |
|
NCBI chr10:14,125,679...14,160,317
Ensembl chr10:13,621,136...13,655,951
|
|
G
|
Tsc22d3
|
TSC22 domain family, member 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TSC22D3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:109,006,410...109,066,389
Ensembl chr X:104,217,925...104,276,861
|
|
G
|
Tsfm
|
Ts translation elongation factor, mitochondrial
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of TSFM protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 7:62,828,997...62,864,784
Ensembl chr 7:62,845,488...62,864,769
|
|
G
|
Tsks
|
testis-specific serine kinase substrate
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of TSKS mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 1:95,414,312...95,441,670
Ensembl chr 1:95,414,157...95,441,662
|
|
G
|
Tsnax
|
translin-associated factor X
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TSNAX protein]
|
CTD |
PMID:32272095 |
|
NCBI chr19:52,975,848...52,989,886
Ensembl chr19:52,975,659...52,989,878
|
|
G
|
Tst
|
thiosulfate sulfurtransferase
|
multiple interactions decreases expression
|
ISO
|
Dextran Sulfate affects the activity of and results in decreased expression of TST protein Dextran Sulfate results in decreased expression of TST mRNA
|
CTD |
PMID:19647029 |
|
NCBI chr 7:111,828,557...111,836,980
Ensembl chr 7:109,948,062...109,957,216
|
|
G
|
Ttn
|
titin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:61,652,432...61,924,912
Ensembl chr 3:61,652,439...61,924,741
|
|
G
|
Ttr
|
transthyretin
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTR mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr18:12,216,684...12,225,972
Ensembl chr18:11,943,789...11,951,008
|
|
G
|
Tuba1a
|
tubulin, alpha 1A
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TUBA1A protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G
|
Tuba4a
|
tubulin, alpha 4A
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TUBA4A protein
|
CTD |
PMID:35999755 |
|
NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918
|
|
G
|
Tubb1
|
tubulin, beta 1 class VI
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of TUBB1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr 3:183,666,189...183,675,656
Ensembl chr 3:163,247,967...163,256,063
|
|
G
|
Tubb6
|
tubulin, beta 6 class V
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TUBB6 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TUBB6 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418
|
|
G
|
Txndc9
|
thioredoxin domain containing 9
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of TXNDC9 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of TXNDC9 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 9:40,211,818...40,221,953
Ensembl chr 9:40,211,412...40,384,279 Ensembl chr 9:40,211,412...40,384,279
|
|
G
|
Tyms
|
thymidylate synthetase
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TYMS mRNA
|
CTD |
PMID:17893519 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:113,313,452...113,329,536
|
|
G
|
Tyrobp
|
transmembrane immune signaling adaptor Tyrobp
|
multiple interactions increases expression
|
ISO
|
huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TYROBP mRNA]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TYROBP protein] Dextran Sulfate results in increased expression of TYROBP mRNA; Dextran Sulfate results in increased expression of TYROBP protein
|
CTD |
PMID:37263316 |
|
NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848
|
|
G
|
Uap1l1
|
UDP-N-acetylglucosamine pyrophosphorylase 1 like 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of UAP1L1 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of UAP1L1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr 3:8,172,335...8,180,505
Ensembl chr 3:8,173,216...8,180,443
|
|
G
|
Uba1
|
ubiquitin-like modifier activating enzyme 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of UBA1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr X:4,062,216...4,084,192
Ensembl chr X:1,508,666...1,530,636
|
|
G
|
Uba7
|
ubiquitin-like modifier activating enzyme 7
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UBA7 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of UBA7 protein]
|
CTD |
PMID:29950665 PMID:35362542 |
|
NCBI chr 8:117,543,902...117,552,709
Ensembl chr 8:108,665,292...108,674,099
|
|
G
|
Ube2d3
|
ubiquitin-conjugating enzyme E2D 3
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of UBE2D3 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 2:223,868,397...223,899,606
Ensembl chr 2:223,868,730...223,898,081
|
|
G
|
Ublcp1
|
ubiquitin-like domain containing CTD phosphatase 1
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of UBLCP1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:28,945,690...28,961,103
Ensembl chr10:28,945,698...28,960,996
|
|
G
|
Ubqln1
|
ubiquilin 1
|
multiple interactions decreases expression
|
ISO
|
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of UBQLN1 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr17:6,439,002...6,477,096
Ensembl chr17:6,439,002...6,477,090
|
|
G
|
Ubtf
|
upstream binding transcription factor
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of UBTF protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of UBTF protein]
|
CTD |
PMID:35362542 |
|
NCBI chr10:87,258,217...87,274,291
Ensembl chr10:87,258,217...87,272,969
|
|
G
|
Uck2
|
uridine-cytidine kinase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UCK2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:79,380,807...79,438,121
Ensembl chr13:79,383,846...79,438,352
|
|
G
|
Ugdh
|
UDP-glucose 6-dehydrogenase
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGDH mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G
|
Ugt1a6
|
UDP glucuronosyltransferase family 1 member A6
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT1A6B mRNA Dextran Sulfate results in decreased expression of UGT1A6B mRNA
|
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G
|
Ugt2a1
|
UDP glucuronosyltransferase family 2 member A1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2A1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:20,521,018...20,545,934
Ensembl chr14:20,517,951...20,545,531
|
|
G
|
Ugt2b7
|
UDP glucuronosyltransferase family 2 member B7
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2B34 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr14:21,251,535...21,274,451
Ensembl chr14:20,896,682...20,919,604
|
|
G
|
Ulk1
|
unc-51 like autophagy activating kinase 1
|
decreases phosphorylation multiple interactions
|
ISO
|
Dextran Sulfate results in decreased phosphorylation of ULK1 protein biochanin A inhibits the reaction [Dextran Sulfate results in decreased phosphorylation of ULK1 protein]
|
CTD |
PMID:38648921 |
|
NCBI chr12:51,511,492...51,537,746
Ensembl chr12:45,851,710...45,877,966
|
|
G
|
Unc80
|
unc-80 homolog, NALCN channel complex subunit
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UNC80 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:68,011,940...68,190,135
Ensembl chr 9:68,011,728...68,187,659
|
|
G
|
Upb1
|
beta-ureidopropionase 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPB1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr20:13,217,252...13,243,590
Ensembl chr20:13,217,258...13,243,590
|
|
G
|
Upf3a
|
UPF3A, regulator of nonsense mediated mRNA decay
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of UPF3A mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr16:75,757,442...75,768,478
Ensembl chr16:75,757,441...75,769,345
|
|
G
|
Upp1
|
uridine phosphorylase 1
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of UPP1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr14:88,023,155...88,043,036
Ensembl chr14:83,809,960...83,829,462
|
|
G
|
Upp2
|
uridine phosphorylase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 3:43,273,048...43,317,417
Ensembl chr 3:43,273,048...43,317,417
|
|
G
|
Uqcrq
|
ubiquinol-cytochrome c reductase, complex III subunit VII
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of UQCRQ mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:38,086,691...38,093,871
Ensembl chr10:37,586,888...37,589,169
|
|
G
|
Urod
|
uroporphyrinogen decarboxylase
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of UROD protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808
|
|
G
|
Vav1
|
vav guanine nucleotide exchange factor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 9:2,248,856...2,295,905
Ensembl chr 9:2,157,900...2,208,937
|
|
G
|
Vav3
|
vav guanine nucleotide exchange factor 3
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV3 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:199,699,861...200,042,344
Ensembl chr 2:197,011,831...197,354,321
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions increases expression
|
ISO
|
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]
|
CTD |
PMID:21724996 PMID:25448682 PMID:38583725 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958
|
|
G
|
Vcan
|
versican
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VCAN mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637
|
|
G
|
Vcl
|
vinculin
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of VCL protein
|
CTD |
PMID:35999755 |
|
NCBI chr15:3,315,069...3,404,891
Ensembl chr15:3,265,815...3,355,606
|
|
G
|
Vdr
|
vitamin D receptor
|
multiple interactions decreases expression
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VDR mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of VDR protein]
|
CTD |
PMID:29950665 PMID:38588969 |
|
NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of VEGFA mRNA; Dextran Sulfate results in increased expression of VEGFA protein
|
CTD |
PMID:20025956 PMID:35093514 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G
|
Vegfc
|
vascular endothelial growth factor C
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFC mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr16:44,445,293...44,560,887
Ensembl chr16:37,712,262...37,827,848
|
|
G
|
Vegfd
|
vascular endothelial growth factor D
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFD mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G
|
Vim
|
vimentin
|
multiple interactions increases expression
|
ISO
|
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of VIM protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIM protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VIM mRNA
|
CTD |
PMID:29950665 PMID:34273909 PMID:36543318 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187
|
|
G
|
Vipr1
|
vasoactive intestinal peptide receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIPR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:130,181,219...130,217,098
Ensembl chr 8:121,310,248...121,339,585
|
|
G
|
Vps26c
|
VPS26 endosomal protein sorting factor C
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of VPS26C protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of VPS26C protein]
|
CTD |
PMID:35362542 |
|
NCBI chr11:33,813,467...33,841,883
Ensembl chr11:33,792,389...33,841,447
|
|
G
|
Wasl
|
WASP like actin nucleation promoting factor
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of WASL protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of WASL protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:54,049,081...54,097,653
Ensembl chr 4:53,083,536...53,132,022
|
|
G
|
Wdr1
|
WD repeat domain 1
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of WDR1 protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:76,470,238...76,504,086
Ensembl chr14:72,257,956...72,291,766
|
|
G
|
Wdr5
|
WD repeat domain 5
|
multiple interactions increases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of WDR5 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 3:10,836,964...10,856,682
Ensembl chr 3:10,837,025...10,856,671
|
|
G
|
Wfdc17
|
WAP four-disulfide core domain 17
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of WFDC17 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr10:68,561,954...68,562,801
Ensembl chr10:68,561,954...68,562,801
|
|
G
|
Wfdc18
|
WAP four-disulfide core domain 18
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of WFDC18 mRNA
|
CTD |
PMID:23894361 |
|
NCBI chr10:68,588,818...68,590,972
Ensembl chr10:68,588,818...68,589,671
|
|
G
|
Wif1
|
Wnt inhibitory factor 1
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WIF1 mRNA; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WIF1 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA]
|
CTD |
PMID:26271895 PMID:31715269 |
|
NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:56,548,053...56,618,360
|
|
G
|
Wnk1
|
WNK lysine deficient protein kinase 1
|
multiple interactions
|
ISO
|
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WNK1 mRNA
|
CTD |
PMID:26271895 |
|
NCBI chr 4:154,800,590...154,926,147
Ensembl chr 4:153,128,334...153,253,905
|
|
G
|
Wnk4
|
WNK lysine deficient protein kinase 4
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNK4 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829
|
|
G
|
Wnt10a
|
Wnt family member 10A
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 9:83,798,594...83,811,060
Ensembl chr 9:76,349,931...76,362,400
|
|
G
|
Wnt2
|
Wnt family member 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of WNT2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 4:47,294,300...47,340,284
Ensembl chr 4:46,333,998...46,374,402
|
|
G
|
Wnt2b
|
Wnt family member 2B
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNT2B mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 2:195,142,573...195,156,945
Ensembl chr 2:192,453,824...192,470,308
|
|
G
|
Wnt3
|
Wnt family member 3
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr10:89,180,224...89,224,195
Ensembl chr10:88,680,248...88,724,099
|
|
G
|
Wnt6
|
Wnt family member 6
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 9:83,778,552...83,792,186
Ensembl chr 9:76,329,882...76,343,523
|
|
G
|
Wnt7b
|
Wnt family member 7B
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA]
|
CTD |
PMID:31715269 |
|
NCBI chr 7:118,514,684...118,559,316
Ensembl chr 7:116,634,814...116,679,581
|
|
G
|
Xcl1
|
X-C motif chemokine ligand 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCL1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr13:77,248,687...77,252,343
Ensembl chr13:77,248,717...77,252,329
|
|
G
|
Xcr1
|
X-C motif chemokine receptor 1
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCR1 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 8:123,479,454...123,516,168
Ensembl chr 8:123,479,590...123,487,226
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of XDH protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:21,530,113...21,592,268
|
|
G
|
Xiap
|
X-linked inhibitor of apoptosis
|
multiple interactions
|
ISO
|
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]
|
CTD |
PMID:25449198 |
|
NCBI chr X:125,756,107...125,803,979
Ensembl chr X:120,897,907...120,934,700
|
|
G
|
Xpnpep1
|
X-prolyl aminopeptidase 1
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of XPNPEP1 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of XPNPEP1 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:262,006,761...262,057,479
Ensembl chr 1:252,001,367...252,051,479
|
|
G
|
Xpnpep2
|
X-prolyl aminopeptidase 2
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XPNPEP2 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr X:132,165,696...132,194,937
Ensembl chr X:127,287,979...127,317,223
|
|
G
|
Yap1
|
Yes1 associated transcriptional regulator
|
multiple interactions
|
ISO
|
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased phosphorylation of and affects the localization of YAP1 protein
|
CTD |
PMID:24146755 |
|
NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:5,095,722...5,167,010
|
|
G
|
Ybx2
|
Y box binding protein 2
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of YBX2 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr10:55,158,420...55,164,077
Ensembl chr10:54,659,719...54,665,371
|
|
G
|
Ywhae
|
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of YWHAE protein
|
CTD |
PMID:35999755 |
|
NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589
|
|
G
|
Ywhah
|
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of YWHAH protein
|
CTD |
PMID:35999755 |
|
NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741
|
|
G
|
Ywhaq
|
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta
|
multiple interactions
|
ISO
|
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of YWHAQ protein
|
CTD |
PMID:35999755 |
|
NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273
|
|
G
|
Ywhaz
|
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
|
decreases expression
|
ISO
|
Dextran Sulfate results in decreased expression of YWHAZ protein
|
CTD |
PMID:35999755 |
|
NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668
|
|
G
|
Zbp1
|
Z-DNA binding protein 1
|
increases expression decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ZBP1 mRNA Dextran Sulfate results in decreased expression of ZBP1 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ZBP1 protein]
|
CTD |
PMID:23894361 PMID:35362542 |
|
NCBI chr 3:161,993,351...162,009,297
Ensembl chr 3:161,993,351...162,003,870
|
|
G
|
Zc3h18
|
zinc finger CCCH-type containing 18
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ZC3H18 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ZC3H18 protein]
|
CTD |
PMID:32272095 |
|
NCBI chr19:50,434,864...50,479,855
Ensembl chr19:50,434,903...50,479,854
|
|
G
|
Zfp422
|
zinc finger protein 422
|
multiple interactions decreases expression
|
ISO
|
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ZFP422 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 4:149,885,805...149,893,287
Ensembl chr 4:149,885,600...149,893,257
|
|
G
|
Zfp821
|
zinc finger protein 821
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of ZFP821 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr19:37,679,937...37,698,831
Ensembl chr19:37,680,628...37,698,831
|
|
G
|
Zfyve9
|
zinc finger FYVE-type containing 9
|
multiple interactions
|
ISO
|
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ZFYVE9 mRNA
|
CTD |
PMID:29950665 |
|
NCBI chr 5:123,370,677...123,529,699
Ensembl chr 5:123,370,677...123,529,699
|
|
G
|
Zg16
|
zymogen granule protein 16
|
decreases expression multiple interactions
|
ISO
|
Dextran Sulfate results in decreased expression of ZG16 protein evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ZG16 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 1:191,088,248...191,090,605
Ensembl chr 1:181,657,722...181,660,079
|
|
G
|
Zmpste24
|
zinc metallopeptidase STE24
|
increases expression multiple interactions
|
ISO
|
Dextran Sulfate results in increased expression of ZMPSTE24 protein evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ZMPSTE24 protein]
|
CTD |
PMID:35362542 |
|
NCBI chr 5:134,627,218...134,660,360
Ensembl chr 5:134,627,229...134,660,110
|
|
G
|
Znrf4
|
zinc and ring finger 4
|
increases expression
|
ISO
|
Dextran Sulfate results in increased expression of ZNRF4 mRNA
|
CTD |
PMID:35093514 |
|
NCBI chr 9:1,353,308...1,354,496
Ensembl chr 9:1,353,306...1,354,584
|
|